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CHAPTER 1 
ARTHRITOGENIC CHARACTERISTICS OF 
INTERLEUKIN-1: 
INTRODUCTION AND OUTLINE OF INVESTIGATION 
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ARTHRITOGENIC CHARACTERISTICS OF INTERLEUKIN-1 
INTRODUCΉON AND OUTLINE OF INVESTIGATION. 
1.1 Interleukin-l, the scope of this study. 
Rheumatoid arthritis (RA) is a systemic illness with polyarticular 
manifestations of chronic inflammation, frequently located in the 
small joints of hand and feet. Among the Dutch population about 
1-2% has this disease and women are more frequently (2:1) 
affected than men [1]. The disease is further characterized by an 
intermittent course of the inflammation in 70% of the patients [2]. 
The pathological features of RA are cartilage loss (joint 
space narrowing), erosions of the cortex of bone, sometimes 
followed by new bone formation (osteophytes) in an attempt at 
repair. Arthropathological changes are also observed in the joint 
capsule, e.g. synovial hyperplasia, hyperthrophied synovial lining 
layer, angiogenesis in the synovial membrane and outgrowth of the 
synovial membrane over the cartilage surface (pannus). 
In contrast to findings in osteoarthrosis, the arthro­
pathological changes coincide with an active synovitis. It was shown 
that synovectomy temporarily arrested the progressive destruction 
of bone and cartilage in RA [3]. An important finding since this 
indicates that the inflamed synovium is likely to participate in this 
process in the arthritic joint. 
Co-cultures of cartilage and synovial tissue resulted in 
severe chondrocyte mediated breakdown of cartilage proteoglycans. 
The responsible factor was isolated and termed catabolin [4]. 
Cartilage destruction was also shown with a factor derived from 
stimulated human monocytes [5-7]. Catabolin and the mononuclear 
cell factor were identified as the same cytokine (extracellular 
soluble mediators) and received the name, interleukin-l (IL-1). 
Interleukin-l is produced by cells of almost all lineages, 
binds specifically to receptors on target cells and triggers them to 
respond. A summary of the properties of IL-1 will be reviewed in 
chapter 1.2. High amounts of IL-1 are present in rheumatoid 
synovial fluid and the levels correlated with the disease activity in 
these patients (chapter 1.3). In the rheumatoid joint, tumor 
necrosis factor (TNF)-a seems to drive the IL-1 production [8]. 
Evidence for IL-1 production in animal models of arthritis are 
summarized in chapter 1.4. 
The objective of our study was to elucidate the role of 
IL-1 in murine models of arthritis (chapter 1.5). 
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1.2 Introduction of IL-1 and level of modulation.1 
Two forms of IL-1 exist and both are non-glycosylated proteins of 
17.5 KDa with different isoelectric points, IL-la, pi 5; IL-lß, pi 7. 
Both IL-1 subtypes are encoded by two tightly linked genes which 
are located at chromosome 2 of man and mouse [21]. The 
homology of IL-la with IL-lß is 40-45% at the nucleic acid level 
and 22-26% at the amino acid level [22]. Both IL-1 forms share the 
same receptors and biological activities, although the immune 
response may be differently regulated by them [23]. Furthermore, 
IL-1 is well conserved between the species, a 71% homology at the 
amino acid level for IL-la and 76% for IL-lß between mouse and 
human, and no cross species differences are found sofar. 
Most IL-1 producing cells also express a 24 KDa 
glycosylated IL-1 receptor antagonist protein (IL-lra), also called 
IRAP or IL-lgamma, even in response to IL-1 [24,25]. For 
example, chondrocytes are able to produce both IL-1 and IL-lra, 
suggesting an autocrine IL-1 production and regulation [26]. IL-lra 
is also encoded at chromosome 2 of mice and man and has 20-30% 
and 19% amino acid homology to IL-lß and IL-la, respectively. 
IL-Іга competes with the IL-1 isoforms to the same receptors, 
however, binding does not result in signal transduction [27,28]. 
Recently it was demonstrated e.g in macrophages and fibroblast 
that an intra-cellular IL-lra form is synthesized which theoretically 
can interfere with IL-1 induced responses. 
CELLULAR PROCESSING OF IL-1 
The IL-1 genes are transcribed into mRNA, translated into 
intracellular 31 KDa precursor peptides, and processed via a 22 
KDa transient intracellular protein into a 17 KDa extracellular 
mature protein. The phosphorylated proform of IL-la but not IL-
1/3 is biologically active whereas both mature forms are biologically 
active [29]. 
The expression of the three IL-1 moieties (α, ß, IL-lra) is 
probably regulated in a complex and by different pathways and the 
exact mechanism is not known up till now [30]. A central role is 
played by protein kinase-C (PKC) in the gene transcription of 
Most of this chapter is a compilation of previous described reviews 
[9-20]. 
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IL-lß but not IL-Ια, and not in the translation and secretion of 
both IL-1 proteins [31-34]. Both IL-1 forms lack a N-terminal 
signal peptide sequence that would normally indicate a natural 
cleavage site characteristic for secretory peptides and do not have 
a hydrophobic transmembrane sequence as seen in membrane 
proteins. In the latest hypothesis2 a pair of two IL-1 converting 
enzyme (ICE) molecules are embodied in the cell membrane, 
forming a gap through which pro-IL-lß passes the cell membrane 
under enzymatic cleavage by ICE into its mature and biologically 
active 17.5 KDa form. Sofar IL-la specific converting enzyme has 
not been identified. Evidence is presented that pro-IL-la is 
attached to the outside of the cell membrane by a lectin-like 
binding [35,36] but others presented data arguing against this [37]. 
The protease responsible for the extracellular cleavage of the 
proform into the mature form of IL-la is not identified although a 
calpain-like protease has this capacity [38]. 
THE TWO IL-1 MEMBRANE RECEPTORS 
The two IL-1 subtypes are recognized by the same IL-1 receptors; 
type I receptor (IL-1 RI), a 80 KDa glycoprotein; type II receptor 
(IL-1RII), a 68 KDa glycoprotein [39]. The receptor numbers may 
differ per celltype ranging from 50 upto several thousands per cell. 
Both receptors possess an intracellular domain, although the IL-
1RII has only a short cytoplasmic segment. The transmembrane 
signal transduction and the intra-cellular second messenger 
pathway are not unravelled. Most cells (macrophage, PMN) 
express both IL-1 receptors although their relative numbers may 
differ. The TH1 and TH2 lymphocyte populations not only have 
specific cytokine profiles but the relative numbers of the two IL-1 
receptors are differently expressed [40-42]. Evidence is emerging 
that only the IL-1 RI mediates signal transduction possibly by 
increasing cAMP and expression of the oncogenes C-myb and C-
myc. However, IL-1 induced phosphorylation of protein-kinase С 
and oncogene expression of C-fos mediated by the IL-1 type II 
receptor was reported. For instance, B-cells exclusively express IL-
1RII and still are responsive to IL-1 [43]. Chondrocytes express 
probably only IL-1 RI [44-46]. 
It is estimated that about 1-2% of IL-1RI occupation with 
IL-1 is sufficient to result in a response. IL-Ira binds to the type I 
Plenary lecture of M Gowen, ORS februari 21-24, 1994. 
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IL-1 receptor with almost the same affinity as IL-la and IL-1/8. 
The IL-1RII demonstrate the following affinity hierarchy; IL-lß > 
IL-la = IL-lra. As an example, IL-lß has a 15 times higher 
affinity compared to IL-la in B-cells and in immature B-cells it is 
even 1000 times higher. Recently, a naturally occuring dimerization 
of IL-1 type II receptors is found. This complex demonstrate a 
higher affinity for IL-la than the monomelic form, but affinity for 
IL-1/3 is unchanged [47]. IL-lra binds the membrane form of IL-
1 RI 100 times better than the IL-1RII and binds to the soluble IL-
1RI but not to the soluble IL-1RII. It is shown that the PMN cells 
can release their IL-1RII and that the soluble IL-1 type II 
receptors are a decoy for IL-ljS but not for IL-lra or IL-la [48-50]. 
Figure 1. LeveL· to interfere with the IL-1 bioactivity. 
The expression of mRNA of IL-la and IL-lß can be increased byphorbol esters 
(PMA), lipopolysaccharide (LPS) and cytokines as IFN-gamma, TNF and IL-1, 
inducing an autocrine and paracrine loop. The mRNA expression can be decreased 
prostaglandin-E2 or cytokines as IL-4, IL-6, IL-10, TGFßl, and probably IL-13. 
e biologically inactive IL-lß precursor is secreted and subsequently activated by 
the IL-1 converting enzyme (ICE). Specific inhibitors for ICE may prevent IL-lß 
secretion and activation. The mechanism of IL-la secretion is still unknown. The 
bioactivity of secreted IL-1 can be controlled by different mechanisms: First, IL-1 
can be scavenged by soluble IL-1 receptors. IL-1 receptor type 11 (RII) is a shedding 
product of PMNs with a high affinity for IL-lß. Second, IL-1 can be antagonized by 
the IL-1 receptor antagonist protein (IL-lra). The expression of IL-lra can be 
enhanced by TGFß and IL-1. Third, the number of IL-1 receptors on the target cells 
can be reduced by IL-1, IL-2 and TGFß or increased by IFN-gamma. Fourth, IL-1 
can simply be counteracted by other cytokines e.g.IGF-1 on chondrocytes. 
% 
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Several groups showed evidence that the IL-1: receptor complex is 
internalized and translocated into mitochondria and the nucleus 
[51]. This suggest that IL-1 bypasses the currently known signal 
transduction pathways and more directly exerts its activity on the 
cell metabolism. Computer analysis showed that the IL-1RI had a 
region with strong amino acid sequence homology with other virus 
associated nuclear factors [52]. Furthermore, it is shown that a 
synthetic IL-Iß fragment is internalized into the cytosol without 
receptor binding and that the IL-1 receptor is not necessary for IL-
1 to exert an effect [53]. Modifications of the tertiary IL-Iß 
structure, point mutations and monoclonal antibody mapping 
demonstrated different regions for IL-1 receptor binding and the 
different biological activities [54-56]. 
The following cells express primarily the IL-1RI: 
chondrocytes, TH2 (subtype of T-cells), fibroblasts, keratinocyten, 
hepatocyten and endothelial cells; whereas type II is predominantly 
expressed on B-cells, TH1, neutrophils, bone marrow cells and 
macrophages. 
1.3 Detection of IL-1: relationship to disease activity in RA. 
In general, IL-Iß levels (several hundreds of pg/ml) in synovial 
fluids from RA patients are far greater than those found in 
osteoarthritis patients in comparative studies and are significantly 
increased compared to normal subjects. IL-1 is detected in synovial 
fluids of patients from different arthropathies: Rheumatoid 
arthritis, Psoriatic arthritis, Reiter's syndrome, Yersinia reactive 
arthritis, Osteoarthritis, Ankylosing spondyltitis, Gout, Traumatic 
arthritis, Lyme disease, but only Staphylococcal-related arthritis is 
reported to be IL-1 negative [57-63]. 
At the systemic level, IL-1 levels in peripheral blood 
plasma and serum are correlated to the disease activity of arthritis 
[64]; synovial fluid IL-Iß levels correlate positively with the 
amounts of C3a des Arg and 1С in Psoriatic arthritis and with C3d 
in RA [65,66], indicating an active inflammatory process. Danis et 
al. showed that the peripheral blood monocytes from RA patients 
spontaneously express IL-la and IL-Iß in culture [67]. Peripheral 
blood mononuclear cells spontaneously produced IL-1 when taken 
at the onset or during a recent relapse of rheumatoid arthritis [68]. 
Duff et al. could only detect IL-la positive peripheral blood cells, 
having a dendritic morphology, using a direct Elispot technic [69], 
and there incidence correlated positively with the index of disease 
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activity in RA [70]. Furthermore, IL-Iß levels in serum but not in 
synovial fluid correlate positively with the pain score, erythrocyte 
sedimentation rate, Ritchie articular index, and histological 
changes and HLA-DR4 expression in the joint capsule in RA [71-
74]. 
At the local level, synovial IL-1 levels correlates 
significantly with the numbers of PMNs in the joint but appeared 
to be unrelated to the total number of leucocytes in both RA and 
OA [74-76]. PMNs have a dual role, they synthesize IL-la and IL-
lß and the IL-1 antagonist IL-Ira [77-79]. Malyak et al. showed 
that the synovial fluid PMNs contributed to the local IL-Ira levels 
[76]. This could explain the higher biological IL-1 levels in synovial 
lavage of sero negative (rheumatoid factor, RF) RA-patients 
compared to seropositive RA with the more severe inflammation.3 
Furthermore, this may explain the absence of correlation of 
synovial IL-1 levels with indices of systemic inflammation in RA-
patients [80]. By antagonizing IL-1, PMNs can attribute to the 
remission of the disease. The interval to recover from Lyme 
disease is linked to the balance of [IL-l]/[IL-lra] in the synovial 
fluid [81]. It would be intersting to consider the role of the PMN in 
Lyme disease as an 'anti-inflammatory' cell. 
Immunohistochemistry showed IL-la positive cells in the 
lining layer, interaggregate area, vascular endothelium, and 
lymphocyte aggregates of synovia. IL-la is also detected in pannus 
tissue and chondrocytes adjacent to pannus [82]. IL-lra is also 
present at the IL-1 positive spots although the incidence is smaller. 
Strangely enough, so far they couldn't find IL-Iß in synovium from 
normal subjects and neither in cartilage nor pannus of RA patients 
[83]. However, Farahat et al. showed that both IL-la and IL-Iß are 
equally expressed by the synovial cells in the connective tissue area 
(number of IL-1 positive cells is 40%), perivascular area (50-55%), 
and the lining layer (80%) [84]. The number of IL-1 positive cells 
in the same areas is significantly smaller in OA-patients than in 
RA-patients. 
In most RA-patients, IL-Iß but not IL-la could be 
detected in synovial fluids. One possible explanation is that IL-la 
is present in the cytoplasm or on cell membranes and IL-la is only 
released after cell death. A likely explanantion, as it is shown that 
isolated synovial macrophages do express both IL-1 isotypes in 
culture with a more prolonged expression of IL-la mRNA 
[67,85,86]. 
Plenary lecture JM DAYER, IAIS, Vienna, October 10-15,1993. 
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Beuscher et al. [87] showed that maturation of macrophages 
coincided with a shift from IL-lß into IL-la producing cells in 
mice infected with Yersinia enterocolitica. Secondly, IL-la could be 
neutralized by autoantibodies present in sera of rheumatoid 
arthritis patients [88-90]. 
Dayer-JM3 found that the synovial fluid levels of IL-1 
correlate good with the disease activity in osteoarthritis and that 
the synovial fluid TNFa levels correlate even beter than the IL-1 
levels with the disease activity in RA. The serum IL-lß levels 
correlate positively with serum TNFa levels [75,91], however, the 
IL-1 levels in synovial fluids are unrelated to the levels of TNFa, 
IL-2 or IFN-gamma.3 Nevertheless, Brennan et al. found that the 
spontaneous IL-1 production could be blocked by anti-TNFa 
antibodies in a culture of synovial lavage cells and isolated 
synoviocytes obtained from RA but not from OA [8.92]. They also 
analysed cellular composition (macrophages and T-cells) in the 
synovial lavage. Interestingly, higher IL-1 production are shown in 
synovial lavage with T-cell:macrophage ratio's greater than 1 
whereas the TNFa production is inversely related to the number of 
T-cells. Yanni et al. found that synovia from RA-patients 
characterized by multiple focal lymphoid aggregates of 
mononuclear cells, show higher IL-1 production than rheumatoid 
synovia with a disperse mononuclear cell infiltrate [93]. The 
infiltrating T-cells are probably TH1-cells as IL-2 and IFN-gamma 
are potent factors to prime fibroblasts [94] whereas the TH2 cell 
derived IL-4 and IL-10 are potent inhibitors of LPS-induced IL-1 
production [95,96]. 
One of the features of RA is cartilage destruction and 
several reports suggested a link with IL-1 bioactivity. Saxne et al. 
reported that synovial fluids and some of the sera of RA patients 
moderately increased degradation of viable bovine nasal septum 
cartilage and markedly inhibited chondrocyte proteoglycan (PG) 
synthesis [97]. Hollander et al. showed by immunoabsorbance in 
different patients that either IL-la, IL-lß, or TNFa were involved 
in the accelerated cartilage loss although the respective 
recombinant cytokines were not as effective in cartilage expiant 
cultures [98,99]. IL-1 was identified as the factor present in 
conditioned medium of RA-synovial membrane derived cells 
(macrophages and fibroblasts) to cause proteoglycan degradation 
in living cartilage [100] and not oxygen-radicals [101]. However, the 
concentrations of PG remnants in the synovial fluid or the 
inhibition of PG synthesis and degradation on cartilage expiants 
could not be correlated with the synovial fluid IL-lß concentrations 
[74]. It must be emphasized that Saxne et al. measured 
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immunoreactive IL-1 instead of the concentrations of bioactive IL-
1. The cytokines leukemia inhibitory factor (LIF) and basic 
fibroblast frowth factor (bFGF) are known to synergize with IL-1 
to cause cartilage destruction [102, 103]. However, a novel yet 
unidentified synovial fibroblast derived factor, chondrocyte 
activating factor (CAF), is implicated in the enhanced chondrocyte 
mediated cartilage breakdown [104]. CAF activity is distinct from 
IL-1, TNF, bFGF, IL-6, and IL-8. 
1.4 Evidence of IL-1 production in experimental models of 
arthritis. 
In the collagen-induced arthritis (CIA) model in rats, the 
spontaneous and LPS-stimulated IL-1 release is increased at the 
onset of arthritis and thereafter [105]. Interestingly, the 
lymphocytes from these rats also spontaneously produce high 
amounts of IL-2. Increased levels of bioactive IL-1 in the soluble 
compartment of bone marrow from tibia and femur precede the 
clinical onset of both adjuvant arthritis (AA) and CIA, and remains 
elevated during the course of arthritis [106]. The elevated levels of 
IL-1 coincide with a shift in the bone marrow cells from a 
predominant lymphoid population into a mixed population of 
myeloid cells and PMNs. At the local level, the course of IL-1 
production as found in whole joint extracts duplicated the course 
of footpad swelling, and is elevated for weeks in CIA in mice [107]. 
In contrast to the rise of IL-1 in the bone-marrow, the peritoneal 
macrophages from AA-rats spontaneously produce reduced levels 
of IL-1 compared to normal rats although equivalent amounts are 
detected after LPS-stimulation [105]. It is unclear whether the 
reduction in IL-1 levels found in the culture supernatant of 
peritoneal macrophages was due to the presence of IL-1 inhibitors 
(TGFß, IL-lra). 
Peritoneal macrophages from a rat strain sensitive for 
Streptococcal cell wall (SCW)-induced arthritis, produce more IL-1 
than macrophages obtained from a resistant strain after SCW-
peptidoglycan-polysaccharide stimulation and this is not due to 
differences in IL-lra production [108]. However, a causal 
relationship between the IL-1 release and the development of 
arthritis was not implicated by these studies. Bioactive IL-1 (8-16 
ng/ml) are also found in joint washes (1 ml saline) of inflamed 
joints at day 1 of antigen (ovalbumin)-induced arthritis in rabbits 
followed by a rapid decline thereafter with an IL-1 level of 
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approximately 25-50 pg/ml at day 4 [109]. The cellular origin of 
IL-1 is not elucidated. Leukocytes harvested from the synovial 
cavity produced high levels of IL-1 (11.9 ng/106 cells/24 h) at day 
7 and only small amounts at day 1 and 21. Furthermore, expiants 
of synovial lining of normal joints and inflamed joints at day 1 of 
arthritis produced about 1 ng/100 mg tissue/96 h, and levels 
increased upto 7 and 16 ng/100 mg tissue/96h at day 7 and 21, 
respectively. This indicate that PMNs, the predominant infiltrating 
cell at day 1 of arthritis, can not be the source of IL-1 present in in 
the synovial fluid at day 1. Furthermore, it suggest that the 
mononuclear cells are responsible for the IL-1 production. 
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Figure!. Role of IL-1 in arthritis. 
Circulating IL-1 levels correlates with parameters of disease activity, and IL-1 is 
implicated in some of the pathological changes in the arthritic joint. At the local 
level, numerous cells are capable of IL-1 synthesis. The extent of IL-1 production 
may depend on the arthritogenictrigger, number and composition of the infiltrating 
inflammatory cells, and the production of the IL-1 receptor antagonist protein (IL-
Ira). Spill-over of IL-1 from the circulation may affect the arthritic process in the 
joint. Abbreviations: ESR, erythrocyte sedimentation rate; TH1, T-helper cell type 1; 
1С, immunecomplex; PG, proteoglycan. 
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The fact that IL-1 could not be found in the synovial fluid after 
day 1 can be explained by the fact that IL-1 is not released into the 
cavity, masked by inhibitors, or under the stringent suppressive 
influence of mediators in situ. It is recently known that both 
monocytes and PMNs are capable of producing the IL-1 isotypes 
and the IL-1 receptor antagonist [77-79]. 
In the mouse model of antigen-induced arthritis, IL-1 
levels are assessed in a 1 h culture of articular specimen. We 
showed a rapid onset of IL-1 bioactivity within the first hours of 
AIA, high levels were found in expiants taken at 6 and 24 hours 
(30 pg/10 mg tissue/1 h), and declined thereafter [110]. In the 
immune-complex mediated arthritis (ICA) model in mice the IL-1 
production declined more rapidly and was absent at 24 h of 
arthritis. The latter may be related to the low antigen amount; 2 ¿ig 
mBSA, a dose equivalent to the antigen dose used in ICA, also 
induced a more transient IL-1 kinetic in AIA [111]. ICA induced in 
neutropenic mice demonstrated the same IL-1 production 
suggesting that PMNs play no role in this. 
The above findings have important consequences for 
timing of IL-1 blocking in vivo as IL-1 production increases prior 
or directly after onset of arthritis. As seen in AA, IL-1 production 
will often be limited to certain areas within the animal. For 
example, peritoneal macrophages of MRL-lpr autoimmune mouse 
do not spontaneously produce IL-1 during arthritis, although they 
expressed increased levels after LPS-stimulation identical to 
control BALB/c mouse [112]. 
Furthermore, these studies suggest that the macrophages 
are possibly the prime candidates of IL-1 production during the 
course of arthritis both at the local and at remote sites. In a recent 
publication, cytoplasmic IL-la is detected in macrophages of the 
synovial lining and sublining of experimental Staphylococcus aureus 
arthritis in mice [113]. 
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1.5 Framework of this study. 
It requires the fullfillment of several criteria to decide that a 
cytokine plays a major role in arthritis: first, the cytokine must 
cause or contribute to the type of pathology observed in arthritis; 
second, to show that there is sufficient cytokine present to cause 
the postulated effects; and third, to show that agents which 
selectively block the action of the cytokine can affect arthritis. 
In chapter 2 the effect of murine recombinant IL-la and 
IL-1/3 on the proteoglycan metabolism in murine articular cartilage 
was tested. Patellae were incubated with IL-1 and the chondrocyte 
proteoglycan synthesis and breakdown were measured with [ S]-
sulfate radiolabel incorporation. The marked effects of IL-1 on the 
proteoglycan metabolism in vitro was also evaluated in vivo. In 
chapter 3 it is shown that intra-articular injections of IL-1 into 
murine knee joints caused a prolonged suppression of the 
proteoglycan synthesis and a transient acceleration of proteoglycan 
degradation. Repeated IL-1 injections caused an arthritic insult and 
the mechanism of cartilage recovery was further investigated by 
detailed of proteoglycan synthesis and degradation in chapter 4. 
To prove that IL-1 played a role in the arthritic process 
mice were treated with neutralizing rabbit anti-IL-1 polyclonal 
antibodies. In chapter 5 the effects of the anti-IL-1 pre-treatment 
on antigen-induced arthritis are described. Anti-IL-1 treatment 
normalization the proteoglycan synthesis but had no effect on the 
onset of joint inflammation. In chapter 6 it is shown that anti-IL-1 
treatment had no effect on the accelerated breakdown in murine 
antigen-induced arthritis. In the comparative study of chapter 7, 
the in vivo roles of IL-1, IL-6 and TNF were examined in antigen-
induced arthritis and the non-immunologically mediated, zymosan-
induced arthritis, an acute inflammatory model in mice. Both IL-6 
and TNF were not involved in the suppression of the proteoglycan 
synthesis, however, IL-1 was responsible for the suppression in 
these models. The long-term effect of the IL-1 blockade on 
inflammation and cartilage proteoglycan matrix was studied in 
antigen-induced arthritis. 
The pro-inflammatory property of IL-1 was investigated 
and described in chapter 8. Intraarticular or systemic injections of 
IL-1 exacerbated the smouldering joint inflammation in the chronic 
phase of antigen-induced arthritis. In chapter 9 the role of IL-1 
was studied using anti-IL-1 antibodies in the T-cell mediated, 
antigen-induced exacerbations of AIA. In this phase, blocking IL-1 
dampened the inflammation and ameliorated cartilage destruction. 
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CHAPTER 2 
EFFECT OF MURINE RECOMBINANT INTERLEUKIN-1 ON 
INTACT HOMOLOGOUS ARTICULAR CARTILAGE: 
A QUANTITATIVE AND AUTORADIOGRAPHIC STUDY 
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Effects of murine recombinant interleukin 1 on intact 
homologous articular cartilage: a quantitative and 
autoradiographic study 
WIM В VAN D E N B E R G , 1 F O N S A J VAN D E L O O , 1 WIL A Z W A R T S , 1 
A N D IVAN G O T T E R N E S S 2 
From the 'Department of Rheumatology, University Hospital St Radboud, Nijmegen, The Netherlands, and 
the 2Department of Immunology, Pfizer Central Research, Groton CT 
SUMMARY Murine recombinant interleukin 1 (ILI) was tested for its ability to affect intact 
murine articular cartilage ILI caused enhanced proteoglycan degradation and severe inhibition 
of chondrocyte synthetic function at a concentration of 3 U/ml (100 pg/ml) Inhibition of 
proteoglycan synthesis appeared to be delayed in onset but occurred consistently after 24 hours 
Pulse chase experiments made it clear that proteoglycan degradation and inhibition of 
proteoglycan synthesis are two distinct actions of ILI No indications were obtained for selective 
degradation of either newly synthesised or processed proteoglycan Moreover, chondrocyte 
synthetic activity appeared to be inhibited uniformly throughout the cartilage matrix, ι e , no 
evidence was found for selective suppression of cells in certain regions ILI uptake measurement 
in the cartilage, using [ I 2 , I]IL1, yielded a partition coefficient far below 1, and autoradiography 
demonstrated a faint but even distribution within the cartilage matrix The coordinated induction 
of enhanced breakdown of proteoglycan and inhibition of proteoglycan synthesis, with such low 
concentrations of ILI reaching the chondrocytes, underlines the impressive destructive potential 
of ILI 
Key words proteoglycan synthesis, cytokines, murine cartilage 
The term interleukin 1 (ILI) was originally intro- breakdown of cartilage proteoglycans The substance 
duced to describe a 17 kilodalton protein, secreted responsible for this effect was termed cdtabolin 4 
by activated cells of the macrophage/monocyte Similar effects were described for mononuclear cell 
lineage, that augmented Τ cell proliferation to factor,5 a product of stimulated human blood 
mitogens and antigens ' This property was formerly monocytes When purified to homogeneity, catabolin 
known as lymphocyte activating factor (LAF) and mononuclear cell factor were shown to have 
activity It has now become evident that ILI can properties identical to those of ILI 6 7 It is now 
affect multiple cell types and functions For instance, known that ILI stimulates the release of metallo-
IL1 may mediate fever, hepatic secretion of acute proteinases from chondrocytes ^ 1 0 Interestingly, 
phase proteins, lymphocyte Chemotaxis, fibroblast ILl-like activity has been identified in synovial fluid 
proliferation, and alterations in bone metabolism 2 from patients with various types of joint disease " 1 2 
Recent work using recombinant ILI has confirmed Moreover.raisedlevelsofcartilagedenved proteases 
that these several biological activities reside within have been detected in cartilage specimens from 
one molecule 3 Earlier studies had suggested that patients with osteoarthritis l i 1 4 
ILI is also involved in cartilage destruction in In the present study we describe the effects of 
arthritic joints Coculture of cartilage and synovial munnerecombinantlLlonchondrocytemetabolism, 
tissue resulted in severe chondrocyte mediated using anatomically intact homologous articular 
cartilage—the murine patella Apart from an 
c ^ ^ J Z ^ T i L ^ Г „ ,
г
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" g «вес' on proteoglycan breakdown, ILI Correspondence to Dr Wim van den Berg Department of 
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Rheumatology University Hospital St Radboud 6525 G  w as shown to inhibit severely chondrocyte proteo-
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Autoradiography was performed to detect potential 
variability in ILI sensitivity of chondrocytes in 
various regions Finally, ILI was radiolabeled to 
determine its partition in intact cartilage 
Materials and methods 
P R E P A R A T I O N O F I L l 
The published amino acid sequence of murine ILla 
was used to synthesise a cDNA fragment and this 
was expressed in Escherichia coli The protein 
consisted of the carboxy terminal amino acids IIS 
to 270 of the II 1 propeptide The molecule was 
purified from inclusion bodies and refolded into the 
biologically active form (G Daumy to be published) 
Cyanogen bromide fragmentation was used for 
structural confirmation Biological activity was 
verified in multiple assays (Otterness et al in 
preparation) In the LAF assav the ILI was found to 
give 1 unit activity consistently in the 10-40 pg/ml 
range Screening for endotoxin activity (Limulus 
assay) was negative up to a concentration of 
100 μg/ml ILI The recombinant ILI preparation 
was stored at -20°C and showed consistent LAF 
activity over the period studied Experiments were 
performed with two batches of ILI prepared on 
different occasions Effects on chondrocyte 
synthesis and cartilage breakdown were completely 
similar 
1 Α Γ A C T I V I T Y 
Murine thymocytes from mice aged 6-7 weeks were 
cultured for four days in the presence of 1 \L%lm\ 
phytohaemagglutinin and various ILI concen­
trations Thymocytes were cultured at a concen­
tration of 107/ml in 200 μ| wells and ['Hjthymidine 
was added (37 kBqywell) during the last day One 
unit of LAF activity was defined as the ILI 
concentration gtving half the plateau of ILI induced 
comitogenic thymocyte proliferation 
C A R T I L A G t A S S A Y 
Whole murine patellae were isolated from C^7BI 
mice leaving the patella embedded in a minimal 
amount of surrounding tissue and used to measure 
chondrocyte metabolism as described previously ' s ' 6 
In brief, patella specimens were cultured in 
RPMI-5% fetal calf serum (How) under 4% C 0 2 
with or without ILI Culture medium was refreshed 
every day To determine chondrocyte proteoglycan 
synthesis the specimens were subsequently pulsed 
with 740 kBq [ S]sulphate/ml for three hours After 
washing, fixation in formalin (10%), and decalcifi­
cation in formic acid (VX>) the patella could easily be 
punched out of the adjacent tissue The 1 ,S content 
of each patella which is a reliable measure of the 
[^Slglycosaminoglycan content ' 7 ' 8 was measured 
bv liquid scintillation counting 
To measure the potential release of labelled 
proteoglycan into the medium 100 μΐ aliquots of the 
three hour [15S]sulphate pulse medium of control 
and ILI incubations were treated with 1% cetyl-
pyridinium chloride Non-labelled proteoglycan was 
added as a carrier After two hours at 37°C the 
precipitate was spun down at 10 000 g for 30 minutes 
and the pellet was washed five times with 0 1% 
cctvlpyndinium chloride to remove adherent 
(3,,S]sulphate r To correct for loss of [ ^ p r o t e o ­
glycan during this procedure the following standard 
was included in the experiment [3,S]proteoglycan 
(2000 cpm) from bovine cartilage supplemented 
with 74 kBq [^SJsulphate 
To determine II 1 mediated degradation the 
patellae were prelabelled with [3,Slsulphate (6-24 h) 
before ILI exposure After the culture period with 
ILI the amount of ^S retained in the patellar 
cartilage was measured and expressed as a percentage 
of the "S content of control cartilage cultured 
without ILI 
Ί ο enable comparison of ILI effects on newly 
synthesised and more extensively processed proteo­
glycans mice were injected intraperitoneal^ with 
74 kBq/g body weight and labelled patellae were 
isolated at days 1 2 and 4 The right patella was 
cultured in the presence of ILI for 24 hours and the 
left patella was cultured without ILI 
The ILI effect was always expressed in com­
parison with the value for the contralateral joint of 
the same animal This approach minimises variation 
due to intenndividual difference in "S incorpor­
ation " 
A U T O R A D I O G R A P H Y 
Patella specimens were fixed and decalcified as 
described above After histological processing 6 μπι 
sections were prepared and mounted on gelatin 
coated slides These were dipped in K, emulsion 
(Ilford, Basildon Essex Fngland) and exposed for 
three to five weeks After this period the slides were 
developed and stained with haematoxyhn and cosin 
C A R T I L A G E H I S T O L O G Y 
Patella sections were stained with alcian blue for 
24 hours The dve was solved in an acetate buffer 
(0 02^ M, pH S 4) at a concentration of 0 06%, in 
the presence of 0 3 M MgCli Decreased staining of 
the cartilage layer reflects loss of proteoglycan 
Similar results were obtained with Safranin О or 
Cuemsa staining 
U P T A K E O F R A D I O L A B E L I E D 11 I 
'
2 S I labelling of ILI was performed by the method of 
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Bolton-Hunter Iodinated ILI was separated from 
free 1 2 5I by Sephadex G 25 fractionation The 
labelled preparation retained full biological activity, 
and the specific activity was approximately 
37 IcBq^g 
Patellae were incubated with [125I]IL1 in phos­
phate buffered saline (pH 7 4) for various time 
periods at 37°C At the end of the incubation the 
specimens were nnsed once, blotted dry, and fixed 
in 10 ml of 2 5% glutaraldehyde or formalin 
(10%)/ethanol for 30 minutes This was followed by 
decalcification in 5% formic acid overnight After a 
short fixation period the whole cartilage layer can 
easily be stripped from the underlying bone,'7 and 
the amount of [I2,I]IL1 present in the cartilage can 
be counted The procedure of fixation of cartilage 
associated protein allows the release of free I 
from the tissue slight contamination of labelled 
protein solutions with free 1 2 5I would otherwise 
introduce significant errors owing to the relatively 
high uptake of free 1 2 SI compared with that of poorly 
penetrating proteins The uptake of [I2,I]IL1 is 
expressed as a partition coefficient, which is the 
concentration in the cartilage divided by the concen­
tration in the incubation medium To obtain the 
partition volume of the patellar cartilage strip the 
cumulative wet and dry weights of 10 specimens 
were determined The fluid phase of one patella 
strip was approximately 0 05 μΙ 
Results 
I N H I B I T I O N OF C H O N D R O C Y T E 
P R O T E O G I Y C A N S Y N T H E S I S 
Initially, whole patellae were incubated with various 
concentrations of murine recombinant ILI for 
48 hours, followed by a three hour pulse with 
[35S]sulphate, to define the effective concentration 
range of ILI ILI caused a dose dependent inhibition 
of p5S]proteoglycan synthesis (Table 1) Concen 
Table 1 Dose dependent effect of ILI on J ' S incorporation 
ILI "S incorporation! Inhibition (%) 
concentration * (cpmlpalella) 
(Ulml) 
— 357 (33) — 
0 03 345 (19) 3 
0 1 309 (25) 13 
0 3 288 (34) 19 
1 0 227 (32) 36 
3 0 161 (39) 55 
10 0 125 (37) 65 
30 0 139 (31) 61 
Patellae were incubaled for 48 hours 
*Values are U/ml based on thymocyte proliferation 
tValues are the mean (SD) of six cartilage specimens 
trations of ILI of 0 1 U/ml or below were essentially 
without effect A plateau of maximal inhibition was 
reached at ILI concentrations of 3 U/ml and higher 
In multiple experiments inhibition ranged between 
50 and 65% with an ILI concentration of 3 U/ml 
Control incubations with recombinant IL2 
(Amersham, England), tested in doses up to 
30 U/ml, failed to inhibit proteoglycan synthesis To 
verify that we were really measuring ILI mediated 
inhibition of synthesis and not enhanced breakdown 
of new proteoglycan synthesised at the same rate we 
checked the culture supernatant for labelled proteo­
glycan fragments The amount released during the 
three hour 3 ,S pulse period was less than 10% of the 
amount incorporated in the cartilage for both the 
control incubation and after 48 hours of ILI 
exposure, and was therefore negligible 
Next, the effect on sulphate incorporation of time 
of exposure to ILI was explored After 24 hours ILI 
exposure the suppression of chondrocyte synthesis 
( S incorporation) was variable (5-20%), only 
rarely reaching statistical significance Exposure of 
patellar cartilage to II1 for 48 hours consistently 
resulted in extensive inhibition of proteoglycan 
synthesis (Table 2) This effect seem« not to depend 
upon exposure of the cartilage to ILI for 48 hours as 
incubation with ILI for 24 hours followed by a 
Table 2 Time dependence of ILI effect on synthesis 
Time ÍL1 , s i incorporation^ Inhibition (%) 
(h) (Ulml) (cpmlpalella) 
24 — 737 (163) — 
24 3 575 (86) 22 
48 — 626 (95) — 
48 3 288 (46) 54' 
Patellae were exposed lo ILI for 24 or 48 hours followed by a 
three hour pulse with |"S]sulphale 
*p<0 U01 compared with 24 hour value (Mann Whitney) 
tValues are the mean (SD) of six cartilage specimens 
Table 3 Time lag in ILI effect on synthesis 
Incubation 
with 
ILI 
(h) 
— 
3 
24 
48 
Length 
of 
chase 
(h) 
48 
45 
24 
— 
355 incorporation' 
(cpmjpatetla) 
540 (67) 
452 (35) 
294 (52) 
278 (35) 
Inhibition 
(%) 
16 
46 
49 
ρ Vatuet 
0 001 
NS 
Patellae were incubated with ILI (3 U/ml) for various periods, 
followed by a chase without ILI At the end of the incubation 
patellae were pulsed with [35S]sulphate for three hours 
•Values are the mean (SD) of six cartridge specimens 
tp Values compared with 48 hour ILI exposure (Mann Whitney) 
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24 hour incubation with medium only led to the 
same total effect (Table 3). These data indicate that 
ILI mediated suppression of chondrocyte proteo­
glycan synthesis is delayed in onset. We never 
observed a suppression exceeding 2 5 % at 24 hours, 
even with ILI concentrations up to 1(X) U/ml. This 
indicates that slow diffusion of ILI into the cartilage, 
reaching a sufficient level of ILI near the chondro­
cyte in a retarded fashion, cannot be the reason for 
this time lag. We also looked for selective effects of 
ILI on chondrocyte incorporation of [3 5S]sulphate 
in different regions of the patella by performing 
autoradiography on semiserial patellar sections of 
cultured specimens. Uniform labelling of the 
cartilage layer was obtained after 48 hours' culture 
and three hours' [ ' ^ s u l p h a t e exposure (Fig. la) . 
When the patellae were cultured in the presence of 
I L I . clear cut suppression of labelling intensity was 
observed (Fig. lb). No evidence was obtained for a 
differential sensitivity to ILI when the central or 
marginal regions, or the chondrocytes in superficial 
and deeper layers, were compared. 
DEGRADATION OF ['" S 1 Ρ R ОТ EO G L Y С A N S 
Patellae prelabelled with [ "Sjsulphate for six hours 
were cultured with or without I L I . and the amount 
of S retained in the patellar cartilage was deter­
mined. Significantly less , 1 S was retained in cartilage 
cultured in the presence of ILI (Table 4). indicating 
that proteoglycan degradation was enhanced. The 
action of ILI was not influenced by the presence of 
fetal calf serum in the medium (Table 4). When 
larger concentrations of ILI (up to 100 U/ml) were 
used, only slightly higher effects on breakdown were 
seen; not always reaching statistical significance 
compared with effects obtained with 3 U/ml. 
To investigate whether there might be a prefer­
ential effect of ILI on newly synthesised proteo­
glycan compared with older, more fully processed 
proteoglycan we carried out the following experi­
ment. Effects of ILI were compared on cartilage 
with variably processed proteoglycans, and for 
optimal physiological processing of labelled proteo­
glycans labelling was performed in vivo. From 
earlier studies it was known that the amount of 
[^Sjproteoglyean in patellar cartilage, after a single 
injection of [ , 5S]sulphate. reaches a plateau 
between two and six hours and gradually decreases 
thereafter. I S Therefore the effect of ILI on patellar 
cartilage isolated on days 1. 2. or 4 after [ , 5S]sulphate 
injection was determined (Table 5). Patellae taken 
at day 1 or 2 and cultured for 24 hours in the 
presence of ILI both contained significantly less , 5 S 
than those cultured in the absence of ILL The 
enhancement of ILI mediated breakdown was of the 
same order of magnitude for days 1 and 2. A similar 
result was found when the comparison was made 
between days 1 and 4. We repeated this experiment 
Table 4 //./ mediated breakdown 
"S Labelling' 
(hi 
6 
6 
li 
li 
24 
24 
ILI 
tU mil 
ì 
— 3 
— 3 
Fetal 
cat) 
serum 
<%) 
— 
— 5 
5 
5 
S 
aS content* 
cpmlpatetla 
1047 (179) 
775 (151) 
1(160 (244) 
748 (ПО) 
1897 (183) 
1367 (189) 
%t 
— 
74 
— 71 
— 72 
'Patellae were prelabelled with ['sS|sulphatc for cither six or 
24 hours, followed by incubation for 24 hours with or without ILI 
fValues are the mean (SD) of six cartilage specimens 
ІCompared with its proper control 
ЩЩЩЯЩЩШ ЪЯр&щяяет 
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Fig. 1 Autoradiography of patellar cartilage after 48 noun ' exposure to (a) medium or to <b) J V ¡LI Imi. followed bv a 
three hour pulse with / ' ' S¡sulphate. Note the distinct labelling in (a) and the uniformly diminished labelling above all cells 
after ILI exposure in lb). p=palella. 
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Table 5 Comparison of the effect of ILI on newly labelled 
and more processed proteoglycan 
Experiment' 
A 
Λ 
A 
A 
В 
В 
в 
в 
Timi 
(h) 
24 
24 
48 
48 
24 
24 
96 
96 
ILI 
(UI ml) 
— 
3 
— 3 
— 3 
— 3 
"S coment* 
cpmlpalellít 
248 (63) 
185 (39) 
228 (63) 
180 (42) 
380 (108) 
275 (59) 
302 (76) 
221 (47) 
%í 
— 
75 
— 79 
— 72 
— 73 
Patellae were isolated and cultured lor 24 hours with or without 
ILI. one patella without and the contralateral patella of the same 
animal with ILI. 
"Mice were given an injection with 1-85 (cxp A) or 2-78 (exp B) 
MBq [,sS)sulphatc 
tValues are the mean (SD) of cartilage specimens of seven mice 
^Compared with its proper control. 
three times, with identical results. Finally, to verify 
that these results were not an artefact of radio-
labelling, patellae were cultured for two days and 
then stained histologically. ILI induced clear 
depletion of proteoglycan in the metabolically active 
superficial layer of the patella (Fig. 2). 
I L I U P T A K E I N C A R T I L A G E 
ILI was radiolabelled to permit measurement of its 
effective concentration in cartilage. The labelled 
preparation retained full biological activity as tested 
in the cartilage and in the LAF assay. Patellae were 
incubated with [ I2T]IL1 for various time periods 
The uptake reached equilibrium within 30 minutes, 
but the partition coefficient of the anionic ILI (pi 5) 
remained far below 1 (Table 6). 
A partition coefficient of 0-2 indicates that the 
local concentration is about five times less than the 
ILI concentration in the incubation medium. In 
contrast, the cationic protein amidated bovine 
serum albumin (aBSA; pi 8-5-9)19 2" accumulated 
to a high extent in the cartilage and equilibrium was 
not reached even after four hours (Table 6). 
Figure 3 depicts the autoradiography of ILI and 
aBSA partition. In contrast with the high affinity of 
aBSA for the patellar cartilage (Fig. 3b), ILI was 
predominantly taken up by the surrounding tissue 
(Fig. 3a). Higher magnification of the cartilage 
(Figs 3c and d) showed that most of the ILI 
radiolabel was present as a superficial lining layer, 
and that the quantitative measurement of the 
partition (Table 6) strongly overestimated the actual 
concentration within the matrix. If. after [125I]IL1 
exposure, the patella specimens were washed with 
saline and then prepared for autoradiography, 
labelling was no longer detectable, either at the 
cartilage surface or within the matrix. The label 
present within the matrix showed a diffuse pattern 
over the whole cartilage area. 
O T H E R E F F E C T S OF M U R I N E R E C O M B I N A N T 
I I I 
Murine ILI (pi 5) was examined in a number of 
Table 6 ILI uptake m patellar cartilage 
Incubation tune 
10 
3D 
6(1 
1211 
240 
Partition 
ILI 
0-08 
1) 15 
016 
0-14 
(i 16 
coefficient* 
aBSAt 
3-8 
N1) 
10 4 
20-2 
33-7 
"The partition coefficient is defined as the concentration in the 
cartilage divided by the concentration in the surrounding fluid 
taBSA-amidated bovine scrum albumin; ND~not done. 
s Ss 1 1 s K% Ш\L· Fig. 2 Staining of the patellar cartilage after 48 hours ' ILI 
exposure. Note the distinct loss of 
staining in the superficial layer, 
which is the metabolically active 
part of the cartilage (see Fig. 1). 
Halo formation around 
chondrocytes was not evident. 
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Fig. 3 Autoradiography, four hours after incubation of patellae with (a, e, dì l'elfi LI or with fb) amidated bovine serum 
albumin l[i:<illaBSA). (af ILI is predominantly present in the surrounding connective tissue and ligament structures. 
(b) The catiotuc protein aBSA shows a high affinity for the patellar cartilage (arrows) and deeply penetrates the matrix. 
(c) and (di are at higher magnification than (a) to show that 11.1 is hardly present within the cartilage matrix. p=patella; 
i—ligament. 
other assays to compare its activity with that of 
native ILI. In vivo, in the mouse, we found it to 
induce fever, leucocytosis. i.e.. elevation of granulo-
cyte numbers, and acute phase reactant synthesis 
(serum amyloid A). In vitro it induced proliferation 
of thymocytes in the LAF assay. In the latter assay 
the ILI was found to give 1 unit of activity 
consistently in the 10-40 pg/ml range. Preliminary 
experiments further indicated that the ILI 
preparation also caused cartilage breakdown and 
proteoglycan synthesis inhibition in vivo upon intra-
articular injection in knee joints (manuscript in 
preparation). 
Discussion 
The present study demonstrated that murine 
recombinant ILI not only enhanced proteoglycan 
breakdown but also extensively inhibited chondro-
cyte proteoglycan synthesis in intact murine articular 
cartilage. As a control the lymphokine IL2 was 
without effect. The combined effects of enhanced 
proteoglycan breakdown and inhibition of restoration 
underline the destructive potential of ILI in disease 
states characterised by ILI overproduction. 
ILI mediated loss of proteoglycans from the 
cartilage matrix does not seem to be a selective 
process. Newly -synthesised proteoglycan and 
proteoglycan processed for four days are affected 
equally (Table 5). Earlier studies with catabolin 
yielded similar results. Release of newly synthesised 
(labelled) proteoglycans and unlabelled proteo-
glycans from catabolin treated cartilage followed the 
same pattern.21 These data are consistent with free 
diffusion of catabolic enzymes away from the 
chondrocyte. It implies that stimulation of proteo-
glycan breakdown is not dependent upon tissue 
proximity to the chondrocyte. 
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Upon stimulation with ILI chondrocytes have 
been shown to release metalloproteinases capable of 
degrading both collagen and proteoglycan8 2 2 
Enzymes found in the medium of ILI treated 
cartilage cultures are in the latent form and must be 
activated before thev can be enzymatically assayed 2 2 
This suggests that ILI stimulated the release of 
latent metalloproteinases from chondrocytes and 
that a proportion of the enzyme is activated in situ in 
the matrix Suggestive evidence for this mechanism 
stems from detailed analysis of cartilage proteo­
glycans after stimulation with ILI 2 1 
In addition to proteoglycan degradation, ILI 
induced extensive inhibition of chondrocyte proteo­
glycan synthesis This inhibition appears to be 
retarded in onset Effects were variable and not 
impressive at 24 hours but very significant at 
48 hours A similar delay in onset of action was 
described for catabohn So far, the second 
messenger involved in the effect of ILI on synthesis 
has not been elucidated A recent report, however, 
clearly demonstrated the presence of specific ILI 
receptors on chondrocytes " One could argue that 
the time lag in ILI action on proteoglycan synthesis 
is compatible with the suggestion that II 1 may 
stimulate new synthesis of degradative enzymes and 
that the apparent inhibition seen at 48 hours is 
therefore due to a high level of proteoglycan 
degrading enzymes and more severe breakdown of 
new proteoglycans svnthesised at a normal, ι e , 
unchanged, rate No evidence has been found 
however, for a faster, more extensive degradation of 
newly synthesised proteoglycan during the short 1SS 
pulse after long term ILI exposure Tyler did not 
observe enhanced amounts of " S labelled proteo 
glycan fragments in the culture medium of such ILI 
treated and briefly 35S pulsed cartilage,24 and in this 
study we obtained similar results Moreover, our 
pulse chase experiment made it clear that 24 hour 
ILI exposure, followed by a chase without ILI, 
resulted in the same extent of inhibition of synthesis 
(Table 3) This makes it highly unlikely that the 
inhibition of synthesis is due to enhanced breakdown 
as it is known that proteoglycan breakdown ceases 
within 24 hours of removal of ILI 2 1 Taken together, 
our data clearly indicate that ILI has two effects on 
cartilage firstly, enhanced degradation of proteo 
glycan, secondly, extensive inhibition of proteoglycan 
synthesis via an as yet unknown mechanism 
ILI has to penetrate the cartilage before it is 
active Uptake of a protein in hyaline cartilage 
depends on both its size and charge Earlier studies 
from our group showed that proteins with an 
isoelectric point (pi) above 8 5 have a high affinity 
for the negatively charged cartilage and easily 
penetrate and accumulate in the dense 
matrix 1 9 Μ ^ 2 8 The data obtained for ILI uptake 
in the present study indicate a partition coefficient 
of 0 2, pointing to concentration of mediator inside 
the cartilage five times lower than in the surrounding 
fluid This value is consistent with published results 
for cartilage distribution of other anionic proteins of 
similar molecular weight 2 9 Our autoradiography 
made it clear however, that most of the radiolabel 
was located at the surface and that the actual II 1 
concentration within the matrix was far less These 
observations stress the need for autoradiographic 
control of radiolabel studies The high amount of 
label at the surface is just a consequence of the 
technique used and does not reflect ILI binding at 
that site In uptake studies patella specimens are not 
washed and surface binding of attached label does 
occur after fixation When washed with saline 
before fixation, this label is not detectable anymore 
Another relevant issue in uptake studies with 
labelled proteins is the potential change in behaviour 
due to labelling We chose the mild ìodination 
according to Bolton-Hunter and checked that the 
[12,I]IL1 retained its full biological activity in our 
cartilage assay Moreover, at most one l2 ,I molecule 
is introduced per ILI molecule, making a behavioural 
change highly unlikely Loss of activity in our 
cartilage assay was clear cut after choramine-T 
lodination of ILI (data not shown) Earlier 
observations from our laboratory have indicated 
that penetration of anionic proteins increases when 
the cartilage matrix is depleted of proteoglycans 2" 26 
This indicates that ILI penetration and interaction 
with chondrocytes could be expected to increase in 
already damaged cartilage of an inflamed joint 
Thus ILI effects may be slightly higher in fibrous 
cartilage than in dense hyaline cartilage owing to 
penetration differences Although the two forms of 
this mediator, ILla (pi 5) and ILlß (pi 7-8), differ 
considerably in isoelectric point, neither form has a 
pi above 8 5, and even ILlß would not be expected 
to accumulate in hyaline cartilage 28 Slight differ-
ences in potency between ILla and ILlß, as noted 
in cartilage assays,7 are not likely to be caused by 
disparity in uptake, and probably relate more to 
differences in ILI chondrocyte (receptor) inter-
action 
In experimental models of murine joint inflam-
mation, such as zymosan or antigen induced arthritis, 
chondrocyte proteoglycan synthesis was already 
significantly suppressed at day 1 l6 3" From the 
present kinetic data it seems unlikely that ILI is 
directly responsible for this early suppression 
Diffusion of mediators of acute inflammation such 
as hydrogen peroxide31 or neutrophil enzymes such 
as elastase32 may play a part in this early phase 
After the first day ILI seems a likely candidate for 
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the continuing suppression of proteoglycan synthesis 
The suppression found in the models of experimental 
arthritis was of the same order of magnitude 
(50-60%) as that obtained with ILI in vitro In vivo 
it was observed that there was a higher vulnerability 
of chondrocytes in certain regions of the articular 
cartilage 3" For instance, suppression of sulphate 
incorporation was more pronounced in chondrocytes 
of the central area of the patellar cartilage than in 
the margins w Evidence for an enhanced suscept­
ibility of particular chondrocytes to ILI effects was 
not observed in vitro in the present study This could 
indicate that ILI is not the mediator of the cartilage 
damage seen in these models In vivo however 
load bearing mav give rise to regional differences 
Moreover diffusion of proteolytic inhibitors or 
other protective factors from the margins supplied 
in vivo, may lead to more pronounced suppression 
in the central area 
The importance of ILI as a mediator of cartilage 
destruction in chronic destructive arthritis is yet to 
be determined ILI activity has been detected in 
synovial fluid of patients with rheumatoid arth 
ritis u 12 Inhibitors are also present in high amounts 
however and measurement of consistent ILI activity 
depends upon separation of ILI and its inhibitors by 
gel chromatography 1 J ^ Some inhibitors appear 
only able to block the ILI comitogenic assay ' 7 
but recently an inhibitor has been described which 
blocked fibroblast collagenase production w and 
this may be an important regulator of tissue destruc 
tion II1 must penetrate cartilage and escape from 
(local) inhibitors before it is active The recent 
observation that ILI could induce joint inflam­
mation and cartilage degradation provides 
further evidence for its role as a kev mediator 
Experiments with selective (synthetic) inhibitors of 
ILI effects or ILI synthesis and release are needed 
to elucidate this issue fully 
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CHAPTER 3 
EFFECT OF MURINE RECOMBINANT INTERLEUKIN-1 
ON SYNOVIAL JOINTS IN MICE: 
MEASUREMENTS OF PATELLAR CARTILAGE 
METABOLISM AND JOINT INFLAMMATION 
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Effects of murine recombinant interleukin 1 on 
synovial joints in mice: measurement of patellar 
cartilage metabolism and joint inflammation. 
A A J van de Loo, W В van den Berg 
Abstract 
Murine recombinant interleukin 1 was injected intra-articularly into 
mice. It induced a clear effect on patellar cartilage within 24 hours. A 
low dose of interleukin 1 (1 ng) elicited a significant reduction in 
[35S]sulphate incorporation (50%) into proteoglycans and an accelerated 
breakdown (twofold) of 35S prelabelled proteoglycan. Proteoglycan 
breakdown returned to normal rates (*10%/day) 48 hours after a single 
interleukin 1 injection. Recovery of proteoglycan synthesis was delayed 
up to 72 hours, however, which implies that repair of the depleted 
cartilage matrix is retarded. Interleukin 1 induced only minor joint 
inflammation, too slight to be held responsible for the strong suppression 
of proteoglycan synthesis. Vehement joint inflammation was found after 
repeated interleukin 1 injections. The plasma extravasation and massive 
infiltration and exudation of leucocytes, predominantly 
polymorphonuclear leucocytes, were not a mere summation of single 
interleukin 1 effects, but point to interleukin 1 induced local 
hypersensitivity. The cartilage matrices of patella and femur were 
heavily depleted. Measurement of the extent of loss of 35S prelabelled 
proteoglycan and the prolonged inhibition of [35S]sulphate incorporation 
indicate that both inhibition of proteoglycan synthesis and enhanced loss 
of proteoglycan contributed substantially to this depletion. 
Interleukin 1 is a 17 kilodalton soluble unglycosylated protein, secreted by 
activated cells of mononuclear origin. Two forms have been described, 
interleukin l a and interleukin Iß, which are related proteins that bind to the 
same receptor and show roughly the same biological effects.1"3 This 
ubiquitous mediator displays many inflammatory and immunoregulatory 
activities.1"5 After systemic administration interleukin 1 gave rise, for 
example, to an acute phase response, enhanced immunoglobulin production, 
and protection against bacterial injury.6"10 Apart from systemic effects, 
related to high concentrations of circulating interleukin 1 during 
inflammatory processes,11 interleukin 1 may also play a more direct part in 
local inflammatory events. It has been shown that interleukin 1 injected into 
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the skin attracted neutrophils, leading to microvascular injury.12"14 Moreover, 
interleukin 1 enhanced the binding of lymphocytes to endothelial cells and 
promoted Chemotaxis of these cells.15"20 Recombinant interleukin 1, injected 
directly into rabbit knee joints induced only minor inflammation,21 but it was 
highly effective in causing an exacerbation of the arthritic process in a 
previously injured joint.22 The important role of interleukin 1 in arthritis is 
further substantiated by the observation that it is produced by the arthritic 
synovium23"24 and it can be detected in substantial amounts in synovial 
fluids.25"29 Whether interleukin 1 is the predominant pathological messenger 
or only one of many effector cytokines in arthritis remains is still unknown. 
In addition, interleukin 1 may contribute to connective tissue ac­
tivation and cartilage destruction. In vitro studies have shown that interleukin 
1 (catabolin) added to living expiants of cartilage induces loss of matrix 
proteoglycans and inhibition of synthesis of proteoglycans.30'37 In vivo 
studies with purified interleukin 1 showed significant loss of proteoglycans 
and inhibition of proteoglycan synthesis after intra-articular injection, and the 
presence of clear joint inflanimation.n~® Recent studies with recombinant 
interleukin 1 disclosed only minor signs of inflammation. Nevertheless, 
proteoglycan loss was clearly shown and it was concluded that degradation 
of cartilage induced by interleukin 1 was unrelated to inflammation.21 41 
Effects on proteoglycan synthesis were not determined. We studied the 
impact of recombinant murine interleukin 1 after single and repeated 
injections in the murine knee joint. Special attention was paid to 
measurement of both the inflammation and two indices of cartilage 
destruction-proteoglycan loss and inhibition of proteoglycan synthesis. 
Materials and Methods 
ANIMALS 
С57Ы/10 mice aged 8-10 weeks at the start of the experiments were used. 
They were fed a standard diet and tabwater freely. 
CHEMICALS 
Recombinant interleukin l a and interleukin Iß were kindly supplied by Dr I 
G Otterness (Pfizer Central Research, Groton CT). Biological activity was 
verified by a lymphocyte activating factor assay. The interleukin 1 gave 1 
unit activity consistently in the 10-40 pg/ml range. Screening for endotoxin 
activity (Limulus assay) was negative up to a concentration of 100 Mg/ml. 
The recombinant interleukin 1 preparation was stored at -20°C and showed 
consistent lymphocyte activating factor activity over the period studied. 
Zymosan A was obtained from Sigma (Saccharomyces cerevisiae, n° 
Z-4250). Zymosan (30 mg) was dissolved in 1 ml saline through heating up 
to 100°С twice, then sonicated to obtain a homogeneous suspension. Batches 
were stored at -20°C. 
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LYMPHOCYTE ACTIVATING FACTOR ACTIVITY 
Murine thymocytes from mice, aged 6-7 weeks, were cultured for four days 
in the presence of 1 ^g/ml phytohaemagglutinin and various interleukin 1 
concentrations. Thymocytes were cultured at a concentration of 107/ml in 
200 μΐ wells, and pHjthymidine was added (37 kBq/well) during the last 
day. One unit of lymphocyte activating factor activity was defined as the 
interleukin 1 concentration giving half the plateau of comitogenic thymocyte 
proliferation induced by interleukin 1. 
INTRA-ARTICULAR INJECTIONS 
Recombinant interleukin 1 or Zymosan was injected through thesuprapatellar 
ligament into the left knee joint space. In experiments investigating the 
proteoglycan metabolism the contralateral joint received an equal volume (6 
μΐ) of saline. In the technetium uptake experiments only an incission into the 
skin was made in the contralateral knee. In these experiments a control 
group was included, in which saline was injected into the left knee joint. 
From the latter experiments it became clear that saline neither induced 
measurable joint inflammation nor influenced proteoglycan metabolism. 
T c UPTAKE MEASUREMENTS 
Joint inflammation was determined by measurements of T c pertechnetate 
uptake in the knee joints.42 Briefly, animals were sedated by intraperitoneal 
administration of 4.5% chloral hydrate, 0.1 ml/10 mg of body weight. 
Approximately 370 kBq ""Tc in 0.2 ml saline was injected subcutaneously 
in the neck region. After 15 minutes the accumulation of isotope in the knee, 
owing to increased blood flow and tissue swelling, was determined by 
external gamma counting. The severity of inflammation was expressed as the 
ratio of the " T c uptake in the left (zymosan or interleukin 1 injected) over 
that in the right knee joint. 
BREAKDOWN OF [35S]PROTEOGLYCANS 
To study in vivo degradation of patellar cartilage, proteoglycans were 
prelabeled with Na^SCv [3SS]Sulphate (1.85-3.7 MBq) was injected 
intraperitoneally 24 hours before intra-articular injection of interleukin 1, 
and patellae were isolated at various time points thereafter. Before intra­
articular injection (t=0) one group of six mice was killed and the 35S content 
was measured. Breakdown of proteoglycans was expressed as the loss of 
[33S]sulphate compared with the 35S content of control patellae taken at t=0. 
SYNTHESIS OF PATELLAR PROTEOGLYCANS 
Proteoglycan synthesis was measured ex vivo. Patellae were dissected, 
leaving a minimal area of non-cartilaginous tissue surrounding the cartilage. 
The patellae (five to six specimens) were placed in 2 ml of incubation 
medium consisting of RPMI-HEPES (Ñ-2-hydrxyethylpiperazine-W-2-
ethanesulphonic acid; Flow Laboratories, Irvine, Scotland) with added 
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penicillin (100 units/ml), streptomycin (100 Mg/ml), and L-glutamine (2 
mmol/1) and 74 kBq 35S04. Labelling was continued for three hours. At the 
end of the incubation period the patellae were fixed overnight in 10% 
formalin and decalcified in formic acid (5%) for four hours. The patella 
could then easily be punched out of the adjacent tissue and was dissolved in 
0.5 ml Luma solve (Hicol, Oud-Beijerland, The Netherlands) at 60°C for 
four hours. The MS-content of each patella, which is a reliable measure of 
the [35S]gIycosaminoglycan content,43 was measured by liquid scintillation. 
IODINATION OF INTERLEUKIN 1 
About 25 μg interleukin la was radiolabelled with 125I 
(Amershamlnternational, Buckinghamshire, UK) by the Bolton and Hunter 
method. The iodinated protein was smaller than 17 kilodaltons as shown by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis, and more than 
90% of the radiolabelled preparation could be precipitated with goat anti-
mouse interleukin la antisera. The labelled preparation also retained full 
biological activity. 
INTERLEUKIN 1 RETENTION MEASUREMENTS 
125I labelled interleukin 1 (800 units) was injected into the right knee joint 
and saline into the left knee joint. At various hours thereafter the 125I 
radioactivity of both knees was measured by external gamma counting. 
Values for the right knee were corrected according to the value for the left 
knee, which represents background activity. Retention was expressed as a 
percentage of the initial count rate measured immediately after 
[125I]interleukin 1 injection. In addition, quantitative measurements were 
made on dissected patellae. 
AUTORADIOGRAPHY 
Dry deparaffinised tissue sections of whole patellae were covered by a 
photographic K5 emulsion (Mord, Basildon, Essex, UK), and exposed for 
three to five weeks. After this period the slides were developed and stained 
with haematoxylin and eosin. 
HISTOLOGY OF KNEE JOINTS 
Histological scoring of the inflamed knees was carried out after dissection 
and processing.44 Standard frontal sections (6 μτή) were prepared and stained 
with haematoxylin and eosin, Giemsa stain, or with safranin O, which 
enables identification of neutrophils and eosinophils. Eosinophils were not 
seen after interleukin 1 injection. The arthritic score was determined by 
grading the infiltrate and the exudate from 0 to + + + , where 0=no change, 
and + + + =large numbers of cells. The scoring of cartilage depletion was 
done on safranin О sections and depletion was graded from 0 to + + + in 
accordance with the degree of loss of staining in the superficial, 
metabolically active cartilage layer. 
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Resulte 
SUPPRESSION OF THE PROTEOGLYCAN SYNTHESIS 
Interleukin 1 induced marked changes in the metabolism of cartilage in vivo. 
The suppression of proteoglycan synthesis in patellar cartilage 24 hours after 
intra-articular injection was dependent on dose (fig 1). There was 
considerable inhibition of proteoglycan synthesis at low doses (3 U) of 
interleukin 1, and 30 U interleukin 1 (about 1 ng) was sufficient to decrease 
the proteoglycan synthesis to 60% of normal. Recombinant murine 
interleukin Iß was as potent as interleukin la in the suppression of 
proteoglycan synthesis (table 1). The in vivo potency of interleukin 1 was 
further shown by the rapid appearance of the interleukin 1 effect. With 30 U 
of interleukin 1 the proteoglycan synthesis showed maximal suppression at 
24 hours, which remained high for up to 48 hours and declined thereafter 
(fig 2). 
When a high dose of interleukin 1 (300 U) was used the suppression 
was greater at 48 hours than with lower doses, though not reaching statistical 
significance compared with 24 hours; suppression was still observed at 72 
hours. Restoration of proteoglycan synthesis was inconsistent. The mean 
value (75% of normal proteoglycan synthesis) was an average that included 
animals which showed full recovery and some animals still with full 
suppression. Although a lower dose of interleukin 1 (30 U) induced the same 
suppression at 24 and 48 hours as 300 U, there was complete recovery of 
proteoglycan synthesis at 72 hours and sometimes enhanced proteoglycan 
synthesis. An overshoot to enhanced synthesis was more marked at later time 
points (data not shown), and this phenomenon contributes to accelerated 
recovery of the depleted matrix. 
Table 1: Comparison of effects of interleukin la (ILla) and interleukin Iß (ILlß) on patellar 
cartilage homeostasis. 
Dose 
(U) 
О 
3 
30 
300 
Synthesis at t-
cpm/patella 
ILla 
626 (41) 
470 (95)" 
290 (22)~ 
242 (20)-
ILlß 
616 (76) 
555 (75) 
269 (18)" 
270 (25)" 
=24 h 
% Of saline 
ILla ILlß 
100 
75 
47 
38 
100 
90 
44 
43 
Breakdown and loss of ¡ 
t=24 h t=48 h 
ILla 
11 
27 
miß 
15 
22 
ILla. 
21 
31 
f'SJsulphate1 
1 
ILlß 
30 
37 
The proteoglycan synthesis after interleukin 1 injection was significantly suppressed- * 
ρ<0.05, ** ρ< 0.001 -as calculated with Student's t test. This representative experiment was 
carried out with groups consisting of six mice each. Values are mean (SD). 
# The 35S content was determined at 24 and 48 hours and the loss of label was expressed as a 
percentage of the 35S content at t=0 (151 (25) cpm/patella). 
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Proteoglycan eyntheele (% of control) 
110 
100 
•о 
во 
70 
во 
со 
40 
S 30 300 
Dose Intorleukk) I (unite) 
Figure 1: Proteoglycan synthesis suppression by interleukin 1. 
Interleukin la was intra-articularly injected into mice; the contralateral knee joint received 
saline. After 24 hours the patellae were dissected and cultured in tissue medium supplemented 
with I11'SJsulphate for three hours. Proteoglycan synthesis was expressed as a percentage of 
control S incorporation in the contralateral. The values represents the mean (SD) of at least 
four experiments consisting of six animals each. Significant differences with respect to saline are 
indicated with * (p < 0.001, Student's t test) and calculated from the cpm values. 
Proteoglycan synthesis (% of control) 
150 
140 
130 
120 
110 
100 
90 
Θ0 
70 
60 
60 
40 
30 
-
I* 
:
 L
* ι 
1 
24 48 72 
Time (h) after IA injection 
Figure 2: Time course of proteoglycan synthesis suppression by interleukin 1. Proteoglycan 
synthesis was measured by ¡"Sjsulphate incorporation (see fig 1) at various days after 
( ) 3 units, (- - - ) 30 units or ( ) 300 units of interleukin la 
injection. Each value represents the mean of at least three experiments consisting of six animals. 
Significant differences with respect to saline are indicated with * (ρ<0.001, student's t test). 
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ACCELERATED BREAKDOWN OF PATELLAR CARTILAGE 
Coincident with significant suppression of proteoglycan synthesis, interleukin 
1 induced an accelerated breakdown of prelabelled proteoglycans (fig 3). A 
low dose of interleukin la (30 U) was almost as effective as the higher dose 
(300 U). This sensitivity of patellar cartilage to interleukin 1 had already 
been seen in the suppression of the proteoglycan synthesis. The basal 
proteoglycan breakdown rate in control patellae was 10.7 (SD 6.0)% (n=9) 
as measured by loss of ["Sjsulphate between 0 and 24 hours. In the presence 
of interleukin la (300 U) the breakdown was 23.0 (9.1)% (n=6) during the 
first 24 hours after injection. This means that interleukin 1 accelerated the 
proteoglycan breakdown rate twofold. Further accelerated loss of 
proteoglycans between 24 and 48 hours after interleukin 1 injection was 
limited. Interleukin Iß also induced significant breakdown, but seemed less 
potent than interleukin la in a comparative experiment (table 1). 
Histologically, in sections of whole knee joints, no clear cut loss of 
cartilage matrix could be seen 24 hours after a single interleukin 1 injection 
(figure 4). 
Breakdown of cartilage (%) 
50 
40 
30 
20 
10 
p<0.01 
] • Saline 
' 30 U 
' 300 U 
24 h 48 h 
Time (h) after IA injection 
Figure 3: Enhanced breakdown of patellar proteoglycan by interleukin la. Animals recieved 
1.85 MBq [35S]sulphate intraperitoneally 24 hours before intra-articular interleukin 1 
administration. The S loss from patellae at 24 and 48 hours was expressed as a percentage of 
the 35S-content at t=0 (235 (50)cpm). The bar of 30 units interleukin 1 represents the mean of 
three experiments and the 300 unit bars of 5 experiments of six animals each. 
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Figure 4: Tissue sections of interleuhn 1 
injected Knee joints stained with safranin 
-O. Detailed representative histology of 
mice from the experiment described in 
table 3. (A) High magnification of joint 
cavity 24 hours after a single (300 U) 
interleukin 1 injection; note the minor 
infiltration of cells into synovial mem-
brane (S). (B) Joint section six hours 
after the last of triple interleukin 1 
injections; note the dense accumulation 
of neutrophils in synovial membrane and 
joint cavity and loss of cartilage matrix 
(C) of femur (F) and patella (P). 
(C) knee joint 48 hours after the last of 
three interleukin 1 injections; note the 
disappearance of the inflammatory cells 
and continued depletion of cartilage 
matrix. 
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SUPPRESSION OF PROTEOGLYCAN SYNTHESIS BY INTERLEUKIN 1 
AND THE EFFECT OF INFLAMMATION 
To investigate whether the effect of interleukin 1 on the articular cartilage 
was related to its potential to induce joint inflammation we compared the 
effect of various doses of the arthritogen zymosan and recombinant 
interleukin 1. A high dose of zymosan (60 ^g) caused marked suppression of 
proteoglycan synthesis (46%) 24 hours after intra-articular injection, and 
technetium uptake measurements, reflecting joint inflammation, were highly 
raised. When the dose of zymosan was lowered, less severe inflammation 
and concomitantly less suppression of proteoglycan synthesis was found, 
indicating that in this dose range there was a correlation between 
inflammation and inhibition of proteoglycan synthesis. A dose of 1.8 μg 
zymosan still induced significant joint swelling (Tc uptake) but the effect on 
proteoglycan synthesis was no longer seen. In contrast, interleukin la in the 
dose range studied did not induce enhanced technetium uptake, but there was 
a marked inhibition of proteoglycan synthesis (table 2). 
Table 2: Comparison of the effect of zymosan and interleukin la on joint inflammation and 
proteoglycan synthesis. Values are given as means (SD). 
Substance 
Saline 
Dose 
(intra-articular) 
_ 
Zymosan O g^/knee) 1.8 
Interleukin la 
(U/knee) 
6.0 
18.0 
60.0 
30 
300 
Inflammation 
'""Te-ratio' 
1.09 (0.08) 
1.23 (0.08) 
1.32 (0.09)* 
1.41 (0.10)" 
1.80 (0.07)" 
1.04 (0.05) 
1.02 (0.05) 
Proteoglycan synthesis* 
cpm/patella % Of control 
1303 (245) 
1087 (106) 
940 (109) 
845 (99)" 
675 (135)" 
732 (51)" 
401 (31)" 
109 
99 
76 
62 
54 
64 
35 
# Joint swelling was detected by enhanced 9 9 m Tc pertechnetate uptake as measured by external 
gamma counting. This was expressed as a ratio of the technetium uptake in the inflamed knee 
over that in the contralateral knee within the same animal, 
f Patellae were dissected and the proteoglycan synthesis was determined by ["S]sulphate 
incorporation. In the untreated contralateral patellae the "S incorporation was stated as 
100%. 
Significant differences- " ρ < 0.001 -with respect to the contralateral knee were calculated 
with the Student's t test. 
Histology showed that after 24 hours there was only minor infiltration of 
polymorphonuclear leucocytes into the synovial membrane (fig 4). 
In conclusion, the inhibition of proteoglycan synthesis by interleukin 1 
must be due to a direct effect on cartilage and was not secundary to 
inflammation induced by interleukin 1. 
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INTERLEUKIN Ια RETENTION IN MURINE KNEE JOINT 
The iodinated interleukin 1 (Bolton and Hunter) retained its full biological 
activity and molecular character. There was a poor retention of 
[125I]interleukin 1 in the naive knee joint (fig 5). One hour after 
[125I] interleukin 1 injection 30% of interleukin 1 was retained, and at six 
hours retention fell below 10%. The penetration of interleukin 1 into the 
patella was poor. Autoradiography carried out shortly after injection showed 
no distinct labelling of the cartilage compared with the joint cavity. At six 
hours after [125I]interleukin 1 injection only 0.02 U [125I]interleukin 1 was 
retrieved in the isolated patella and autoradiography showed that interleukin 
1 was faintly dispersed in the patellar cartilage matrix. Distinct association 
with chondrocytes was never found. 
Interleukin I retention (% of Initial count rat·) 
0 1 2 3 4 6 6 7 
Time (h) after IA injection 24 
Figure 5: Interleukin la retention in murine knee joint and penetration into patellar cartibge. 
Interleukin 1 iodinated by the method described by Bolton and Hunter remained biologically 
active as based on costimuUttion of thymocyte proliferation. In naive kneejoints 800 units of 
f^ïjinterleukin 1 (about 20ng or 3x10" cpm) was injected. The retention of [,2SI]interleukin 1 in 
the knee joint was measured by external gamma counting. f^Ijinterleukin 1 content in dissected 
patellae was an estimation of the interleukin 1 penetration into cartilage. Six hours after 
injection 80 cpm (about 0.02 units interleukin 1) could be retrieved. The proteoglycan synthesis 
in patellar cartilage 24 hours after injection of f^IJinterleukin 1 was suppressed (41%). 
JOINT INFLAMMATION AND MATRIX DEPLETION AFTER 
REPEATED INTERLEUKIN 1 INJECTIONS 
Although a single interleukin 1 (300 U) injection did not result in significant 
joint swelling, interleukin l a did cause minor inflammatory changes, like 
scant polymorphonuclear leucocyte influx in the synovial membranes and the 
joint cavity at six hours with a decline in cell influx at 24 hours. When 
interleukin 1 was repeatedly injected every two days, however, clear cut 
joint inflammation was measurable at six hours (Tc uptake values in table 3). 
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Histologic observations showed major infiltration of polymorphonuclear 
leucocytes into the synovium and an exudate in the joint cavity, which 
persisted for up to 24 hours after the last injection and slowly declined 
thereafter. 
Apart from infiltration of inflammatory cells, repeated injections of 
interleukin 1 resulted in impressive proteoglycan depletion in the articular 
cartilage surface layers (table 3). 
Table 3: The inflammatory response of single and repeated interleukin la injections and the 
effects on cartilage matrix. 
Variable Single IL1{ injection Triple ILI injections 
6 h 24 h 48 h 6 h 24 h 48 h 
Infiltration ND + ± + + + + + ± 
Exudation ND ± 0 + ± 0 
Proteoglycan depletion ND 0 0 + + + + + + + + 
""Tc ratio (mean(SD)) 1.03(0.09) 1.02(0.05) ND 1.22(0.06)" 1.03(0.06) ND 
Representative experiment in which single and triple (three times on alternate days) interleukin 1 
injections were compared for their inflammatory effect, six to 48 hours after the last injection. 
The joint sections were scored on: infiltration of leucocytes into the synovial membrane, 
exudation of polymorphonuclear cells into the joint cavity, and proteoglycan depletion of 
cartilage matrix. Histological changes were arbitrarily represented as 0=no changes, ± =slight, 
+ =moderate, + + =marked, + + + =strong. Joint swelling was expressed by an enhanced ratio 
of Wm Tc pertechnetate uptake, and significant differences- * p<0.001-were calculated by 
Student's t test. Repeated saline injections did not cause an enhanced " T c ratio, 
f IL 1= interleukin 1. 
This depletion was even enhanced at 48 hours after the last injection. It 
might be the result of both the accelerated cumulative breakdown (18%, 
table 4) and the insufficient resynthesis of proteoglycan (persistent inhibition, 
table 4). Although the cartilage matrix was heavily depleted of 
proteoglycans, the chondrocytes were still alive. No other dramatic his-
tological disturbances in the articular components, such as bony changes, 
synovium haemorrhage, or cartilage cracks and loss of structure, were seen 
(fig 4). Proteoglycans were fully restored to the matrices seven days after 
withholding interleukin 1, indicating that the interleukin 1 effects were not 
related to mere toxicity. Repeated interleukin 1 injections into the knee joint 
prolonged the interleukin 1 induced disturbance of the cartilage metabolism, 
suggesting that prolonged exposure to interleukin 1 during chronic joint 
inflammation may ultimately be responsible for the cartilage damage so 
typical of some forms of chronic arthritis. 
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Table 4: Effects of single and repeated interleukin la injections on patellar proteoglycan 
metabolism. 
Variable Substance 
Oh 
Breakdown 380 (156) 
Saline 
Interleukin 1 
Synthesis ND 
Saline 
Interleukin 1 
cpm/patella ' 
24 h 
339 (82) 
311 (92) 
1195(101) 
421 (35)* 
120 h 
240 (44) 
170 (45) 
1062 (145) 
563 (78)' 
Oh 
100 
% Cf control 
24 h 
89 
82 
100 
36 
120 h 
63 
45 
100 
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Representative experiment in which the effect on proteoglycan metabolism was compared at 24 
hours after a single injection or triple injections (120 h) of saline or interleukin 1 (300 U). 
Breakdown of patellar cartilage was measured as loss of ["Sjsulphate and expressed relative to 
the 35S content at t=0. Proteoglycan synthesis of patellae was measured as the amount of 
[35S]sulphate incorporated. Significant differences- * ρ < 0.001 -with respect to saline were 
calculated by Student's t test. [Values are means (SD). 
Discussion 
Our observations on the effects of recombinant interleukin 1 show two 
distinct alterations in synovial joints: (a) induction of granulocyte 
accumulation in the joint and (b) disturbance of the cartilage metabolism. 
A single injection of interleukin 1 was only slightly inflammatory: it 
induced no enhanced plasma extravasation (tables 2 and 3) at 24 hours and 
only minor infiltration in the synovial membrane and exudation into the joint 
cavity, predominantly polymorphonuclear leucocytes (table 3, fig 4). It is 
known that interleukin 1 stimulates vascular endothelial cells to express a 
neutrophil CD 18 antigen. This antigen facilitated the adhesiveness of 
neutrophils.13 ** Although new protein synthesis was required for this, the 
accumulation of neutrophils peaked at four hours but had subsided by 24 
hours.13 15 Even when we injected high doses of interleukin 1 (up to 800 U) 
still only minor inflammation could be observed at four and six hours (data 
not shown). Signs resembling experimental arthritis, like synovitis and 
severe cartilage matrix depletion, were only seen after repeated interleukin 1 
injections; these signs were probably related to rapid interleukin 1 clearance 
from the joint (fig 5). The massive infiltration and major exudation of 
leucocytes after triple interleukin 1 injections were not a mere summation of 
the effects of each interleukin 1 injection. A local hypersensitivity for 
interleukin 1 as seen in the interleukin 1 induced local Shwartzman reaction 
in rabbit skin might be postulated.46 4 7 Similar interleukin 1 hyperreactivity 
was also seen in arthritic flares of joints previously injured with bacterial cell 
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wall preparations,22 and we have recently shown that interleukin 1 causes 
flares of smouldering zymosan or antigen induced arthritis in mice.48 In 
addition, the onset of type II collagen induced arthritis in mice was enhanced 
by continuous administration of interleukin l.49 
The question arises whether inflammation was at least partially 
responsible for interleukin 1 induced cartilage depletion. We have shown that 
suppression of the proteoglycan synthesis induced by one single interleukin 1 
injection was not caused by continuing inflammation. Compared with 
zymosan, interleukin 1 induced slight inflammation, too little to promote 
strong inhibition of proteoglycan synthesis (table 2). The suppression of 
proteoglycan synthesis after repeated interleukin 1 injections did not 
significantly differ from that after a single injection. Although significant 
inflammation was found after repeated interleukin 1 injections, it seems 
unlikely that the cumulative loss of [33S]proteoglycan was related to this. The 
overall loss was 18% (table 4) and might well be explained by triple 
interleukin 1 insults, each resulting in 7-8% [^proteoglycan degradation. 
Recent studies from Pettipher et cd also provided evidence indicating a minor 
role of the inflammatory exudate in proteoglycan degradation.21 Proteoglycan 
loss from cartilage induced by interleukin 1 was unimpaired in neutropenic 
animals,41 and pronounced proteoglycan degradation was still found during 
antigen induced arthritis in neutropenic rabbits. 41 Earlier studies in inflamed 
air pouches already pointed to the incompetence of an acute inflammatory 
exudate in cartilage breakdown.* It may even be postulated that neutrophils 
prevent interleukin 1 effects as they contain a specific interleukin 1 
inhibitor.5152 
The marked depletion of cartilage matrix after repeated interleukin 1 
injections as shown by histology (fig 4) is probably the final result of both 
cumulative breakdown of proteoglycan (18%, table 4) and prolonged 
suppression of proteoglycan synthesis (50%, table 4). At day 1 after a single 
interleukin 1 injection about 10% proteoglycan depletion was found, and the 
lack of clear-cut proteoglycan loss on histologic sections taken at that time 
(fig 4) indicates that this degree of depletion is beyond the detection limit. 
The marked depletion after repeated interleukin 1 injections must therefore 
reflect a much higher degree of proteoglycan depletion and this may only be 
explained by a considerable lack of sufficient resynthesis of new 
proteoglycan. Kinetic studies on this subject are in progress. Earlier studies 
with purified interleukin 1 preparations given once a day yielded high 
degrees of proteoglycan depletion,39 *° but the possibility that this was caused 
by other mediators present in the interleukin 1 preparation cannot be 
excluded. Moreover, in those studies the recovery was also very poor during 
the days after interleukin 1 exposure,35 *° in sharp contrast with the full 
recovery of the matrix seen with recombinant interleukin 1 in rabbits41 and 
in mice in this study. Five days after the last of triple interleukin 1 injections 
inflammation was absent and cartilage was again heavily stainable with 
safranin-O. At that stage an overshoot to enhanced proteoglycan synthesis 
was evident (data not shown). 
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The most outstanding action of interleukin 1 in vivo was its 
impressive longlasting inhibition of proteoglycan synthesis. This inhibition 
was not related to toxicity as full recovery was seen later. As stated above 
this inhibition contributes to proteoglycan depletion in the metabolically 
active murine cartilage matrix. It remains to be seen whether the inhibition 
of proteoglycan synthesis contributes in a similar degree to matrix depletion 
in older animals or in other species as it is obvious that it depends on 
turnover rates. Preliminary studies in our laboratory show that interleukin 1 
induced even more prolonged inhibition of proteoglycan synthesis in the 
cartilage of old mice (18 months). 
A recent study with isolated chondrocytes showed the onset of 
interleukin 1 induced suppression of proteoglycan synthesis six hours after 
first exposure and complete recovery to normal synthesis was found 48 
hours after withholding interleukin 1, effects in agreement with our in vivo 
results. 
We found a comparable degree of suppression of proteoglycan syn-
thesis and breakdown with recombinant interleukin la and ß (table 2); this is 
consistent with other studies. The effects of interleukin 1 on rabbit 
chondrocytes (prostaglandin Ej synthesis, phospolipase A2 secretion, neutral 
protease release) or on human chondrocytes (caseinase secretion, 
prostaglandin^ production) or on cartilage resorption in expiants show that 
both interleukin 1 species are almost equally potent.54'37 This is not 
surprising because chondrocytes posses a common class of receptors for 
interleukin la and ß, with similar affinity.58 w The overall effect of 
interleukin 1 on cartilage was dramatic: a joint suppression of proteoglycan 
synthesis and enhancement of proteoglycan breakdown, which amplifies 
matrix depletion. Both phenomena are clearly seen in experimental arthritis 
models and interleukin 1 seems a likely cause of both effects. The follow up 
of interleukin 1 studies may elucidate the exact role of interleukin 1 in 
various forms of arthritis. 
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CHAPTER 4 
PROTEOGLYCAN LOSS AND SUBSEQUENT 
REPLENISHMENT IN ARTICULAR CARTILAGE AFTER A 
MILD ARTHRITIC INSULT BY IL-1 IN MICE: IMPAIRED 
PROTEOGLYCAN TURNOVER IN THE RECOVERY PHASE 
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Abstract. The reparative responses of articular cartilage 
after an arthritic insult have not been studied extensively 
to this day In the present study, we injected interleukin-1 
(IL-1) into knee joints of mice to provoke a mild and 
transient arthritic insult, and characterized both the 
catabolic and the subsequent recovery phase In the 
catabolic phase, which lasted 2 days after IL-1 injection, 
proteoglycan (PG) breakdown was profoundly acceler-
ated and PG synthesis was markedly inhibited Sulfation 
and polysaccharide synthesis were not affected, yet the 
number of chondroilin sulfate chains was decreased The 
general chondrocyte protein synthesis was not inhibited 
by IL-1 IL-1 injected every other day for a total of three 
injections prolonged this catabolic phase and resulted in 
frank loss of articular cartilage proteoglycans In the re-
covery phase, started 3 days after IL-1, PG synthesis 
was enhanced (1 7 times the normal) and proteoglycans 
had normal hydrodynamic properties Remarkably, PG 
degradation was significantly decreased (approximately 
50% of the normal) Zymographic analysis demonstrated 
enhanced expression of gelatinolytic activities in the ex-
tracts of the articular tissues shortly after IL-1 exposure 
and decreased levels in the recovery phase We found that 
the overshoot of PG synthesis and impaired degradation 
act together to facilitate full cartilage repair 7 days after 
the last of the three IL-1 injections 
Key words: Patella - Chondrocyte metabolism - Gela-
tinase-activities - Zymography - Glycosaminoglycan -
Interleukin-1 
Cartilage, a highly specialized coating tissue on bones, 
forms the articular joint surfaces The macromolccular 
structure of this tissue consists of a collagen type II fibre 
frame embedded in proteoglycans The proteoglycans are 
Correspondence to A A J van dc Loo 
large aggregates (aggrecan) of highly sulfated polysacchar-
ides and they create a large osmotic swelling pressure [1] 
Water uptake will tense the collagen network creating 
a resilient structure which enables smooth joint move-
ments and can restrain compressive loading stress [2] In 
contrast to collagen, the proteoglycans are continuously 
turned over and chondrocytes maintain their extracellular 
matrix by synthesis of proteoglycans The chondrocyte 
metabolic activity is controlled by a range of cytokines 
and growth factors [3] Cartilage PG loss can occur after 
a trauma, immobilization of the joint, or as a consequence 
of a local inflammation 
In mice, we demonstrated that an intra-articular injec-
tion of the inflammatory cytokine, interleukin-la, induced 
suppression of PG synthesis and a concomitant acceler-
ated breakdown [4, 5] Furthermore, we recently elucid-
ated the role of IL-1 in the antigen-induced arthritis (AIA) 
and collagen-induced arthritis m mice Suppression of 
chondrocyte PG synthesis in AIA could be prevented by 
treatment with neutralizing anti-IL-1 antibodies [6, 7], 
implicating a key role of IL-1 in this process 
At present, the bulk oí research is focused on unravel-
ing the mechanism behind cartilage depletion and on 
cessation by enzyme inhibitors and cytokine antagonists 
[8] Due to low cellulanty, the capacity of cartilage to re-
pair major PG loss is limited, but not refractory The 
ensuing replenishment of proteoglycans is a neglected 
area. 
In mio reparative responses of cartilage have been 
examined after papain digestion of the matrix, immobiliz-
ation of the joint, and after traumatizing by full-tickness 
cartilage defects or transection of the anterior cruciate 
ligament The last mentioned is also a model of osteoarthri-
tis (OA) in which osteophytes stabilize thejoint followed by 
hypertrophic cartilage repair (fibrocartilage) [9] 
In the present study, IL-1 action on the murine joint 
was examined by detailed analysis of cartilage PG metabol-
ism, and metalloproteinases expression in tissues from the 
capsula articulons and patellae In addition, the IL-l-in-
duced cartilage insult was utilized as an m iwo model system 
to characterize further the subsequent recovery phase 
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Materials and methods 
Animals and induction of an arthritic insult 
The experiments were performed on male C57Bl'6 mice aged 8-10 
weeks Mice were obtained from our Central Animal I aboratory 
breeding facility and were free of specific pathogenic viruses They 
were fed a standard diet and tapwater ad libitum Mice were injected 
intra-articularly along (he suprapatellar ligament into joint cavity 
The right knee joints received IL-Ія (10 ng) and the contralateral 
knee joint received an equivalent volume (6 μ!) of saline and served 
as a within animal control Wc demonstrated previously that saline 
or Ì U (01 ng) of IL-1 had no significant effect on chondrocyte 
metabolism [4] Murine recombinant IL-toe cloned in Hcheni.hu 
coll [10] had less than 1 ppm endotoxin in the Limulus lysate assay 
BioaUmty was checked in the one stage bioassay a cocullurc of ihe 
IL-1-specihc subclone of the murine thymoma cell line H -4 desig-
nated NOB-1 which produces IL 2 and II 4 together with the 
IL-2-responsive CTLL2 cells Half-maximal proliferation was ob-
tained at a concentration of 1 pg'ml of IL-1 and could be blocked 
by rabbit anti-IL 1 antibodies [6] 
Anaix tical procedures 
Assessment of proteoqhean <,\nthests Patellae with a minimal 
amount of adjoining soft tissue (6 pieces) were incubated for 1 h in 
2 ml RPMI 1640 (Dutch modification Flow Laboratories Irvine 
Scotland) supplemented with gcntamvcin (50μg,ml^ L-glutaminc 
(2 m M) and 40 μΟ 35S-sulfale (Du Pont de Nemours s Herlogcn-
bosch. The Netherlands) at 37 С in a humidified 5% C 0 2 atmo­
sphere Thereafter patellae were thoroughly washed fixed in 10°/o 
formalin and subsequently decalcified in 5"о formic acid Patellae 
were punched out of the adjacent tissues and dissolved in 0 S ml 
I umasolve(Hicol Oud Beijerland The Netherlands) at 60 С The 
3SS-conlent of each patella was measured by liquid scintillation 
counting (LSC) More than 95% of the radiolabel was incorporated 
into the proteoglycans by this method [11] 
Assessment of proteoglycan breakdown Mice were injected with 
50-100 μΟ 3 5 S sulfate mlrapentoneally After 24 h and al later 
limepoints (indicated in the legends) patellae were dissected and 
processed as described above Breakdown was cither expressed as 
a ratio of 34S-content of treated over untreated contralateral joints 
or expressed аь a percentage of the first limepoint i24 h) taken, as 
will be indicated in the corresponding experiments 
Glycosammoghcan measurements of patellar cartilage Fstimation of 
sulfated glycosaminoglycan (GAG) content in cartilage was carried 
out using the colorimetrie method ofParndale [12] After dissection, 
patellae were fixed in ethyl alcohol (96%) overnight and decalcified 
in 5% formic acid for 4 h before use The cartilage layer was stripped 
from the patella with a pair of tweezers and subsequently digested 
with 200 μΐ of 5 mg ml papain (Type IV Sigma St Louis MO) in 
01 M sodium acetate pH 6 5, lQmAf L-cysteine and 50 mM di 
sodium EDTA per patella overnight at 60 С The GAG content per 
patella was estimated by the dimethylmcthylcnc blue dye binding at 
535 nm using shark chondroitin sulfate (Sigma) as a standard 
Measurements of hyaluronic acid sxnthesis Patellae (n = 6) were in 
cubated for 20 h in 2 ml RPMI tissue-culture medium supplemented 
with 100 μΟ 3H-glucosamine and 30% normal mouse serum to 
maintain proteoglycan synthesis at the in ino level Supcrnatants of 
a papain malnx digest (sec above) were applied to a cellulose acetate 
strip Hyaluronic acid and chondroitin sulfate were separated by 
electrophoresis (60 10 mA 80 V) The spots were visualized by 
0 1% alcian blue in 5% acetic acid and 10% ethyl alcohol cut out 
and the amount of %H-label was measured in aqualuma by LSC As 
a specificity control supernatants were día I y zed and vacuum dried 
and treated with 100 Ъ of hyaluronidase (Streptomyces) in 0 1 M 
sodium acetate 0 15 M NaCl pH 4 0 After 20 h incubation at 37 C, 
the supernatant was applied to the cellulose strips 
Gel permeation chromât ograph\ of proteoglycans Since bovine pro-
teoglycan monomers are included more on Sephacryl S-1000 (Kav 
0 38) than on Sepharose CL-2B (Kav 0 28) fractionation on Sephac-
rvl S 1000 allowed a more clear resolution [13] and a distinct 
separation of proteoglycan monomers with large or small hy-
drodynamic volume of murine patellar cartilage [14] Patellae were 
cultured for 4 h in RPMI 1640 DM medium containing 3*S-suIfate 
(10 patellae per 40 μΟ ml) followed by thorough nnsing in physiolo­
gical saline Proteoglycans were extracted immediately thereafter or 
the labelling interval was followed by a 4R h chase period in RPMI 
supplemented with hrlGh-l (O^igml serum equivalence) Sub­
sequently the patellae were decalcified in 1 5% Na2EDTA solution 
(osmolanty 270 mmol kg) (Sigma Chemical Company St l ouïs 
MO) for 4 h and the cartilage layer was stripped from the underlying 
bone using forceps The cartilage layers were ground with an 
all-glass mortar and pestle followed by proteoglycan extraction at 
4 С Гог 48 h in 4 Vi guamdine HCl (GuHCl) in 0 5 M sodium 
acetate buffer (pH 5 6) in the presence of protease inhibitors (0 01 M 
EDTA 0 Ι Vf 6-aminocaproic acid (Sigma) 0 005 Vf benzamidine 
hydrochloride (Sigma) 5 mg ml trypsin inhibitor (Sigma) 0005 M 
lodoacetate (Sigma)) This extraction procedure resulted in the ex­
traction of over 90% of the incorporated radiolabel Extracted 
proteoglycans were supplemented with 1 mg of an unlabelled bovine 
proteoglycan mixture as a carrier and applied το an analytical 
Sephacryl S-1000 column (lOOx 1 6cm) The column was equilib­
rated and elulcd with 4 Vf GuHCl (dissociative) The column was 
eluled at a flow of 9 ml h and fractions of 3 ml were collected 
Ahquots of each column fraction were analyzed for glycosamino-
glycans (barndale) and radioactivity (1 SO Slices of articular carti­
lage obtained from the metacarpal joints of bovine were extracted 
with 4 M GuHCl and dialyzed against 0 5 V/ GLHC1 to reassociate 
into aggregates To void volume (1
 0) of the column was character­
ized by these bovine proteoglycan aggregates under associative 
elution conditions (0 5 V/ GUFICI) (elution position in fraction 29) 
Bed packing was checked with dexlran blue 2000 (2 χ 106 MW), and 
eluted with a Kav of 0 64 (dissociative running conditions) Total 
bed volume (l·,) was characterized by unbound 35S-sulfate which 
eluted at fraction 67 (dissociative running conditions) All samples 
were analyzed on the same column and reproducibility was checked 
by the comparison of the elution profile of the unlabelled bovine 
carrier proteoglycans 
Characterization of nevi I \ wnthesized chondrocyte proteins Patellae 
(n= 10 per group) were dissected with a minimal amount of sur­
rounding tissue and incubated with 2 ml methionine-frec RPMI 
tissue-culture medium containing 100 μΟ 3 5S methionine plus cold 
L-mcthionine to a final concentration of 0 5 mg L 5% FCS and 
1 5 mg, L tunicamycin for 4 h at 37 С in a humidified atmosphere 
Patellae were then washed thoroughly and decalcified in a physiolo­
gical aqueous solution of 3 5% (w v) Na2EDTA, glucose (I g L), 
supplemented with minimal essential amino acids (MEM 50 χ 
ammo acid solution Whitlaker M A Bioproducts Walkersville, 
MD), 2 h at 37 С or 4 h at 4 С The patellar cartilage could be 
removed from the bone using forceps Chondrocytes were freed 
from the cartilage by enzymatic digestion of the cartilage matrix 
with 2000 L ml collagenase ΙΛ (from Clostridium hi stol y tu urn), 
20 U ml pronase l· (Protease type XIV from Streptomxces gnseus) 
and 0 5 U ml chondroilinase ABC (from Proteus vulgaris) and 2% 
BSA in HAM s И 2 culture medium After 45 60 mm the chon­
drocytes were centnfuged at 250 χ g for 10 min and resuspended in 
0 1% EDTA in saline Viabilttv was checked by trypan-blue exclu­
sion and the cell number was determined 
Chondrocytes were washed in PBS and spun-down at 300 χ g for 
5 min, and resuspended in 50 μΐ Ivsis buffer 50m\f KCl lOmVf 
NaCl 1 m Vf EDTA 50 mV/potassium phosphate 10% NP-40 and 
0 25 m V/ PMSF Nuclei were separated in an Eppcndorf centrifuge 
at 1200 y. g The supernatant was diluted 1 5 with sample buffer 
(OOllg/ml dithiothreitol, 0 1 gyml SDS in 04 M Tris HCl pH 68 
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with 45% glycerol and bromophenol blue) and heated at 100 С for 
2 min. 
Gel analysis. Equal amounts of radiolabel were subjected to 
SDS-polyacrylamide gel electrophoresis (Daiichi 10 20% gradient 
gels, ISS-enprotech, Massuchusetts, USA) and run for 1 h at 
40-60 mA, constant current. Gels were silver-stained according to 
the manufactures procedures (2-D-silver stain-II Daiichi) and after­
wards submerged in an autoradiography enhancer (EN3HANCE. 
Biotechnology Systems NEN, Massachusetts, USA) and vacuum 
dried. Gels were exposed to X-ray film for a defined length of time at 
— 70 С All films were scanned using a Molecular Dynamics laser 
scanner and protein bands were quantitated using PDQ-Scan soft­
ware (Protein Databases, Inc., USA). Protein bands were matched 
between lanes on the gels of each experiment, and apparent molec­
ular weight assignments were made based on internal standards: 
Phosporylase β (95.5 kDa), glutamate dehydrogenase (55 kDa). 
ovalbumin (43 kDa), lactate dehydrogenase (36 kDa), carbonic an-
hydrase (29 kDa), lactoglobulin (18.4 kDa), and cytochrome 
С (12.4 kDa). 
Isolation of metalloproteases from patellae. Patellae immediately 
frozen in liquid nitrogen were punched out of their surrounding soft 
tissue (joint capsule) without defrosting, and both were immediately 
extracted for 48 h at 4 С in a 10 mM cacodylate buffer (pH 6) 
containing 0.3 M NaCl, 5 mM CaCl2l 1 μΜ ZnCl2, 0.02% (v/v) 
NaN 3, 0.1% (v/v) Triton X-100, and 0.7 mg/1 pepstatin. In some 
experiments, cartilage layers were cut off from the underlying bone 
and extracted. Samples were storedat —70 С, and before use mixed 
with an equal volume of the sample buffer (10% sodium dodec>l 
sulfate (SDS), 4% sucrose, 0.02% NaN3) with bromophenol blue, 
and subjected to zymography. 
Substrate-gel analysis (zymography) of metalloproteinases. Slab 
gels (84 χ 90 χ 1.0 mm) containing the appropriate gelatin substrate 
(2.5 mg/10 ml, Difco Lab., Detroit, Ml) were copolymerized in 7.5% 
Polyacrylamide as described [15]. Slab gels were run at 4 C, at 
a constant voltage (200 V). After electrophoresis, the slab gels were 
washed twice for 20 min in 50 mM Tris (pH 7.5), 5 mM CaCl2. 
1 mM ZnCl2, 0.02% (w/v) NaN3, and 2.5% (v/v) Triton X-100 at 
room temperature to remove the SDS. To detect gelatinase activity, 
the gels were incubated in 50 mM Tris (pH 7.5), 5 mM CaCl2, 1 mM 
ZnCl2, 0.02% (w/v) NaN3, and 1% (v/v) Triton X-100, with or 
without 1 mM АРМА, for 18-48 h at 37 °C. Gels were stained in 
0.25% (w/v) Coomassie blue G250 in 50% methanol, 7% acetic acid, 
and destained in 40% methanol, 10% acetic acid. Enzymes were 
detected as a clear band within the blue background. Zymography 
allowed us to detect both proenzymes and active enzymes based on 
their apparent molecular weights and in their original ratios. For 
this, we activated proenzymes with АРМА after the electrophoretic 
separation and not before. 
Statistical analysis. Data are expressed as mean values ± standard 
deviation (SD) unless stated otherwise. Statistical significance was 
tested using the Mann-Whitney U test. 
Results 
Cartilage metabolism after a single IL-l injection, 
the catabolic phase 
Chondrocyte protein synthesis. Murine recombinant ÏL-
loc (10 ng) was injected intra-articularly into the murine 
knee joint. Twenty-four hours later, protein synthesis of 
patellar chondrocytes was measured by the incorporation 
of 3 5S-methionine ex vivo. The newly synthesized proteins 
were retained intracellularly by blocking the glycosyla-
tion/secretion pathway with tunicamycin [16]. IL-l did 
A B Ä В' 
m.w. 
• Ш 
-
95.5 -—95KDa 
Fig. 1. Electrophoretic separation of chondrocyte intracellular pro­
teins. The preexisting (A, B; silver-stained!, and the newly syn­
thesized proteins (A', B'; autoradiography) were analyzed on 
a 10-20% Polyacrylamide gel. 25.000 CPM (1-1.5 Mg protein) was 
applied to each lane. Lane A and A', normal chondrocytes; lane 
В and B', IL-la (10 ng)-trcated cartilage (24 h). Autoradiographs 
were laser-scanned and apparent relative increases of matched 
bands between lane A' and B' were indicated by arrows, with their 
appropriate molecular weights. 
not lead to a significant inhibition (8%) of the overall 
protein synthesis as compared to chondrocytes in normal 
cartilage. Detailed analysis of these chondrocyte-derived 
proteins by P A G E did not reveal significant changes in 
preexisting proteins, whereas of the newly synthesized 
proteins, the expression of a 33 k D a protein became 
markedly increased (Fig. 1). 
Chondrocyte proteoglycan synthesis. Chondrocyte pro­
teoglycan synthesis, as measured by 3 5S-sulfate incorpora­
tion, was markedly suppressed after IL-l (10 ng) exposure 
(Table 1). IL-l did not cause alteration in the enzyme 
activities of the sulfation pathway as identical results 
were obtained by 3 H-glucosamine incorporation. Elec­
trophoretic separation of the polysaccharide chains of the 
newly synthesized proteoglycans demonstrated that the 
a m o u n t of 3H-labelled chondroitin sulfate chains was 
decreased, whereas the amount of 3H-labelled hyaluronic 
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Table 1 f-ffect οΓ IL-1 on the synthesis of 
chondroitin sulfate chains and hyaluronic, 
acid of patellar cartilage separated by 
cellulose acetate electrophoresis 
Tabic 2, Breakdown of newly synthesi7ed 
and the more processed proteoglycans by 
IL-1 
Labclb Radioactivity' 
Contralateral IL-1 injected IL-I'conlralatcral + SD 
Patella 
Patella 
CS 
HA' 
3,S-sulfale 
3 H glucose 
3H-glucose 
3H-gIucose 
764 + 138 
2485 ±511 
2067 ± 387 
207 + 161 
400 + 59* 
1603 ± 304·* 
1182 + 226" 
187+ 105nt 
053 + 012 
066 + 015 
0 6 0 ± 0 2 0 
090 + 033 
1
 Whole patellae extracts cellulose acetate spots of chondroitin sulfate (CS), and hyaluronic 
acid (HA) were counted and expressed as С PM ± SD or as a ratio 
" Patellae (n — 6) 24 h after a single IL-1 injection and their matched contralateral untreated 
joints were incubated with 35S-sulfalc (20 μΟ ml) for 3 h or 3 H glucosamine (glucose) 
(100 pCi ml) for 20 h in scrum enriched medium 
' Approximately 85% of JH glucosamine labelled HA was hyaluromdase-degradable mater­
ial 
jj-valucs compared with the contralateral joints (Mann Whitney) * ρ < 0001,** ρ < 005 ns, 
not significant 
Proteoglycans 
evaluated 
Period after 
IL-1 
challenge (days) 
Ratio "S-content" 
II -1 contralateral 
( + SD) 
New" 
Processed* 
New" 
0 8 3 ± 0 0 5 
082 ± 0 0 4 
0 7 6 ± 0 1 1 
Accelerated loss 
of label by IL-1 
(1 - ratio) x l 00 (%) 
17* 
18* 
24* 
a
 Mean ratio (n = 6) from 35S-incorporalion of IL-1 injected over contralateral kneejoints 
calculated from paired measurements of six mice each Average CPM value of contralateral 
joints was 158 ± 28 cpm (n = 24) ν 
ь
 IL-1 effect on newly synthesized (IL-1 injected 2 davs after 35S-labelhng) Two IL-1-challcnge 
periods were studied 1 and 9 days over which degradation was quantitated 
c
 IL-1 effect on processed proteoglycans (IL-1 injected 10 days after ,4S-Iabelling) 
* ρ < 0 05 compared with the contralateral joints (Mann-Whitney) Accelerated loss by PBS 
was 1 ± 3% 
acid chains remained the same after IL-1 exposure (Table 
1) This excludes an altered glucosamine precursor pool in 
chondrocytes 
Matrix proteoglycan breakdown lnterleuktn-1 injected 
2 days after 35S-sulfate labelling of the articular proteo­
glycans resulted in an accelerated breakdown of 17% 
within the first 24 h (Table 2) To exclude the possibility 
that IL-1 only induced degradation of a small subpopula-
tion of newly synthesued proteoglycans, the effect oflL-1 
on more processed proteoglycans was studied For this, 
the IL-1 injection was delayed for 10 days after 35S-sulfate 
injection With 18% enhanced degradation, the more pro­
cessed matured proteoglycans were as susceptible to the 
IL-1 induced degradation The measured cumulative loss 
of 24% of 35S-proteoglycans 9 days after a single IL-1 
injection demonstrated that the major loss occurred with­
in the first 24 h after IL-1 injection, and that the remaining 
"S-labelled proteoglycans had a normal (not impaired) 
turnover (Table 2) 
Cartilage proteoglycan depletion by repeated 
IL-1 injections, the cataboltc phase 
Proteoglycan turnoier Intra-articularly injected IL-1 is 
rapidly cleared from the joint with a half-life of 30 mm 
though proteoglycan synthesis suppression lasted for 2-3 
successive days [4] IL-1 injected every other day for 
a total of three injections, inhibited proteoglycan synthesis 
to the same extent (*40%) as a single IL-1 injection 
(Table 3) Cartilage proteoglycan breakdown was also 
extended after repeated IL-1 injections A cumulative ac­
celerated breakdown of 36% was found, as compared to 
ІЗУо after a single injection (Table 3) 
Glycosaminoqlycan content patellae The prolonged sup­
pression of proteoglycan synthesis and a repeated evoca­
tion of degradation may have a profound impact on 
articular cartilage proteoglycan content The patellar car­
tilage matrix was dissected from the bone and digested 
with papain Total GAG content of patellar cartilage was 
determined to be 2 75+0 6 μg (и = 70 patellae) in normal 
cartilage and was significantly reduced (20 + 5%, mean of 
4 experiments) in the 3 χ IL-1-treated knee joint (Table 4) 
The IL-1-induced GAG-depleted cartilage was almost 
completely replenished within 7 days after the third IL-1 
injection (Table 4) 
Recoier\ of proteoglyean-depleted cartilage, 
the reparut η e phase 
Proteoglycan synthesis Both a single and three IL-1 
injections caused a marked inhibition of proteoglycan 
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Table 3. IL-1 effect on m vivo proteoglycan 
turnover in patellar cartilage 
Table 4. Diminished glycosaminoglycan 
content of patellae after IL-1 treatment 
Number of 
3x 
PG synthesis: 
Ratio of IL-1/ 
saline joint 
( ± SD)" 
0 55 ± 0 1 2 · 
(π = 120)" 
0.58 + 008· 
(η = 48) 
Proteoglycan 
Remaining s' 
Saline 
A 
81 
(л = 18) 
51 
(n = 30) 
breakdown' 
S-PG's (%) 
IL-1 
В 
70 
(л = 18) 
33 
(η = 30) 
Accelerated loss 
- by IL-1 (A-B)/A 
(ratio ± SD) 
0 13 + 007 
036 + 008** 
' IL-la (10 ng) was injected intraarticular^ once (day 1) or three times (on day 1,3 and 5), and 
the contralateral joints received saline at the same time 
ь
 PG synthesis was measured 24 h after the single (day 2) or after the third injection (day 6) 
' '
!S-sulfale was injected on day 0 On day 1, the 3,S-sulfate content of patellae (n = 6) was 
measured and the content at laler timepoints was expressed as a percentage of the amount on 
day 1 From the absolute incorporation, the accelerated loss by IL-1 was calculated and 
expressed as a ratio ± SD 
6
 Number of mice evaluated is stated in parentheses 
Different from saline-injected joint at * ρ Í 0001, at · · ρ < 005 
Time in 
days* 
2 
7 
Effect on 
PG synthesis 
55% 
170% 
GAG-content in pg/patellab 
Contralateral IL-1 injected 
2.47 + 0 14 1 91 ± 0.12 
2.75 ± 0 17 261 ± 0 3 0 
IL-1 effect 
- 2 3 · 
- 5 
'Indicated time of days after the last of triple IL-1 injections 
b
 GAG content of the patellae was measured by the Farndale assay, and values represent the 
mean of four measurements consisting of two patellae each 
* ρ < 005, compared with the contralateral joints (Mann-Whitney) 
Mean GAG loss calculated from a total of four identical experiments day 2 (20 ± 5%); day 
7 (7 + 4%). 
synthesis which was followed within 2-3 days by an 
overshoot of PG synthesis to supranormal levels (Fig. 2). 
The recovery of PG synthesis was significantly faster on 
day 3 of three IL-1 injections than after a single IL-1 
injection (p<0.01) The enhancement in PG synthesis 
after repeated IL-1 injections peaked on days 4-5 after the 
last injection with a mean stimulation index of 2.31 ± 0 59 
(mean of 7 experiments) compared to the contralateral 
(noninjected) joints. Contralateral joints were unaffected 
by the IL-1 regimen when compared to joints of untreated 
animals there was no stimulation ( 1.01 + 0 16, η = 4 experi­
ments). Two weeks later, normalization of the PG syn­
thesis rate occurred. 
Hydrodynamic properties of proteoglycans. The hydro-
dynamic volume of the newly synthesized proteoglycans 
was analyzed by gel permeation chromatography immedi­
ately after pulse labelling and after a 48 h chase. As shown 
in Fig. ЗА, В, the newly synthesized proteoglycans in 
normal cartilage and the unlabelled bulk of preexisting 
matrix proteoglycans monomers had a K,„ (of a: 0.44 and 
are considerably smaller than proteoglycan monomers 
from bovine cartilage (K
a v
 0.38) as described by others 
[17, 18], with shorter glycosaminoglycan chains [ 9 ] . 
Proteoglycans synthesized in the recovery phase had an 
identical hydrodynamic volume as untreated cartilage 
PG-Synthesis (CPM χ 1000) 
• -*— Salin« 
i s 4 * 3 " l l •- , 
« 3 - " „ 
•0 001 
/ 
«0 001 
/»οοοϊ4^^ 
1 г з 4 s e 7 β 
Time alter last injection (Days) 
Fig, 2. Time course of patellar proteoglycan synthesis after one or 
three IL-la (10 ng) injections on alternate days Proteoglycan syn­
thesis was measured by 39S-sulfate incorporation (n = 6 per group) 
IL-1-treated cartilage which is different from saline-treated cartilage 
at p-values is indicated in the figure. 
(Fig. 3C). A 48 h ш vitro chase did not alter the hydro-
dynamic volume of these 3 5S-labelled proteoglycans 
(Fig. 3B-D). 
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Breakdown of newly synthesized proteoglycans. Degrada­
tion of proteoglycans synthesized on day 5 after the last 
IL-1 injection, at the time of supranormal proteoglycan 
synthesis, was markedly reduced: 2 3 % compared to 6 0 % 
loss over a 48 h chase period in control patellae (Table 5). 
This circumstantial evidence of impaired breakdown of 
the newly synthesized proteoglycans was further substan­
tiated in vivo. Mice were injected with 3 5S-sulfate on day 
3 after the last IL-1 injection. Proteoglycan synthesis in 
the IL-1-treated knee was two times higher than in the 
normal contralateral knee joint (Table 6). Total loss of 
3 5 S-proteoglycans labelled in the recovery phase was 3 3 % 
after 6 days in the IL-1-treated knee and this was a signifi­
cant reduction compared to the 5 3 % loss in the contra­
lateral normal cartilage (Table 6). 
Expression of gelatinöses in both phases of 
IL-1-treated articular tissues 
The accelerated degradation of cartilage proteoglycans 
coincide with enhanced expression of gelatinolytic activ-
ities in both patellae and tissues of the joint capsule 
(Fig. 4). Extracts were prepared from the joint capsule 
tissue, the whole patellae and cartilage slices on days 1 and 
5 after the last of triple IL-1 injections. These tissue ex-
tracts were subjected to gelatin substrate PAGE and gel-
atinolytic proteases were demonstrated as clear bands in 
the dark-stained gel. 
In the extracts of whole patellae, consistent expression 
of four distinct gelatinolytic bands were found: two small 
clearing bands of approximately 218 and 242 kDa, a mod-
erate band of 59 kDa and a major band of 97 kDa (Fig. 4). 
After IL-1 exposure, markedly enhanced expression was 
seen and additional minor bands arose. No clearing bands 
emerged in gelatin gels incubated in the presence of 1 mM 
EDTA, or using irrelevant substrates, e.g., serum albumin, 
and fibrinogen, suggesting that the gelatinolytic bands 
could originate from metalloproteinase activity. When 
the cartilage was stripped from the patellae, the pat-
tern was identical, although less pronounced due to the 
Table 5. Reduced breakdown of proteoglycans synthesized in the 
recovery phase during an in vitro chase. 
Table 6. Reduced breakdown of proteoglycans synthesized in the 
recovery phase in π ι α 
Chase 
Oh 
48 h 
35S-sulfate content 
Contralateral 
(CPM + SD) 
10166 + 1540 
4070±702*(60%) 
IL-1 injected 
(CPM±SD) 
18153±5323 
14011+ 1236** (23%) 
Interleukin-1 (10 ng) was injected on three alternate days. 5 days 
later, patellae (n = 5) were dissected and labelled with 40 μΟ 3 SS-
sulfate for 4 h. 
• After thorough rinsing, patellae were either counted directly or 
cultured for another 48 h in RPMI supplemented with 0.5 μg/ 
mlhrIGF-1. 
Loss of incorporated radiolabel in the 48 h time interval is indicated 
in parentheses. In a second experiment. 35S-PG loss was 46% for 
contralateral joints, and 25% for the IL-1-treated joints. 
p-values compared with its proper control (0 h chase) (Mann-
Whitney): *p<0.001. *p <0.01. 
Days after Days after 
3 5 S a IL-1" 
5S-sulfate content 
Contralateral 
(CPM + SD) 
IL-1 injected 
(CPM + SD) 
4 929±253 1713 + 255 
6 573+119*(38%Г 1424±417(17%) 
10 437±106** (53%) 1153 + 241* (33%) 
a 35S-sulfate (150 цСі) was injected intraperitoneal^ one day 3 after 
the IL-1 treatment, π = 6 per group. 
b
 lL-la was injected on three alternate days. This caused a 41% loss 
of 35S-prelabelled proteoglycans (p = 0.125). and a significant inhibi­
tion of PG synthesis of 50% on day 1 after the last injection. 
1
 Percentage in parentheses represents the cumulative loss of 3 5S-
labelled proteoglycans as calculated from the 35S-suIfatc content on 
day 4 after IL-1 injection. In a second experiment. 3 5S-PG loss was 
42% for the contralateral joints and 26% for the IL-1-treated joints 
between day 4 and 10. 
p-values compared with the contralateral joints or the IL-1-injected 
joint on day 4(Mann-Whitney): *p<0.05; **p<0.01. 
огт тг-г.ис 
Fig. 4. Zymography of cacodylate extracts of patellae and joint 
capsules (soft tissue). Interleukin-la (10 ng) or phosphate-buffered 
saline (PBS) was injected intra-articularly on three alternate days. 
Proteoglycan synthesis. 1 day (D 1) and 5 days (D 5) after the last 
IL-1 injection were 0.53 times and 1.89 times the saline-injected 
group, respectively. Extracts were normalized based on the dry 
weights of the tissues. Clear bands on the dark gel indicated gelati­
nolytic activities. Two middle lanes: prestained molecular weight 
markers. 
minimal amount of cartilage isolated with this proce­
dure. 
In the tissues of the joint capsule, 59 k D a appeared to 
be the major band. Shortly after phosphate-buffered saline 
(PBS) injection, the 97 k D a band was as prominent, 
whereas after IL-1 exposure a similar set of bands was 
noted as compared to the patella. In contrast, this expres­
sion returned to the baseline on day 5, whereas moder­
ately enhanced expression was still present in the patella. 
Discussion 
The objective of this study was to analyze the reparative 
responses of articular cartilage after an arthritic insult as 
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induced by intra articular injections of IL-1 into murine 
knee joints IL-1 was used for a number of reasons first, 
we recently demonstrated that IL-1 plays a key role in 
cartilage destruction m several experimental arthritis 
models in mice [6, 7], second, IL-1 was rapidly cleared 
from the joint, third, IL-1 caused only a mild and transient 
joint inflammation [4] Detailed analysis of initial carti­
lage proteoglycan depletion was performed to provide 
a basis to study the reparative response 
A single IL-1 injection increased the degradation of 
" S P G loss by 1 55-fold within the first 24 h Three re­
peated IL-1 injections did not further increase the rate of 
loss, but rather extended the time period during which the 
cartilage was in a catabohc state We measured an addi­
tional loss of 36% over normal Although both newly 
synthesized and the more processed proteoglycans were as 
sensitive for IL-1-induced degradation, the measured loss 
of unlabelled glycosaminoglycans was only 20% This 
underestimates cartilage depletion since only the superfi­
cial layer, physically unseparable from the calcified carti­
lage layer, became depleted after IL-1 exposure [4, 5] 
IL-1 induced suppression of chondrocyte proteoglycan 
synthesis also contributes to the cartilage proteoglycan 
depletion With ihc use of radiolabels and electrophoretic 
separation, we demonstrated that the synthesis of chon-
droitin sulfate was suppressed, whereas the synthesis of 
hyaluronic acid chains, aggrecan backbone, was not affec­
ted This further indicates that polysaccharide synthesis in 
general was not affected Benton and Tyler [20], using 
expiants of pig articular cartilage, and Morales and Has 
call [21], using bovine articular cartilage, showed that 
IL 1 down-regulated proteoglycan synthesis at the level of 
core-protein This suggests that the synthesis of core-
protein and chondroitine sulfate chains were linked Total 
chondrocyte protein synthesis was not affected by IL-1 
and we found no dramatic changes which could be used as 
markers for IL-1 signalling of chondrocytes Analysis of 
the first phase, the catabohc phase set the parameters to 
be studied in the recovery phase proteoglycan synthesis 
and degradation 
Articular cartilage fully recovers from the IL-l-in-
duced arthritic insult within 7 days after the last IL-1 
injection Recovery was accelerated by an overshoot to 
enhanced chondrocyte proteoglycan synthesis for a pro­
longed period of lime In rabbits it was also demonstrated 
that part of the driving force to recuperate from an II -1 
insult was an overshoot to enhanced PG synthesis [22] 
Proteoglycan recovery after an IL-1 insult occurred 
earlier in mice than in rabbits This is consistent with the 
high rate of cartilage proteoglycan turnover (ca 10 15% 
per day) in young mice, and the high chondrocyte content 
per wet weight of cartilage (1 75 + 0 76 χ IO5 cells per 
70 μg wet-weight per patella) compared with other species 
[24] Recovery of the cartilage of rats after an IL-I insult 
was not accompanied by supranormal PG synthesis 
Moreover, the ability to recover was impaired after a sec­
ond IL-1 injection [24] This was probably due to the 
much higher IL-1 dose used in rats (150 μg) as compared 
to our 10 ng injection in mice We found that the recovery 
was not impaired It even reached significantly higher 
synthesis at an earlier time point after the last of the three 
IL-1 injections as compared to a single injection 
In two replenishment of PGs after papain-mduced 
depletion was preceded by an increased activity of chon­
drocyte oxidative metabolism (2-fold) and an increased 
activity of undine diphosphoglucose dehydrogenase 
(UDPGD) (1 5-fold), an enzyme directly linked to PG 
synthesis [25] This may also provide part of the driving 
force for the supernormal PG synthesis in the reparative 
phase of IL-1-affected cartilage 
In addition, we found evidence for a second, highly 
relevant recovery mechanism, which may substantially 
contribute to the replenishment of articular matrices after 
an IL-1 insult Degradation of proteoglycans was signifi­
cantly decreased during the recovery phase and was re­
duced to rates of about 50% of those found in normal 
cartilage To our knowledge, this novel mechanism has 
not been described before In normal murine costal carti­
lage, two populations of 35S-labelled, newly synthesized 
proteoglycan monomers are found, a major one (85%) of 
large hydrodynamic size and a minor one (15%) of small 
hydrodynamic size with half lives of 180 and 247 h, re­
spectively [17] It was interesting to find that the cal­
culated half-lives of •"S-labelled proteoglycans in normal 
patellae and from patellae in the IL 1 recovery phase were 
144 and 216 h, respectively We found no evidence that the 
impaired PG breakdown was related to a shift towards 
predominant synthesis of small hydrodynamic size PG 
monomers The newly synthesized PGs (95%) in the re­
covery phase have a hydrodynamic volume identical to 
that of proteoglycansVither newly synthesized or preexist­
ing in normal, untreated cartilage A 48 h chase period 
did not shift the PG monomers synthesized in the recov­
ery phase from large to small hydrodynamic size (pro­
cessing) 
Decreased degradation of proteoglycans could be a re­
sult of reduced enzymatic activity The preferable cleavage 
site of many enzymes, including stromelysin, collagenases 
and the gelatinases (72 and 95 kDa) is between the Gl and 
G2 domain of the core-protein of proteoglycans [26, 27] 
It remains to be defined which enzyme is responsible for 
the cleavage of proteoglycans Based on sequence data, 
the IL-1-induced cleavage of core-protein appears not to 
be at one of the above-mentioned or other known en­
zymes [28] hor this, we examined extracts from tissues of 
the joint capsule, patellae and articular cartilage by 
zymography Using copolymenzed gelatin as a substrate 
allowed us to detect a broad range of enzymes, e g , 
gelatinases, collagenases, cathepsins, plasmm, and 
stromelysin On day 1 after the third IL-1 injection, all 
articular tissues expressed enhanced gelatinolytic activ­
ities and the 97 kDa protein became the dominant gela-
tinase Lefcbre et al [29] reported that IL-1 enhanced 
expression of proMMP9 (91 kDa type IV collagenase) 
and 55 kDa, either ргоММРЗ and/or proMMPl (57 kDa 
interstitial type 1 collagenase) in rabbit articular chon­
drocytes In the recovery phase, gelatinolytic levels sub­
sided but were still above baseline This did not correlate 
with the markedly impaired degradation of the newly 
synthesized proteoglycans Two possibilities exist first, 
the gelatinases were not responsible for the PG loss, 
although capable of doing so, second, gelatinase activity 
was antagonized by inhibitors, eg, tissue inhibitor of 
metalloproteinases (TIMP) [30] 
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In this study, changes in proteoglycan synthesis and 
degradation coincided in both phases of the I L-l -induced 
insult This does not necessarily have to mean that both 
processes were linked Arner and Pratta [31] found 
in IL-1-challenged bovine nasal cartilage, that both 
processes were mediated by independent post-receptor 
mechanisms We demonstrated that the recovery of IL-
1-induced arthritic insult in mice was facilitated by en­
hanced proteoglycan synthesis and impaired degradation 
of proteoglycans Studies are in progress to understand 
the mechanism of decreased proteoglycan degradation 
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CHAPTER 5 
PROTECTION AGAINST CARTILAGE PROTEOGLYCAN 
SYNTHESIS INHIBITION BY ANTI-INTERLEUKIN-1 
ANTIBODIES IN EXPERIMENTAL ARTHRITIS 
The Journal of Rheumatology 1992;19:348-356 

Protection Against Cartilage Proteoglycan Synthesis Inhibition 
by Antiinterleukin 1 Antibodies in Experimental Arthritis 
FONS A.J. van de LOO, ONNO J. ARNTZ, IVAN G. OTTERNESS, and WIM В. van den BERG 
Abstract. We have used neutralizing antibodies raised against murine recombinant interleukin 1 
( I H ) to demonstrate a role for IL-1 in the cartilage destruction and inflammation of antigen 
induced arthritis. Ex vivo production of IL-1 was demonstrated in tissue cultures of joint cross 
sections shortly after arthritis induction. Neutralizing antimurine IL-1 antibodies identified the 
activity to be about 80% IL-la 24 h after onset of arthritis. In animals receiving a single injec­
tion of anti-IL-1 antisera at Day - 3 , cartilage proteoglycan synthesis suppression during the 
first 2 days of arthritis was prevented. Normal proteoglycan synthesis was maintained until 
Day 4 when anti-IL-1 antisera was given at Days - 2 , 0 , and 2 of arthritis. Dose response experi­
ments showed that the reduction in inflammation was insufficient to account for the clearcut 
reduction in cartilage proteoglycan synthesis Inhibition. Our results demonstrate that IL-1 plays 
a role In cartilage pathology in murine antigen induced arthritis. (J Rheumatol 1992,19:348-56) 
Key Indexing Terms. 
INTERLEUKIN 1 
INFLAMMATION 
EXPERIMENTAL ARTHRITIS 
BLOCKING STUDIES 
CARTILAGE 
MICE 
A central role of interleukin 1 (IL-1 ) in the pathology of rheu­
matoid arthritis (RA) has been proposed, because it can be 
produced by and has effects on numerous cell types present 
in the arthritic joint'2. 
It is known that IL-1 has profound catabolic effects on 
articular cartilage. This has been demonstrated in vitro on 
living cartilage expiants derived from different species, 
including murine patellar cartilage'5. Moreover, intraartic­
ular injections of IL-1 in rabbits48, rats', and mice10 
resulted in marked depletion of cartilage matrix, a 
predominant influx of neutrophils into the joint, and syno­
vitis similar to that seen in experimental arthritis. It has also 
been reported that IL-1 could modulate immune responses 
associated with the arthritic process. Systemic IL-1 can 
accelerate onset and increase incidence of collagen type II 
arthritis in DBA mice" ' 2, and may potentiate spontaneous 
arthritis in MRL mice11. Intraarticular IL-1 injections 
reduced antigen methylated bovine serum albumin (mBSA) 
induced swelling and histopathology of joints of immunized 
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rats"1, but potentiated the effects of antigen induced inflam­
mation in nonscnsitizcd mice13 In the chronic phase of both 
antigen induced arthritis (AIA) and peptidoglycanpolysac-
chande induced arthritis, intraarticular IL-1 injection induced 
exacerbation of the smouldering inflammation'6 " 
Finally, IL-1 has been reported to be present in synovial 
fluids of patients with RA". 
These observations fulfill criteria for IL-1 to be a poten­
tial mediator in arthritis, and suggest it may have a role in 
the disease process. These studies do not, however, provide 
direct evidence for IL-1 involvement as a mediator of 
arthritis. Moreover, other cytokines, such as TNF and IL-6, 
also fulfill these criteria to some extent" 2 2. It is therefore 
imperative that direct methods are used to determine if IL-1 
has a role in arthritis. 
Using antibodies directed against murine recombinant 
IL-1, we have demonstrated that in murine antigen induced 
arthritis, synovial tissue releases IL-1 and that the neutralizing 
antibodies block the cartilage changes and partially inhibit 
the acute inflammation of antigen induced arthritis (AIA). 
These data provide the first direct evidence that IL-1 plays 
a role in cartilage pathology of AIA. 
MATERIALS AND METHODS 
induction and treatment of experimental arthritis C57b I /6 mice, aged 6-8 
weeks at the stari of the experiments, were immunized with mBSA (Sigma 
Chemical Company, St Louis, MO, USA) as described23 Arthritis was 
induced 21 days after the start of the immunization by injecting 60 /ig mBSA 
in phosphate buffered saline (PBS) into the left knee joint 
Assessment of joint inflammation Joint inflammation was measured by 
"Technetium ( " T c ) pertechnetate uptake in the knee joints24 Briefly, 
animals were sedated by intraperitoneal administration of 4 5% chloral 
hydrate, 0 1 ml/10 mg of body weight About 10 μΟ " T c in 0 2 ml saline 
was injected subcutaneously in the neck region After 15 mm the accumu­
lation of the isotope in the knee due to increased blood flow and tissue swell· 
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ing was determined by external gamma counting. The severity of inflam­
mation was expressed as the ratio of the ^^Tc uptake in inflamed over con­
tralateral knee joint. 
Assessment of proteoglycan synthesis. Patellae (5 or 6 pieces), in a minimal 
amount of adjoining soft tissue, were placed in a 2 ml RPMI-HEPES 
medium (Flow Laboratories, Irvine, Scotland) with gentamicin (50 μg/ml), 
and L-glutamine (2 mM) and 40 μΟί -,sS-sulfate. At the end of the 3 h 
incubation period, patellae were fixed in 10% formalin and subsequently 
decalcified in formic acid (5%) for 4 h. Patellae were punched out of adjacent 
tissue, and dissolved in 0.5 ml Luma solve (Hicol, Oud-Beijerland, The 
Netherlands). The •1SS content of each patella was measured by liquid scin­
tillation counting. 
Histology of knee joints. The left and right joints were dissected and processed 
for histology as described2-1. Standard frontal sections (7 μτη) were prepared 
and stained with safranin-O, and depletion was visualized by diminished 
staining of the cartilage matrix. 
IL-I production by synovial tissue. A cross section of synovial tissue was 
taken ventrally at the knee joint. It contains, in addition to the synovia, the 
patella and adjoining tendon. Synovial tissue comprised of specimen from 
6 knees to exclude variation between specimens was incubated in 2 ml RPMI 
medium at 37°C in a C 0 2 incubator for 1, 6, and 24 h. Dilutions of these 
culture media were tested for 1L-1 activity by a sensitive bioassay based 
on the IL-1 specific EL-4 NOB-1 line in conjunction with the IL-2 responder 
CTLL line. More IL-1 bioactivity was delected in 1 h than in prolonged 
tissue incubations. Recovery ofcxogenously added IL-I to the supernatant 
was 85% and 60% in the 1 h and 24 h tissue incubations, respectively. This 
was not due to cytotoxicity of the culture media, because viability and cell 
numbers in the bioassay were unchanged. 
Assessment of protein levels. Protei η-I e veis of synovial tissue conditioned 
media were measured by a colorimetrie method based on the coomassie 
brilliant blue G250 color shift according to the manufacturer's procedure 
(Bio-Rad Protein-assay kit I, Bio-Rad Laboratories). 
Bioassay for IL-I. IL-1 activity was measured in the one-stage bioassay 
for IL I as described by Gearing, c\ afi*. In short, the assay was performed 
as a coculture of the IL-1 specific subclone of the murine thymoma cell 
line EL 4, designated NOB-1 producing IL-2 and IL-4 with the lymphokine 
responder CTLL line. The cells were plated out in concentrations of I x 
10s well NOB-1 cells and 4 x 1&я well CTLL cells in RMPI supplemented 
with 10% fetal calf scrum; after 18 h 0.5 ^Ci/well of 'H-TdR was added 
and incorporation was measured after 3 h. Samples were tested in tripli­
cate, and in a monoculture of CTLL line to exclude possible IL-2 impuri­
ties of the samples. The sensitivity limit of the NOB-1 assay was less than 
0.1 pg/ml, 200 x more sensitive than the original leukocyte associated func­
tion assay, Titration of IL-1 showed that the NOH-1 line was almost as 
sensitive to mrlL-la as to mrlL-Wl (Figure I A), with half-maximal prolifer­
ation at about 1 pg/ml. 
Antiserum treatment of mice. Polyclonal rabbit antimurinc IL-lit antiserum 
and polyclonal goat antimurine recombinant IL-la antiserum were prepared 
by immunization with complete Freund's adjuvant against cloned, purified 
biologically active mature 1L-Ia2 h and IL-lfl27. Anti-IL-la antiserum was 
8 x more potent in neutralizing IL-I in the NOB-1 assay than anti-IL-lfì 
antiserum (Figure IB), and showed no cross reactivity (not shown). Each 
of the preparations of antibodies (ami IL-1 α or anti-IL-lli) was tested in 
vitro and showed no neutralizing crossreactiviry against IL-6, rumor necrosis 
factor (TNF), and granulocyte macrophage colony stimulating factor 
(unpublished). Western analysis and intracellular labelling of macrophages 
further subscribed the specificity of anti-IL-l antibodies2"'24. For in vivo 
treatment, mice were injected sc with 200 μΙ of a 1:1 mixture of both anti-
sera, and administered at various times relative to the induction of arthritis 
as described in Results. In all experiments. 200 μ! of a 1:1 of goal and rab­
bit normal sera was administered to groups of mice to control for nonspecific 
effects of sera. 
Purification of anti-IL-l antiserum by chromatographic separation. The initial 
van de Loo, et al: Anti-IL-l antibody treatment of arthritic mice 
step in the IgG purification process of the sera was a limited precipitation 
of proteins with 45 % ammonium sulfate in serum. The precipitate was spun 
down, and the pellet was redissolved and dialyzed against bidislilled water 
at 4°C. 
Immunoglobulins from the rabbit anti-IL-l antiserum were purified by 
affinity chromatographic separation on a protein A sepharose CL4B column. 
Serum proteins were present in the void volume, and immunoglobulins were 
separated from the column with the elution buffer, 0.1 M glycine-HCl, 
pH 2.5. Fractions were dialyzed against bidislilled water and concentrated 
down lo the starting point volume. The protein fractions were added back 
to the dialyzed ammonium sulfate supernatant. 
Immunoglobulins from the goat anti-IL-l antiserum were purified by ion 
exchange chromatography on a DEAE-Trisacryl M column. Immunoglobu­
lins were detached from the column by low salt elution, 0.025 M Tris-HCl, 
0.035 M NaCl, pH 8.8, and the other scrum proteins were isolated from 
the column by the high salt elution buffer, 0.1 M Tris-HCI. I M NaCl, 
pH 8.8. Column fractions were dialyzed against bidislilled water, concen­
trated to the original volume. The second fraction was added back to the 
dialyzed ammonium sulfate supernatant. 
All the individual fractions were tested for anti-IL-l antibody by ELISA, 
and this demonstrated that the chromatographic separation of anti-IL-l anti­
bodies was absolute. 
RESULTS 
IL-1 production by synovial tissue from inflamed joints. Syn­
ovial tissues were removed from knee joints of normal and 
AIA mice and examined for their ability to release IL-1 into 
the culture supernatant. Preliminary experiments had shown 
that 1 h incubation was sufficient to obtain a significant 
release of IL-1 activity from AIA, but not normal tissue. 
Therefore, all tissue samples were incubated for 1 h in tis­
sue culture medium and the supernatant assayed for IL-1 
using the NOB-1 assay. 
A distinct IL-1 signal was obtained 3 h after induction of 
arthritis. Time course studies showed further increases at 6 
and 12 h and maximal production at 24 h (Figure 2). IL-1 
levels declined thereafter. The IL-1 released from tissues of 
untreated joints, or inflamed joints on Day 4, were below 
the detection limit of 0.1 pg/ml. IL-1 production could also 
be induced by mBSA in nonimmune mice, although to a low 
extent (Figure 2). In several experiments, the estimated 
amount of IL-1 released during the 1 h incubation was 10-30 
pg/synovia, using tissue from 24 h AIA, whereas only 1-2 
pg was released by tissue from mBSA injected, nonimmune 
mice. Conditioned media of noninflamed tissue contained 
0.16 ± 0.07 mg protein (n= 10 different conditioned media 
samples). Protein levels in culture media of inflamed tissues 
taken from Day 1 of AIA were twice that high. Correction 
of IL-1 levels for total protein content of conditioned media 
still resulted in significant IL-1 levels of 5-15 pg. 
Blocking by specific antiserum demonstrated that about 
80% of the NOB-1 activity released from the tissue at Day 
1 of arthritis could be ascribed to IL-lar (Figure 3). IL-1 
levels in serum were not significantly elevated at any time 
point (not shown). Our results demonstrate that local IL-1 
production is induced in articular tissue immediately after 
the onset of arthritis. 
In vivo demonstration of the neutralizing capacity of the anti-
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Fig. 1. Titration of IL-1 and anti-IL-1 antiserum in NOB-1 assay. (A) Dose dependent effect of mrlL-la ( о—о ) and IL-1B ( Δ - Δ ) on CTLL cells 
cocultured with EL4-NOB-1 cells for 24 h- Proliferation response was measured by 3 H TdR incorporation and expressed as CPM values. (B) iL-! stan­
dards (31 pg/ml) were preincubaled for 1 h with different dilutions of anti-IL-1 antiserum. The residual IL-Ì activity was measured in the NOB-Ì assay 
and expressed as a percentage of maximal proliferation (IL-la, 11,270 cpm; II.-1 β, 15,955 cpm}. 
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Fig. 2. IL· I released by synovial tissue ex vivo. Patellae with adjoining soft 
tissue were dissected at different times after intraarticular injection of mBSA 
(60 μ$) in normal or mBSA preimmunized mice. Six specimens were 
incubated in 2 ml RPMI medium for l h and dilutions (1/20 and I/40) of 
the media were tested in triplicate for IL I activity in the NOB assay. Titration 
of mrIL-ia served as a control. Proliferation expressed as stimulation index 
(SI). 3H-TdR incorporation, background 2000 cpm; maximum 27,737 cpm. 
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Fig. 3. Identification of IL-1 in the culture supernatants by neutralizing anti-
bodies. Culture supernatant of joint tissues taken 6 and 24 h of AIA was 
incubated in the presence of ÍI /8000 diluted) neutralizing antiserum to IL- l a 
(AIL-la) and IL-IB (AIL-lb) or a combination of both (AIL-la+b). Methods 
as described in Figure I. 
IL-1 antisera. The in vivo effectiveness of the anti-IL-1 anti-
serum was tested by examining its ability to neutralize intra-
articularly injected IL-1. Injections of IL-1 into the joint 
cavity induced a significant suppression of proteoglycan syn-
thesis by patellar cartilage. Kinetics revealed that anti-IL-1 
antisera given shortly before 1 or 10 ng of IL-1 blocked the 
IL-1 suppression of proteoglycan synthesis significantly 
(Figure 4). Inhibition of high dose intraarticular IL-Iß and 
IL-Ια (10 ng) was further enhanced by extending anti-IL-1 
antisera treatment of mice to Days - 2 , and - 1 . This shows 
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Fig. 4. Prevention of iL- i induced proteoglycan synthesis suppression by 
in iñw administration of antiserum to mrlL-1. !L-1 was injected intraartic-
ularly; IL Iß, I ng (A); IL-lß 10 ng, (B); IL-la 10 ng (C). Proteoglycan 
synthesis at Day 2 was measured ex vivo by 35S-sulfate incorporation as 
described in Materials and Methods. Mice received 100 μΐ anti-IL-l anti­
serum (AIL-1) sc at Days 6. 4, 2 and/or I before IL-1 injection. Statistical 
significance was calculated with Student's t test; * ρ < 0.05; ** ρ < 0.01 ; 
# ρ < 0.001. from proteoglycan synthesis of IL-1 injected compared to 
healthy knee joints. 
that the anti-IL-1 antisera has sufficient activity to neutral­
ize locally synthesized IL-1, and is suitable for exploring the 
role of IL-1 in AIA. 
Effect of anti-lh-l antisera treatment on arthritis. A sub­
cutaneous injection of 200 μΐ of anti-IL-1 antiscra, or con­
trol sera at Day - 3 , induced a slight reduction in edema as 
measured by decreased ВДтТс uptake of the inflamed joint 
at Day 2 (Table 1). The mean reduction in edema by anti-
IL-1 antisera treatment from 4 replicate experiments was 12 
± 10% at Day 2. On Day 2 of arthritis, proteoglycan syn­
thesis in patellae was about 55 + 21 % of normal value. Anti-
IL-1 antisera treatment significantly maintained the pro­
teoglycan synthesis at 98 ± 2 3 % of the normal synthesis 
(mean of 4 separate experiments). On Day 4 of arthritis, a 
significant reduction in edema was measured after anti-IL-1 
antisera treatment, but the proteoglycan synthesis was slightly 
suppressed (Table 1). Histology of the whole arthritic knee 
joint at Day 4 showed depletion of articular cartilage, and 
a single injection of anti-IL-1 antisera at Day - 3 did not 
improve the outcome (not shown). Moreover, treatment 
started 2 days after AIA induction was insufficient to abrogate 
suppression of chondrocyte proteoglycan synthesis (57 %, 
p<0.001) and joint inflammation (1.68 ± 0.41) at Day 4. 
To determine whether this was due to a depletion of anti-
IL-1 antibody or whether IL-1 antisera treatment was no 
longer important in Day 4 arthritis, the anti-IL-1 antisera 
treatment was prolonged; animals were injected sc at Days 
- 2 , 0, and 2 of arthritis. The anti-IL-1 antisera treatment 
induced a consistent reduction of edema at Day 2 (22 ± 
18%), and Day 4 (29 ± 7%). Now, in addition, there was 
a significant prevention of the inhibition of 35S-proteoglycan 
synthesis at Days 2 and 4 of arthritis (Table 2). The mean 
proteoglycan synthesis from 3 replicate experiments went 
from 47 ± 9% of the normal value to 98 ± 22% at Day 
4 of arthritis. Control serum reduced the inflammation by 
8 ± 15%, at Day 2 and by 12 ± 18% at Day 4, but this had 
no beneficial effect on cartilage metabolism. 
Effect of purified anti-IL-1 antibodies. To demonstrate that 
the active principle in the anti-IL-1 antisera could be ascribed 
to anti-IL-1 antibodies, we purified the immunoglobulins and 
performed a comparative study with IgG depleted serum and 
irrelevant antibodies. Treatment was started 24 h prior, to 
induction of antigen-induced arthritis. Normal serum, puri­
fied antibodies against the irrelevant antigen lysozyme, and 
serum devoid of immunoglobulins had no effect on the 
proteoglycan synthesis suppression at Day 2 of arthritis. 
Complete anti-IL-1 antiserum and the purified anti-IL-1 anti­
bodies prevented the proteoglycan synthesis suppression to 
full extent (Figure 5). This result demonstrated that anti-IL-1 
Table 1. Effect of a single injection of anti-IL-1 antibodies on AIA 
Treatment 
Normal sera 
Anti-IL-1 
Normal sera 
Anti-IL-1 
Time 
Day 2 
Day 2 
Day 2 
Day 4 
Day 4 
Day 4 
Tc Uptake 
(L'R) 
1.95±0.29 
1.94 ±0.18 
1.68±0.30 
1.65 ±0.53 
1.51±0.31 
1.21*±0.07 
Proteoglycan 
Control 
932±218 
842 ±102 
900+104 
992 ±112 
1001 ±81 
1085 ±340 
synthesis* 
Arthritic 
632*+152 
622** ± 9 0 
I078±191 
6 3 1 * ± ! 7 3 
477*±83 
770 ±273 
68 % 
74% 
120% 
64% 
46% 
71% 
Representative of 4 experiments. Each value represents the mean ± SD calculated from groups of 5 or 6 mice. 
Mice were injected sc 3 day;* before induction of arthritis with 200 μ\ of normal or anti-IL-1 antiserum. 
Edema was expressed as ratio of *>mTc uptake by inflamed joint (L) over the contralateral joint (R). A value 
near 1.0 is typical for untreated mice. 
* Proteoglycan synthesis was measured ex VÌVO by 3 5S04 incorporation (CPM), and expressed as a percentage 
of contralateral patellae. The statistical significance of differences from control 35S incorporation was calcu-
lated with Student's t test, and the statistical significance of the " T c ratios with the Wilcoxon rank sum test; 
* ρ < 005, ** ρ < 0.01; * ρ < 0.001. 
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Table 2. Prolonged treatment of arthritic mice with antibodies directed against IL-1 
Treatment 
Normal sera 
Anti-IL-1 
Normal sera 
Anti-IL-1 
Time 
Day 2 
Day 2 
Day 2 
Day 4 
Day 4 
Day 4 
Tc Uptake 
(L/R) 
2.27 ±0.50 
2.42 ±0.32 
2.32 ±0.46 
1.61 ±0.15 
l.32*±0.13 
l.20*±O.I7 
Proteoglycan 
Control 
876 ±225 
852 ±108 
861 ± 152 
856 ± 92 
722 ± 61 
680 ± 72 
Synthesis 
Arthritic 
486* ±101 
480* ± 69 
817 ±153 
395*± 85 
468* ± 29 
833* ±133 
55% 
56% 
95% 
46% 
65« 
123% 
Treatment consisted of sc injections at Days -2,0, and 2 of arthritis. Arthritis was induced with 60 pg mBSA, 
Day 2 and Day 4 were examined. Methods and statistics as described in legend of Table 1. 
1000-
800 
600 
400 
200-
35S-incorporation (CPM) 
l—I P<0.01 
P<0.01 
Salin· N.aara A.aera iLlAb LyaAb Sera-lgQ 
I I normal I arthritic 
antibodies in the antiserum were responsible for the observed 
effects on cartilage. 
Direct interference with IL-1 action on cartilage. Dose 
response experiments showed that the reduction in inflam­
mation exerted by the anti-IL-1 antibodies could not account 
for the complete prevention of articular proteoglycan syn­
thesis suppression (Table 3). The lower antigen dose elicit­
ed significantly less joint inflammation, as reflected by Tc 
uptake, but nevertheless the suppression of proteoglycan syn­
thesis inhibition in the articular cartilage was in the same 
order of magnitude as that obtained with the high antigen 
dose. Again, anti-IL-1 antibody treatment reduced both the 
inflammation and proteoglycan synthesis suppression. 
Histology further confirmed the protective effect of anti-
IL-1 antibodies on cartilage pathology. Whole knee joint sec­
tions revealed marked proteoglycan depletion in the arthritic 
cartilage of the control group and clear cut reduction of this 
depletion in the anti-IL-1 group. Moreover, less chondro­
cyte death occurred in the latter group (Figure 6). 
Taken together, our results show that IL-1 is a key medi­
ator in cartilage destruction in the early stage of AIA in mice. 
Fig. 5. Prevention of proteoglycan synthesis suppression in arthritis by 
purified anti-IL-1 antibodies. Mice were injected intraperitoneally with 200 
μί anti-IL-1ÜC + Il antisera (A.sera) or an equivalent of anti-IL-la+ 8 anti-
bodies (ILlAb) at 24 h before induction of AIA. As a control, mice were 
treated with saline, antilysozyme antibodies (LysAb), or normal complete 
sera (N.sera). Patellar proteoglycan synthesis was measured at Day 2 of 
arthritis. Methods and statistics as described in legend of Table I. 
DISCUSSION 
We set out to obtain direct evidence for the involvement of 
IL-1 in AIA in mice. As many studies have demonstrated 
that IL-1 has effects in vitro and in vivo consistent with a 
role in arthritis, we felt that 2 additional criteria needed to 
be fulfilled before we could declare that IL-1 has a signifi-
cant pathogenic role: first, that IL-1 is present at the disease 
Table 3. Prevention of proteoglycan synthesis suppression is independent of decreased 
joint inflammation 
Treatment Dose Tc Uptake 
(L/R) 
Proteoglycan Synthesis 
Control Arthritic 
Anti-IL-1 
2 0 « 
60
 re 
60 μ
β 
I.28±0.20 
1.45 ±0.27 
1.27±0.24 
690± 76 
712+ 127 
824 ±128 
377*+ 72 
457*+ 76 
675 ±167 
55% 
64% 
82% 
Treatment consisted of sc injections at Days -2.0, and 2 of arthritis. Arthritis was induced with 20 or 60 /tg 
mBSA and was examined on Day 4. Methods and statistics as described in legend of Table !. 
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Fig. 6. Frontal scellons of knees from Day 4 of arthritis stained with sairanin O. Cartilage proteoglycan depletion in the femoropatellar joint (patella is 
removed) in the arthritic mice (A). Cells in infiltrate and exudate arc predominantly PMN ( * ). Prolonged treatment with anti-IL-1 antisera, 3 sc injections 
at Days - 2 . 0, and 2 of arthritis, resulted in reduced cartilage depletion (B). Higher magnification of the femorotlbial joint showed proteoglycan loss and 
the presence of pyenotic chondrocytes (C. arrow). Note the absence of these characteristics of arthritis after prolonged treatment with anti-IL-1 antisera (D). 
Abbreviations: B, bone; C. cartilage: F. femur: G. growth plate: M. meniscus: T, tibia. 
locus, and second, that inhibition of IL- I's effects would lead 
to an amelioration of the disease. 
Because of the impracticability of obtaining synovial fluid 
(SF) from a mouse, we elected to determine if IL-1 was 
released from joint tissue. We used a short 1 h incubation 
time so that measurements would be made of ongoing syn-
thesis rather than synthesis induced by tissue treatment. Thus, 
within 1 h of LPS stimulation, murine macrophages did not 
produce significant amounts of IL-1 by Western analysis. 
Culture for 1 h of joint cross sections dissected from arthritic 
joints showed substantial release of IL-1 during the first 2 
days of AIA (Figure 2). Tissue taken at later time points or 
from normal joints failed to release detectable IL-1. IL-1 and 
protein levels were not related because total protein levels 
in the culture media of inflamed tissues were doubled com-
pared to noninflamed synovial tissues from Day 1 to Day 
7 of AIA. Thus IL-1 production coincides with the acute onset 
of inflammation and precedes the depletion of articular 
cartilage. 
We had found that intraarticularly injected IL-1 causes a 
marked suppression of proteoglycan synthesis in mice within 
24 h10J0. This could account for the observed inhibition of 
proteoglycan synthesis at Day 2 of arthritis. This implies a 
link between IL-1 synthesis and the pathology of articular 
cartilage. 
We identified the synovial tissue released IL-1 activity to 
be primarily IL- la by specific antibody blocking (Figure 3). 
It has been reported that both IL-la and IL-Iß are present 
in the SF of patients with arthritis". IL-lß is in part 
released in an inactive precursor form2* ", and may not be 
detected in the NOB-1 bioassay. In tissue culture of murine 
macrophages, we find that IL-111 is secreted rapidly and com-
pletely within 24 h of stimulation by LPS, whereas IL-la 
continues to be released for at least 96 h after stimulation 
(unpublished). Our results should therefore be taken as defini-
tive evidence that IL-1 is present. However, it does not indi-
cate either absolute or relative amounts of IL-la or IL-1 li 
in the arthritic joint. Further studies on this subject are 
ongoing. 
Having demonstrated that IL-1 is present in the arthritic 
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tissue, the next question was whether it plays a pathological 
role in AIA Cytokines other than IL-1 are known to have 
the potential to cause arthritis Transforming growth factor-
ß injected intraarticular^ into the knee joints of DBA mice 
accelerated the onset of type II collagen arthritis12, and 
could cause arthritis directly in rats11 Other mediators such 
as TNFa", and some as yet uncharactenzed Τ cell 
lymphognes" have all been shown to cause arthritis upon 
direct intraarticular injection Moreover, evidence has been 
presented that most of these cytokines are present in SF Thus 
it is important to prove whether there is a direct role for IL-1 
in the pathogenesis of AIA 
Several methods are available to directly block the activity 
of IL-1 with sufficient specificity to determine whether IL-1 
plays a pathologic role in cartilage destruction A monoclonal 
antibody directed against the IL-1 receptor, which blocks the 
action of IL-1, although effective in other diseases35, may 
not be useful here because immunoglobulins do not easily 
penetrate articular cartilage1* An IL-1 receptor antagonist 
(IL Ira) has been isolated, cloned and sequenced, which anta­
gonizes IL-1 action m vitro and in vivo31 Cartilage is acces­
sible for IL-1 ra because of its size of 23-26 kDa Neverthe 
less, it is difficult to obtain good inhibitor levels in articular 
cartilage at the chondrocyte receptor because it has a short 
half-life (t,,) and inability to accumulate in cartilage 
In addition, there is a soluble form of the IL-1 receptor 
that binds to IL-1 and thereby may prevent its binding to cell 
bound receptors'7 A short t|/2 (2 h) may limit its use in 
chronic studies18 We chose to use polyclonal neutralizing 
antibody for our studies in chronic AIA because they have 
an in vivo t,
 2 of 7 days and because we had been able to 
document complete blockage of in vivo IL-1 effects on car­
tilage (Figure 4) Unlike antireceptor antibody, it does not 
need to penetrate the cartilage to be effective 
We found in AIA that specific elimination of IL-1 by poly­
clonal anti-IL-1 antibodies resulted in significant suppres­
sion of edema, diminished influx of inflammatory cells and 
maintenance of chondrocyte proteoglycan synthesis Histo 
logic sections demonstrated that treatment of mice with anti-
IL-1 antiserum prevented cartilage loss and chondrocyte 
death, both typical pathological sequelae of antigen induced 
arthritis 
The effects of the anti IL-1 antisera on inflammation and 
on cartilage metabolism must be regarded as independent 
phenomena Multiple doses of normal sera could suppress 
the inflammation, but could not prevent the suppression of 
chondrocyte proteoglycan synthesis When anti-IL-1 antisera 
was given as a single dose 3 days before disease induction, 
the nonspecific effect of serum injection was absent, yet a 
significant inhibition of inflammation by anti-IL-1 was still 
observed (Table 1) This indicates IL-1 involvement in the 
inflammatory process However, when a low dose of anti­
gen (20 /ig mBSA) was given, it induced a mild level of joint 
inflammation (1 28 ± 0 20) at Day 4 of AIA, comparable 
354 
to that found in the antisera or normal sera treated mice 
(Table 1), yet the proteoglycan synthesis was still markedly 
suppressed Therefore, the reduction of inflammation by anti-
IL-1 antisera was too small to account for the abrogation of 
proteoglycan synthesis inhibition This indicates that the anti-
sera directly interferes with IL-1 action on cartilage 
metabolism We have shown that both ¡n vitro IL-17 and 
intraarticular IL-11050 can directly inhibit cartilage pro-
teoglycan synthesis m the mouse We believe this is the first 
demonstration that during an arthritic process, IL-1 directly 
asserts this effect on the cartilage 
Patellar cartilage breakdown as measured by loss of 
35S-sulfate prelabelled proteoglycans is currently under 
investigation Preliminary results demonstrated that the 
= 45 % breakdown of proteoglycans from patellar cartilage at 
Day 2 of arthritis remained unchanged regardless of anti-
IL 1 antiserum treatment This implies that the cartilage pro-
teoglycan breakdown is not an IL-1 driven process in both 
the nonimmunologically mediated zymosan induced arthri-
tis and antigen driven arthritis, AIA The beneficial effects 
of anti-IL-1 antibody treatment on the diminished cartilage 
proteoglycan loss as observed with histology indicates that 
chondrocyte proteoglycan synthesis inhibition contributes to 
the total proteoglycan loss by insufficient resynthesis 
In a previous study, we demonstrated that the normal daily 
loss of 12% was redoubled once after a single intraarticular 
injection of 10 ng IL-Ια10 Depletion of the articular car­
tilage was histologically observed only after repeated IL-1 
injections, and the longterm proteoglycan synthesis suppres­
sion by IL 1 accounted for at least half the total proteogly­
can loss 
Therefore, continuous suppression of chondrocyte pro­
teoglycan synthesis by de novo synthesized IL-1 during the 
early phase of experimental arthritis contributes to the overall 
depletion of cartilage matrix In humans, the proteoglycan 
turnover rate is 2-5 times slower than in murine articular 
cartilage, and proteoglycan synthesis inhibition by endo­
genous IL-1 will only affect the cartilage matrix in the long 
run 
Chondrocyte death is found to be a common accompani­
ment of experimental arthritis and inflammation The pro­
tective effect of anti-IL-1 antiscra on this phenomenon was 
unexpected Decreased inflammation per se cannot account 
for the decreased chondrocyte death as it occurs in the milder 
20 /tg mBSA arthritis, and in the arthritis where inflamma­
tion was suppressed by the administration of normal sera 
Although cellular cytotoxicity induced by IL-1 has been 
reported for some cell types39 *, it has not been reported for 
chondrocytes It is more likely that IL-1 participates indirectly 
in eliciting chondrocyte death Mechanisms such as synergy 
with other cytokines as TNF, potentiation of oxygen radical 
formation, enhancing cell infiltration or activating inflam­
matory cells via IL-8 induction, or facilitating release of other 
toxic mediators may provide a more likely explanation 
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We have shown that in the acute induction phase οΓ AIA 
IL 1 plays a major role in proteoglycan depletion by inhibí 
tion of proteoglycan synthesis and chondrocyte death These 
results show that interference with IL 1 can lead to a favor 
able therapeutic effect on a form of experimental arthritis 
Because of the many similarities of AIA with human RA, 
it suggests that IL 1 could also play a major role in the human 
disease 
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Modulation of cartilage destruction in murine arthritis 
with anti-IL-1 antibodies 
F A J van de Loo'*, О J Arntz1, I G Otterness2 and W В van den Berg1 
1
 Department of Rheumatology University Hospital St Radboud, Nijmegen The Netherlands,2 Department of 
Immunology and Infectious diseases Pfizer Central Research Groton CT USA 
Abstract 
One of the early events in murine antigen-induced arthritis is the generation of IL-1 in the inflamed joint 
We investigated the role of IL-1 in the acute phase of the arthritic process by selective blockage of IL-1 
bioactivity by treatment with neutralizing antibodies Pretreatment with anti-IL-1 antibodies moderately 
suppressed joint swelling The decrease in chondrocyte proteoglycan synthesis seen in the acute phase of 
arthritis was prevented by treatment with anti-IL-1 antibodies IL-1 does not appear to be a major 
contributor to the accelerated breakdown of articular cartilage in this model The major impact of anti-IL-1 
antibodies was the prevention of proteoglycan synthesis inhibition which clearly reduced articular cartilage 
depletion by maintaining normal proteoglycan synthesis 
Introduction 
The importance of IL-1 in the arthritic process is 
based on IL-l's impact on connective tissue integ­
rity, and its pivotal function in humoral and cellu­
lar inflammatory processes Furthermore, IL-1 
mRNA was found to be present in inflamed syn­
ovial tissue [1], and IL-1 levels m sera correlates 
well with disease activity [2] 
Recent attention is focused on the use of cloned, 
naturally occurring IL-1 inhibitor, IL-1 receptor 
antagonist (IL-lra) Although effective in many 
acute systemic diseases [3], its use in arthritis is 
hampered for several reasons First, IL-Ira's half-
life m vwo was only about 30 min, secondly a 1000-
fold excess of this inhibitor is commonly required 
* Author for correspondence Fons van de Loo Department of 
Rheumatology, University Hospital St Radboud Geert Groote­
plein Zuid 8 6525 GA Nijmegen, The Netherlands 
to suppress effectively IL-l's acitivity In order to 
elucidate the role of IL-1 in antigen-induced arthri­
tis model (AIA), we treated mice with neutralizing 
antibodies directed against murine recombinant 
IL-1 The treatment started prior to induction оГ 
arthritis, but after a fully developed immune re­
sponse to the antigen We measured joint swelling, 
chondrocyte proteoglycan (PG) synthesis and 
breakdown in the arthritic knee joint 
Materials and methods 
Assessment of experimental arthritis 
Arthritis was evoked with 60 μg mBSA injected 
into the right knee joint cavity in sensitized male 
C57B1/6 mice Joint swelling was measured ex­
ternally by enhanced uptake of """Technetium 
pertechnetate of the inflamed knee joint from the 
circulation, compared with the normal contralat­
eral joint [5] Chondrocyte proteoglycan synthesis 
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in patellar cartilage was measured ex ino by a 1 h 
incubation with " S sulfate enriched RPMI [6] 
Proteogljcan breakdown was measured as loss of 
in π ιο 3SS-prelabeled cartilage Cartilage depletion 
was either quantilated by measuring glycosamino-
glycan content of papain-digested patellar cartilage 
with the Farndale assay [4J or by histological 
scoring of knee joint sections stained with safra-
nine О 
Measurement of cytokine release vwift bioassa\s 
Patella with adjacent synovial tissue was taken and 
six specimen were incubated in 2 ml RPMI-me-
diumal37 С in a C02-incubator for 1 h Dilutions 
of these culture media were tested for IL-1 and IL-6 
bioactivity IL-1 activity was measured in the one 
stage bioassay for IL-1, a coculture of the IL-1-
specfic subclone of the murine thymoma EL-4 
NOB-1 cell, producing IL-2 with the IL-2 re­
sponder CTLL cell IL-6 activity was measured as 
a proliferative response of B9-cells IL-1 and IL-6 
activities were verified by neutralizing antibodies 
Antiserum treatment oj mice 
Rabbit anti-munne IL-1/? antiserum, and rabbit 
anti-munne recombinant IL-lï antiserum were 
prepared by immunization against cloned, purified 
biologically active mature IL-la, and IL-1/Í emul-
sified in aluminium hydroxide (Imject"1 Alum, 
Pierce, Rochford. Illinios, USA) Both antisera 
showed no cross reactivity or neutralizing reactiv-
ity against IL-6, IL-4, and II-2 Antibodies were 
purified by affinity chromatographic separation on 
protein A sepharose CL4B column Mice were 
given 1 mg of purified antibodies or 100 μΐ of each 
antiserum intravenously 18 h before induction of 
arthritis or thereafter 
Results and discussion 
Cytokine profiles of IL-1 and IL-6 were recorded in 
wash-outs of joint tissues taken from mice with 
AIA High levels of IL-1 and IL-6 were released by 
inflamed tissue taken at day 1 of arthritis (Table 1) 
By use of neutralizing antibodies we identified 
IL-la to account for 80% of the IL-1 bioactivity At 
day 4, no IL-1 could be detected but IL-6 was still 
elevated Pretreatment of mice with anti-IL-1 anti-
sera (against IL-lot and IL-Iß) completely eliminate 
IL-1 bioactivity in the joint at day I indicating that 
Agents Actions Special Conference Issue (1993) 
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ТаЫс2 
Effect of anti-IL-1 pretreatment оГілісе on cartilage destruction in AIA 
Treatment 
NRS 
ML-W + ß 
Fdema 
Tc-ratio 
Day 2 
2 4 ± 0 3 
2 3 ± 0 5 
Day 7 
15 + 0 3 
1 4 ± 0 3 
"S-PG contei 
(CPM) 
Ufi 
481 ±108 
431± 95 
nt day 2 
Right 
2 1 8 ± 5 7 " 
2 1 8 ± 7 0 · · 
PG -content 
(^g/patella) 
Left 
2 4 6 ± 0 2 6 
2 4 5 ± 0 3 2 
day 7 
Right 
1 7 0 + 0 4 5 · · 
2 0 3 ± 0 2 2 · * 
Rabbit anti-I L-1 anlisera ( 100 μΙ anli-IL-1 j + 100 μΙ anli-I L-1 β) or 200 μΙ normal rabbit serum (NRS) were given as a single ι ν injection 
18 h before induction of arthritis Edema was measured at days 2 and 7 of AIA Proteoglycan (PG) breakdown at day 2 of arthritis was 
measured as in tuo loss of the 3sS-sulfate content ofprelabeled patellar cartilage Cartilage depletion of proteoglycans by arthritis was 
measured as loss of glycosaminoglycan content of patellar cartilage at day 7 of arthritis Statistical significance of differences from 
control (left joint) was calculated with Student s t-test, * p < 0 0 0 5 , ·* p<00001 
the treatment was effective IL-6 levels in the wash­
outs of tissue from day 1 were unchanged and only 
slightly decreased at day 4. This suggested that the 
cascade IL-1 —»IL-6 was not essential in this arthri­
tis model. A recent publication demonstrated that 
elevations of IL-6 levels coincided with improve­
ment of the arthritic process in RA [7] In this 
sense, blockage of IL-1 and not IL-6 by anti-IL-1 
antibody treatment may have a dual benefit in the 
management of arthritis 
Knowing that anli-IL-1 antisera pretrealmenl of 
mice effectively scavenged IL-1, we investigated 
how these antibodies would influence the outcome 
of AIA Anti-IL-1 antisera pretreatment caused 
moderate suppression of joint swelling at day 4 of 
AIA (Table 1). The results are consistent with IL-1 
as an inducer of prostaglandins known to mediate 
edema On the contrary, intra-articularly injected 
mrIL-1 caused insignificant swelling [8] 
Chondrocyte PG-synthesis was already suppressed 
at day 1 of AIA and carried on for days and was one 
of the marked events in the inflamed joint IL-1 
was a likely candidate to be involved as the IL-1 
induced PG-synthesis suppression in vivo is well 
documented [8] Pretreatment of mice with whole 
serum or affinity purified anti-IL-1 antibodies 
prevented this inhibition of PG-synthesis in AIA 
(Table 1) Affinity purified antibodies against an 
irrelevant antigen eg. lysozyme, normal rabbit 
immunoglobulin or anti-IL-1 antiserum devoid of 
immunoglobulin had no effects Scavenge of both 
IL-la and IL-1/Î was necessary to normalize PG-
synthesis, blockage of each separately did not effect 
PG-synthesis 
The suppression of chondrocyte PG-synthesis in 
AIA was not related to the influx of neutrophils into 
the joint cavity We started anti-IL-1 treatment at 
6 h after ehcitating AIA and still could prevent PG-
synthesis inhibition completely (Table 1) At 6 h of 
AIA the neutrophil influx is a prominent feature. 
Treatment started after the first day of arthritis, so 
after the peak ofIL-1 production, did not affect the 
ongoing PG-synthesis suppression IL-1 levels in 
wash-outs of inflamed tissue taken at day 4 of AIA 
were below the detection level of the bioassay 
(Table 1) We demonstrated that in this arthritis 
model IL-1 caused the chondrocyte synthesis sup-
pression Futhermore, we hypothesize that the 
nonresponsive slate of arthritic chondrocyte to 
insulin-like growth factor (IFG) maintained this 
suppression of the PG-synthesis in this model [9] 
The accelerated breakdown of 35S-prelabeled PC's 
in AIA was not affected by the anti-IL-1 treatment 
(Table 2) This could be due to the modest effect of 
anti-IL-1 antibodies on joint inflammation. Never-
theless, anti-IL-1 antibody treatment prevented 
substantially the articular cartilage depletion as 
observed histologically and by reduced loss of 
glycosaminoglycans from patellar cartilage at day 7 
(Table 2) We concluded that cartilage matrix 
depletion in AIA was caused by accelerated PG-
breakdown and decreased PG-synthesis Therefore, 
maintaining PG-synthesis by anti-IL-1 treatment 
during arthritis might be of therapeutic interest 
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Role of interleukin-1 (IL-1), tumor necrosis factor 
(TNF)-a and interleukin-6 (IL-6) in cartilage prote­
oglycan metabolism and destruction: effect of in 
situ blocking in murine antigen- and zymosan 
induced arthritis. 
Fons A J van de Loo, Leo А В Joosten, Peter L E M van Lent, 
Onno J Arntz, and Wim В van den Berg 
Objective. To determine the involvement of IL-1, TNF and IL-6 in the 
cartilage pathology of murine antigen-induced arthritis (AIA) and zymosan-
induced arthritis (ZIA). 
Methods. Arthritis was induced either by i.a. injection of zymosan in naive 
mice or by methylated bovine serum albumin (mBSA) in sensitized animals. 
Mini-osmotic pumps releasing human recombinant IL-1 receptor antagonist 
(IL-lra) protein were implanted intraperitoneally two days before arthritis 
induction, and neutralizing antibodies directed against murine IL-la, IL-1 β, 
TNF«, or IL-6 were administered one day before. Proteoglycan (PG) 
synthesis and degradation were assessed in patellar cartilage. 
Results. Murine IL-la and ß injected intra-articularly suppressed 
chondrocyte PG synthesis at doses of 0.1-100 ng. The highest dose of 100 
ng TNF tested decreased the PG synthesis marginally. In contrast, the 
maximum dose of 1 μg IL-6 stimulated PG synthesis two days after 
injection. Treatment of AIA with neutralizing monoclonal antibodies against 
either TNFa or IL-6 neither reduced PG degradation nor the suppression of 
its synthesis. However, treatment with anti-IL-1 (a + ß) polyclonal 
antibodies totally prevented PG suppression although the initial breakdown of 
PG was unaffected. This effect was confirmed when IL-lra was administered 
in high doses. Moreover, treatment of ZIA with anti-IL-1 (a + β) but not 
with anti-TNF resulted in normal PG synthesis confirming the key role 
played by IL-1 in the inhibition of PG synthesis. Treatment of AIA with 
anti-IL-1 did not affect inflammation during the acute phase but a significant 
reduction in ongoing inflammation was noted at day 7 and there was a 
marked reduction in the loss of cartilage PG. 
Conclusion. The suppression of PG synthesis in both ZIA and AIA in mice 
is due to the combined local action of IL-1 (a + ß) and neither IL-6 nor 
TNF are involved. Moreover, the normalization of PG synthesis brought 
about by blocking IL-1 ameliorates the cartilage damage associated with 
AIA. 
91 
Role of IL-1, TNF, and IL-6 in murine arthritis 
Introduction 
Rheumatoid arthritis (RA) is a systemic illness characterized by chronic 
inflammation of the joints and severe cartilage pathology such as joint space 
narrowing. Tumor-necrosis factor (TNF), interleukin-1 (IL-1) and 
interleukin-6 (IL-6) are clearly involved in the arthritic process since all 
three cytokines are present in synovial fluid and can be detected 
immunohistochemically in the inflamed rheumatoid synovium (1,2). 
Furthermore, both local and systemic levels of each cytokine correspond 
with disease activity (3-5), and TNF and IL-1 have profound catabolic 
effects on articular cartilage expiants of numerous species (6,7). 
The spontaneous production of IL-1 by rheumatoid synoviocytes can 
be inhibited by anti-TNF-antibodies (8) suggesting that TNF was earlier in 
the cascade than IL-1 whereas IL-6 occupies a position later in the cascade 
being produced in response to either TNF or IL-1 (9,10). Furthermore, IL-1 
induces IL-6 synthesis by the chondrocytes and is a cofactor in the IL-1 
induced suppression of PG synthesis (11). 
Intra-articular injections of TNF and IL-1 cause an influx of 
neutrophils into the joint and synovitis similar to that seen in experimental 
arthritis but only IL-1 results in marked depletion of the cartilage matrix (Π­
Ι 5). In vitro, TNF is also less potent than IL-1 in suppressing PG synthesis 
in cartilage expiants (16,17). 
Direct evidence that TNF and IL-1 play a role in the pathogenesis of 
experimental arthritis has been obtained in animal models in which blocking 
the action of these cytokines delayed the onset of collagen-induced arthritis, 
suppressed inflammation and ameliorated cartilage destruction which 
corresponded to the anti-inflammatory response (18-23). These studies 
focused on macroscopic scoring of the affected joints and histological 
evaluation but did not analyse cartilage metabolism in detail nor did they 
investigate the effect of anti-IL-6 treatment. 
We therefore undertook to investigate the potency of IL-1, IL-6 and 
TNF on PG synthesis and degradation of murine cartilage and the effect of 
blocking endogenous IL-1, TNF or IL-6 in murine arthritis induced either by 
antigen or zymosan (24,25), which is a potent inducer of both IL-1 and TNF 
in vivo (26,27). The effect of treatment with neutralizing antibodies on acute 
joint swelling and inflammation was assessed and PG synthesis and 
degradation was measured in cartilage. 
Materials and methods 
ANIMALS 
Male C57B1/6 mice were obtained from our own breeding facilities and were 
given a standard diet and tapwater ad libitum. 
CYTOKINES 
Purified and biologically active mature murine recombinant IL-la and IL-lß 
were generously donated by I.G. Ottterness (Pfizer Central Research, Groton 
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CT, USA), purified murine recombinant IL-6 by G. Ciliberto (I.R.B.M., 
Rome Italy), and purified recombinant human IL-Ira by Synergen (Boulder, 
Colorado). Murine recombinant TNFa (carrier free) was purchased from 
R&D Systems Ltd (Europe). 
NEUTRALIZING ΑΝΤΙ-CYTOKINE ANTIBODIES 
Rat anti mouse TNFa monoclonal antibody (Vlq) was kindly given by P.H. 
Krammer (German Cancer Research Center, Heidelberg, F.R.G.), rabbit 
anti-mouse TNF polyclonal antiserum by SL Kunkel (University of Michigan 
Medical School, Ann Arbor, MI, USA) and another rabbit anti-mouse TNF 
polyclonal antiserum by GE Grau (University of Geneva, Geneve, 
Switzerland). Rabbit anti mouse IL-6 polyclonal antiserum was donated by 
M. Fuller (Univ. Alabama, Birmingham Alabama, USA). Rat anti-mouse 
IL-6 monoclonal antibody was purchased by Genzyme Corp (Cambridge 
MA, USA). Neutralizing capacity was verified with specific bioassay for the 
cytokines. 
GENERATION OF RABBIT ANTI-MOUSE IL-1 ANTISERUM 
Polyclonal antibodies directed against each type of murine recombinant IL-1 
were prepared by immunization according to the method of Hogquist et al. 
(28), with some modifications. Briefly, 250 μg IL-1 in 2.25 mL PBS was 
suspended in 500 /iL IMJECT™ ALUM (aluminium hydroxide, Pierce, 
Rockford, Illinois, USA) which was injected into female New Zealand White 
rabbits in four s.c. injections of 500 μι . A further four s.c. injections of 
500 μΐ. CFA/PBS were given adjacent to the IL-1/ALUM injections. Every 
4-6 weeks, rabbits received 50 μg IL-1 s.c. suspended in ALUM in 3 
divided doses, IFA/PBS s.c. adjacent and 5 μg IL-1 i.V.. Ten days after 
every booster, 50 mL blood was aspirated, coagulated and serum stored at -
70 °C, and decomplemented at 56 °C before use. 
PURIFICATION AND CHARACTERIZATION OF RABBIT ANTI-IL-1 
ANTIBODIES 
Immunoglobulins were purified by affinity chromatographic separation on a 
Protein G sepharose CL4B column. Immunoglobulins (IgG) were eluted 
from the column with 0.1 M Glycine-HCl pH 3.0 and immediately 
neutralized with 50 mM Tris-HCl pH 8.0. IgG fractions were then pooled, 
concentrated and dialysed against PBS at ambient temperature. Antibodies 
directed against the α or β form of IL-1 were tested in vitro for their 
neutralizing capacity, and it was found that dilutions in the range of 
1/64.000 to 1/128.000 could fully block 5 pg/mL IL-1 (lowest plateau 
concentration) in the NOBl-proliferation assay. Antibodies showed no 
neutralizing cross-reactivity against each other nor against IL-2 which was 
tested in the CTLL proliferation assay, IL-4 in the CT.4.S proliferation 
assay, IL-6 in the B9 proliferation assay, and TNFa in the L929-cytotoxicity 
assay. The anti-IL-1 antibodies had a half-life of more than 3 days in the 
circulation. 
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INDUCTION OF ANTIGEN-INDUCED ARTHRITIS 
Mice aged between 8-10 weeks were immunized by two s.c. injections into 
the flank skin and two into the footpad of both forelegs, with a total of 100 
μg methylated bovine serum albumin (mBSA, Sigma Chemical Company, 
St. Louis, Missouri, U.S.A.) suspended in 100 μ ι Complete Freunds 
Adjuvant per animal. Heat-killed Bordetella pertussis at 2x10' organisms 
(National Institute of Public Health, Bilthoven, The Netherlands) were 
administered intraperitoneally as an additional adjuvant. Two s.c. booster 
injections were given with 100 μg mBSA/CFA were given in the neck 
region on day 7. Arthritis was induced 14 days after these injections by 
intra-articular (i.a.) injection of 60 ^g mBSA in 6 μ ι saline into the right 
knee joint. 
INDUCTION OF ZYMOSAN-INDUCED ARTHRITIS 
A homogeneous suspension of 30 mg zymosan A (Saccharomyces 
cerevisiae), dissolved in 1 mL endotoxin free saline, was obtained by boiling 
twice, and sonic emulsification. Arthritis was induced by i.a. injection of 
180 μg zymosan into the right knee. 
ASSESSMENT OF JOINT SWELLING 
Animals were injected s.c. with 10 μ0\ Technetium pertechnetate ("Tc) 
in 0.2 mL saline in the neck region. After 15 minutes, the isotope 
accumulates in the knee due to the increased blood flow and edema, and the 
ammount of " T c was determined by external gamma counting. Joint 
swelling was expressed as the ratio of the " T c uptake in the inflamed knee 
joint over its non-inflamed counterpart with a ratio higher than 1.1 indicating 
joint swelling. 
ASSESSMENT OF PROTEOGLYCAN SYNTHESIS 
Six patellae were prepared so as to minimize the amount of adjoining 
synovium, tendon and muscle, and placed in 2 mL RPMI-HEPES-medium 
(Flow Laboratories, Irvine, Scotland) supplemented with gentamicin (50 
mg/L), L-glutamine (2 mM) and 40 μα S-sulfate. At the end of 3 hour 
incubation, patellae were fixed in 10% formalin, decalcified in formic acid 
(4%), dissected and then dissolved in 0.5 mL Lumasolve (Hicol, Oud-
Beijerland, The Netherlands). The 35S-content of each patella was measured 
by liquid scintillation counting and expressed as counts per minute (CPM). 
ASSESSMENT OF PROTEOGLYCAN BREAKDOWN 
Mice were injected with 50-100 μα 35S-sulfate into the peritoneal cavity 2 
days before inducing arthritis. Arthritis was induced after one day and a 
further two days later, patellae were dissected and processed to measure the 
35S04 content as described above. 
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GLYCOSAMINOGLYCAN MEASUREMENTS OF PATELLAR 
CARTILAGE 
Patellae were fixed in ethyl alcohol (96%) and decalcified in formic acid 
after which the cartilage layer could be stripped from its underlying bone 
and subsequently digested overnight at 60°C in 200 μ ι of 5 mg/mL papain 
(Type IV, Sigma, St Louis, MO) in 0.1 M sodium-acetate pH 6.5, 10 mM 
L-cysteine and 50 mM disodium-EDTA per patella. The PG content per 
patella was estimated by the dimethylmethylene blue dye-binding at 535 nm 
using the colorimetrie method of Farndale (29). 
HISTOLOGICAL PROCESSING AND ANALYSIS OF KNEE JOINTS. 
Knee joints were dissected, fixed, decalcified, dehydrated and embedded in 
paraffin. Standard frontal sections of 7 μιη were prepared and stained with 
safranin-O, and counterstained with fast green. Cartilage depletion was 
visualized by diminished staining of the matrix and scored as 0 when normal 
and 1 to 3 according to the degree of cartilage depletion (loss of staining). 
For autoradiographic analysis of 35S-sulfate incorporation, radiolabeled 
sulfate was injected intraperitoneally 6 hours before dissection of the knee 
joints. Seven 7 μιη sections of paraffin embedded joints were mounted on 
gelatin coated slides which were immersed in K5 emulsion (Ilford, Basildon, 
Essex, UK) and exposed for several weeks before being developed and 
stained with hematoxylin and eosin. 
ΑΝΤΙ-CYTOKINE TREATMENT OF MICE 
Antibodies were injected i.v. into the orbita plexus of mice, 18-24 hours 
before induction of arthritis. Each experimental group consisted out of at 
least 7 animals. 
ANTI-IL-1 (a + β) ANTIBODY TREATMENT 
Mice were injected i.v. with 200 μ ι standard dose of 2 mg purified rabbit 
anti-IL-1 antibodies with a total neutralizing capacity of 32 ng of both 
subtypes of IL-1 when tested in the NOBl-assay, and was sufficient to block 
the effect of 1 ng of IL-la and β on PG synthesis completely in vivo. 
Normal rabbit IgG's or polyclonal anti-ovalbumin antibodies, served to 
control the non-specific effects of treatment. 
ANTI-TNF AND ANTI-IL-6 TREATMENT 
Mice were given a dose of 90.000 U neutralizing monoclonal antibodies 
directed against TNFo (Vlq) which was sufficient to block 7.8 μg of TNF« 
in the L929 bioassay. Some mice were given rat anti-mouse IL-6 IgGl with 
a total neutralizing capacity of 175 ng IL-6 in the B9-bioassay whereas 
others received normal rat IgG as a control. 
TREATMENT OF MICE WITH IL-Ira 
Mini-osmotic pumps (Alzet 1007D, Alza corp., Palo Alto CA, USA) were 
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implanted into the peritoneal cavity two days before arthritis induction, and 
set to release 37.5 μg of IL-lra per hour for the next 7 days. The mean 
steady-state level of IL-lra in blood was 4.7 ^g/mL from the first day after 
implantation as was measured in the NOBl-assay. 
Results 
Effect ofIL-1, TNF and IL-6 on PG metabolism in vivo. 
Intra-articular injection of IL-la or β suppressed PG synthesis in patellar 
cartilage within a day of administration and was dose-related (Table 1). 
Marked suppression of 50-60% lasted at least two days and recovered 
thereafter.13 Chondrocyte PG synthesis was only suppressed by 100 ng of 
TNFa, and lower doses having no effect after one day but actually 
stimulating PG synthesis after two days. Low doses of IL-6 also had no 
effect whereas 1 μg significantly enhanced the PG synthesis by 32% after 
two days. 
Table 1: In vivo effect ofIL-1, TNF or IL-6 on PG synthesis. 
Dose 
ng/ 
joint 
0.1 
0.3 
1 
10 
100 
1000 
IL-la 
Day 1 
70 (12)* 
65 (17)· 
50 ar 
43 (9)~ 
47 (9)-
nd 
PROTEOGLYCAN SYNTHESIS (% of Normal Cartilage, 
¡L-lß 
Day 1 
90(17) 
72 (14)" 
54 (13)-
48 (15Γ 
44(7)" 
nd 
TNFa 
Day 1 
nd 
nd 
97(37) 
91 (29) 
80 (17)* 
nd 
TNFa 
Day 2 
nd 
nd 
148 (23) 
113 (19) 
79 (29) 
nd 
IL-6 
Day I 
nd 
nd 
81 (10) 
105 (26) 
103 (23) 
104 (24) 
)' 
IL-6 
Day 2 
nd 
nd 
94(21) 
105 (33) 
120 (22) 
132 (23)* 
Murine recombinant IL-1, TNF or IL-6 were injected into the right knee joint cavity. 
f PG synthesis was determined by "SO., incorporation ex vivo and expressed as a percentage 
(SD) of the normal synthesis in patellae of joints injected with saline at day 1 and 2 after 
injection. 
Significantly different (*, p<0.05; **, p<0.01) compared to the saline injected joint (Mann 
Whitney-U-test of CPM-values). 
Effect of anti-cytokine pre-treatment on PG synthesis in murine antigen- and 
zymosan-induced arthritis. 
Chrondrocyte PG synthesis was markedly suppressed in both murine arthritis 
models. Anti-IL-6 and anti-TNF antibody pre-treatment of mice did not 
reverse the inhibition of PG synthesis at day 2 of AIA and ZIA 
whereas pre-treatment with anti-IL-1 (a+ß) did (Figure 1A). Selective 
elimination of either IL-la or IL-1/3 did not prevent the suppression of PG 
synthesis (Figure IB), indicating that both subtypes reached optimal effective 
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Proteoglycan synthesis (CPM) 
Normal Normal Anti- Anti- Anti- Normal Normal Anti- Anti- Anti-
cartilage Rabbit IL-1a IL-* IL-1a*b Cartilage Rabbit IL-1a IL-1b l£-1a-b 
Figure 1: Role of cytokines in PG synthesis suppression of antigen-induced arthritis (AIA) or 
zymosan-induced arthritis (ZIA). PG synthesis was assessed in patellae at day 2 of arthritis by 
S04 incorporation ex vivo. A) Mice (n = 7 per group) received rat anti-mouse IL-6 monoclonal 
antibodies (AIL-6) [total neutralizing capacity of 175 ng of IL-6 in the B9-bioassayJ, or rabbit 
anti-mouse IL-1 polyclonal antibodies (AIL-1) [neutralizing capacity of 32 ng of both IL-1 
subtypes in the NOBl-bioassay, a dose found to be effective in blocking the effect of 1 ng of 
intra-articularly injected IL-1 on PG synthesis], or rat anti-mouse TNF monoclonal antibody 
(ATNF) [with a neutralizing capacity of 90.000 UofTNFot in the L929-bioassay] intravenously, 
one day before arthritis induction. B) Relative role of IL-1 a and IL-1 β in the suppression ofPG-
synthesis in both arthritis models. Mice received rabbit anti-IL-1 polyclonal antibodies against 
either ¡L-la and IL-lß separately or against both subtypes intravenously, one day before 
arthritis induction. Mice receiving 1 mg of normal rabbit IgG served as a control. 
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concentrations in the joints. The acute joint swelling in AIA was as severe as 
in ZIA on the second day of arthritis. In AIA, joint swelling was not 
significantly affected by treatment with anti-IL-1, anti-TNF or anti-IL-6, and 
in ZIA it was only moderately reduced by 18% by anti-TNF but not by anti-
IL-1. Effect of IL-lra on PG synthesis in AIA. 
In the first experiments, mice received bolus injections of either 2 
mg/kg or 10 mg/kg IL-lra into the peritoneal cavity, before and during 
arthritis and PG synthesis remained significantly suppressed at day 2 of 
arthritis (Table 2). In further experiments, the high amount of IL-lra 
delivered to mice via mini-osmotic pumps prevented the inhibition of the PG 
synthesis at day 2 of AIA and confirmed the results obtained after pre-
treatment with anti-IL-1 antibody in AIA. 
Consequence of anti-IL-1 pre-treatment on cartilage pathology in chronic 
phase of AIA. 
In AIA, PG synthesis was suppressed for the first 7 days of arthritis or more 
whereas the suppression in ZIA was more transient. A single intravenous 
injection of anti-IL-1 antibodies prior to arthritis induction, fully prevented 
the suppression of PG synthesis for this whole period (not shown). 
Autoradiography of 33S pulse labeled knee joints at day 4 of AIA 
demonstrated marked inhibition of label incorporation indicating reduced PG 
synthesis in the cartilage matrices. Normalized incorporation was noted after 
anti-IL-1 pre-treatment of the arthritic mice (Figure 2). 
Table 2: Effect of JL-1 receptor antagonist (IL-lra) protein on PG synthesis in AIA. 
PROTEOGLYCAN SYNTHESIS* 
Experiment I Experiment II Experiment III 
2 mg/kg IL-lra1 10 mg/kg IL-lra+ 37.5 ßg/h IL-lra b 
Treatment Normal AIA Normal AIA Normal AIA 
Saline 1172(101) 431(69) nd nd 1270(139) 500(153) 
IL-lra 1107(141) 598(142) 1230(140) 627(93) 1241(251) 1268(228) 
-|- 35S04 incorporation in patellae ex vivo 48 hours after induction of AIA, expressed as the 
mean (SD) in at least 6 patellae. 
=lp IL-lra (2 mg/kg) or saline was injected into the peritoneal cavity two hours before arthritis 
induction and at 4, 10, 16, 22, 28, 46 hours after arthritis induction. Total cumulative 
dose is approximately 0.35 mg/mouse. 
J IL-lra (10 mg/kg) or saline was injected into the peritoneal cavity two hours before 
arthritis induction and every 3 hours the first day, and every 6 hours the second day of 
arthritis. Total cumulative dose is approximately 3 mg/mouse. |- Mini osmotic pumps were implanted i.p. two days before arthritis induction and set to 
deliver 37.5 /ig IL-lra per hour or saline (control group) for the next 4 days. Total 
cumulative dose is approximately 3.6 mg/mouse. Representative of three experiments. 
** Significantly different ρ < 0.01, compared to the saline treated arthritic joint (Mann 
Whitney-U-test). 
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Figure 2. Histology of the femoral-tibial joint of the knee. Photographs (A, B, C) represents 
autoradiography of 35S04-incorporation into newly synthesized PGs. Photographs (D, E, F) 
represents safranin-O stained sections. Diminished staining indicating cartilage PG loss. A and 
D: normal contralateral joint. В and E: arthritic joint day 4 AIA. С and F: arthritic joint of 
anti-IL-1 treated mouse. C: cartilage. F: Femur. T: Tibia. M: Meniscus. 
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In the next experiment, cartilage degradation was accelerated since the 35S-
sulfate content in prelabeled patellar cartilage at day two was reduced by 52 
± 10% in AIA and 43 ± 11% in ZIA. Anti-IL-1 (a + /3) pre-treatment did 
not prevent this in either form of arthritis with losses of 50 ± 12% and 35 
± 9 % being measured, suggesting that IL-1 was not involved in initiating 
this process. 
The combined action of reduced synthesis and enhanced degradation 
led to a profound loss of cartilage PG in AIA, which was much less by pre-
treatment with anti-IL-1, as reflected by PG measurements of cartilage at 
days 4 and 7 of AIA (Table 3). Histological analysis of whole knee joints 
showed significant amelioration of the damage to the cartilage. Safranin-0 
staining of the articular cartilage matrices was greater in the arthritic joints 
of anti-IL-1 treated as compared to control treated mice indicating a higher 
PG content (Figure 2). 
Although blocking of IL-1 had no anti-inflammatory effect on the 
acute inflammation, ongoing inflammation of the joint was much lower in 
later phases of AIA after pre-treatment with anti-IL-1. Joint swelling and 
synovitis were significantly reduced at day 7 of AIA (Table 3). 
Table 3. Effect of anti-IL-1 treatment on inflammation and cartilage loss in AIA. 
Treatment* 
N. Rabbit IgG 
Anti-IL-1 
Joint swelling^ 
(Tc-ratio) 
Day 7 AIA 
1.44(0.25) 
1.23 (0.16)* 
Synovitis* 
Day 7 AIA 
2.3 (0.8) 
1.3 (0.9)* 
dycosaminoglycan content^ 
(ßg per patella) 
Day 4 AIA 
1.56(0.50) 
2.30 (0.46)"* 
Day 7 AIA 
1.70(0.45) 
2.03 (0.22) 
J Normal rabbit IgG or antibodies against IL-1 (a + 0) were injected intravenously one day 
before arthritis induction, 
f Joint swelling was expressed as a ratio (SD) of the enhanced uptake of ""Technetium 
pertechnetate in the arthritic over the contralateral normal joint (M&M). 
-|f- Whole knee joint sections were analyzed for leukocyte infiltration into the synovium and 
arbitrary scored from 0; no cells, to a maximum score of 3; large number of cells. 
-\- Glycosaminoglycan content measured as described in M&M. Content in patellar cartilage 
of the contralateral knee joint was 2.58 ± 0.39; day 4, 2.45 ± 0.31 μ ;^ day 7. 
Significantly different compared to the normal rabbit treated animals, *; p< 0.05, **; 
ρ<0.01, ne; not significant from normal rabbit treated animals (Mann Whitney-U-test). 
Discussion 
Direct evidence for the involvement of cytokines in the process of joint 
inflammation and cartilage destruction in RA is still lacking. We therefore 
undertook to investigate in a comparative study the potency of TNFa, IL-1 
and IL-6 to affect chondrocyte function in vivo and the effect of selective 
blocking on murine arthritis. 
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The PG synthesis was markedly suppressed after i.a. injections of IL-la or 
IL-1/3 whereas higher doses of TNFa were needed for this. In previous 
studies, we and others convincingly demonstrated that i.a. injections of IL-1 
into synovial joints causes marked cartilage PG degradation and cartilage 
depletion in various species (12-14). Of interest, this effect seems to be 
independent of the inflammatory reaction (13,30). A single i.a. injection of 
TNFa did not cause edema nor enhanced PG degradation in the tested dose-
range of 1-100 ng in mouse (data not shown). Although TNF may cause 
cartilage destruction in vitro (16), evidence for such a role in vivo is lacking 
(14,15). 
TNF and IL-1 are potent inducers of IL-6 production but we clearly 
showed that IL-6 is not a destructive mediator in the murine joint and even 
may play a protective role in the joint since IL-6 stimulates PG synthesis. 
Moreover, IL-6 enhances the expression of inhibitors (e.g. TIMP) of 
cartilage destructive enzymes in synovial fibroblasts (31). 
It was shown in rheumatoid synovia that TNF may be an important 
driving force in the production of IL-1 (8). Although TNF does not seem to 
be a major cartilage destructive mediator, its regulating role makes it an 
interesting target for therapy. Recent studies with chimeric antibodies to 
TNFa proved efficacious in suppressing signs of inflammation in short trials 
(32), but the protection against ongoing cartilage destruction has yet to be 
demonstrated. Given the existence of separate pathways of IL-1 production, 
in addition to TNF driven pathways, it is tempting to suggest that blocking 
of IL-1 would be a more valid approach with respect to amelioration of 
cartilage destruction. 
Pre-treatment of mice with rabbit polyclonal anti-IL-1 antibodies 
protected the chondrocyte function in both ZIA and AIA. The IL-1 subtypes 
had to be blocked together to prevent suppression of PG synthesis in arthritis 
whereas pre-treatment with anti-TNF or anti-IL-6 antibodies had no effect. 
This result is in agreement with the relative potencies of these cytokines after 
i.a. injection into the murine knee joint. Although it is reported that IL-6 is a 
cofactor in IL-1 induced suppression of PG synthesis in human cartilage 
expiants (11), this has yet to be confirmed in vivo. 
A major role of TNF and/or IL-1 in cartilage PG degradation can not 
be deducted from the present study in the acute phase of murine AIA and 
ZIA, and this result is in line with observations in AIA in the rabbit (33,34). 
This may point to mere overkill by other mediators, or imply that IL-1 
levels in AIA are anyway insufficient. In that respect it is intriguing to note 
that chondrocyte PG synthesis inhibition can be achieved with relatively 
small doses of IL-1, whereas considerable IL-1 levels are needed to cause 
substantial PG degradation (13,16,17). 
The overall effect of cytokine neutralization seems to depend both on 
the type and the phase of the arthritis. Anti-TNF treatment in collagen-
induced arthritis (CIA) resulted in a marked amelioration of joint 
inflammation and cartilage destruction in a prophylactic protocol, but was 
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markedly less efficient when treatment was started in the established disease 
(36). In contrast, neutralization of IL-1 was still efficacious when treatment 
was started late and marked protection of cartilage damage was observed 
(19,35). In the present study, anti-TNF pre-treatment using the same 
antibodies (Vlq) as was used in CIA, did not diminish acute joint swelling 
nor did it protect against cartilage damage in murine AIA. Furthermore, 
neutralization of IL-1 also using the same anti-IL-1 antibodies as in CIA did 
not reduce acute joint inflammation either, yet markedly ameliorated 
cartilage destruction after day 2 of AIA. 
These findings in the various models suggest that protection against 
cartilage destruction with neutralizing anti-cytokine antibodies can be 
obtained in two ways. First, indirect effect, when IL-1 and/or TNF are key 
elements in the inflammatory process. Second, a direct effect, when 
inflammation is caused by substantial overkill by other mediators, yet 
elimination of a destructive mediator like IL-1 may still cause substantial 
protection. In the first situation a direct, destructive role of IL-1 can never 
be proven, but in the present study in AIA and ZIA, where the acute 
inflammation seems highly IL-1 and TNF independent, a key role of IL-1 in 
the suppression of PG synthesis is now established. However, we cannot 
exclude that the cartilage amelioration in the anti-IL-1 treated mice was due 
to decreased PG degradation either directly or as a consequence of relief of 
the ongoing flanimation as was shown at day 4 and 7 of AIA. 
The role of IL-1 in PG synthesis suppression is confirmed in IL-lra 
treated mouse. Conflicting results were reported in the past. Lewthwaite et 
al. (34) could block IL-1 induced inflammation in the rabbit, but were 
unable to protect PG synthesis in rabbit AIA using repeated s.c. injections 
with huIL-lra. Whooley et al. (18) reported also a failure to modulate 
murine AIA. We had similar, negative observations using repeated IL-lra 
injections, but efficacy was clearly proven when continuous high levels were 
generated using Alzet mini-osmotic pumps. Using a similar approach we 
recently proved efficacy also in murine CIA and ICA (manuscripts in 
preparation). The relevance of this approach is obvious, given the poor 
pharmacokinetic profile of IL-lra. Moreover, continuous blocking of almost 
all IL-1 receptors is needed to prevent cell activation, obliging a continuous 
excess of at least 1000-10.000 fold amount of IL-lra (36). 
In RA much emphasis is now focused on blocking TNFa using either 
chimeric antibodies or fusion proteins with TNF soluble receptor. In 
addition, first trials are underway with IL-lra. Our experimental studies 
suggest that IL-1 is an important target in protection against cartilage 
destruction. Moreover, continuous high levels of IL-lra are needed to 
control IL-1 in arthritic processes and it is debatable whether IL-lra dosages 
used in clinical trials are high enough. It is hoped that antagonist proteins 
with a beter profile, or selective inhibitors of IL-1 production become 
available in the near future. 
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Our present study does not show efficacy of anti-IL-6 antibody treatment. 
Given the high levels of IL-6 in the circulation and inflamed joints, it can 
not be excluded that some IL-6 escapes neutralization. This holds in 
particular for the local production in cartilage, since antibodies will not 
penetrate to a great extent. The role of IL-6 remains to be elucidated but we 
expect that it plays a protective role in arthritis. 
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CHAPTER 8 
FLARE OF EXPERIMENTAL ARTHRTTIS IN MICE 
WITH MURINE RECOMBINANT IL-1 
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Flare-up of experimental arthritis in mice with murine 
recombinant IL-1 
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SUMMARY 
Intra-articular injections of murine recombinant IL-1 (mrIL-1) during the chronic phase of antigen-
induLcd arthritis (AIA) induced a flare-up of the smouldering inflammation The exacerbation was 
characterized by acute and transient joint swelling and this coincided with the extravascular 
accumulation of neutrophils IL-1 injected into arthritic joints ofneutropenic mice demonstrated that 
joint swelling was independent of the neutrophil influx into the joint Both phenomena were absent 
when IL-1 was injected into a naive |0inl The IL-1 -induced flare-up was not Τ cell mediated as in the 
antigen-induced flare-up, and suggestive evidence is presented that IL-1 sensitivity depended on the 
resident macrophage population This explained why the hypersensitivity is not restricted to the 
immunologically mediated arthritis but reflects a more general hypersensitivity of previously injured 
joints e g zymosan-induced arthritis and IL-1 -affected joints Inaddmon IL-1 could also potentiate 
(he antigen-specific flare-up ofchronic AIA and prolongs the duration of the exacerbation Our data 
indicale that joints bearing a chronic infiltrate are at risk from exacerbations in two ways a Τ cell 
mediated rechallenge with antigen and a non-specific reactivation by svstemic and local IL-1 
generation 
Keywords IL-1 synovial joint flare-up experimental arthritis mice 
I N T R O D U C T I O N 
The clinical course ol rheumatoid arthritis (RA) is characterized 
b\ pathology of the connective tissues and recurrent secondary 
flare-ups of the smouldering chronic inflammation IL-1 has 
been reported to be present in synovial fluid of patients with RA 
[1-3) Noleworlhv is the linkage of the spontaneous IL-1 
svnthesis by human monocytes lo the early onset of the relapse 
of RA [4] Furthermore, plasma IL iß levels correlated with 
patients' disease activity and followed secondary flare ups in 
RA [5] 
Effects of IL-1 on single cell populations and tissue expiants 
laken from the joint strongly imply lhat IL 1 is involved in the 
arthntic process [6-8] Furthermore in ι но administration of 
IL-1 in rodents illustrated lhat IL-1 had cartilage destructive 
and infiammato™ activities [9-12] affecting the synovial joint 
comparable to experimental models of arthritis We recently 
demonstrated that IL-1 is directly involved in ihe pathological 
processes of arthritis Anligen-induccd arthritic mice treated 
with neutralizing antibodies raised against IL-1 demonstrated 
that chondrocyte synthesis inhibition and to some extent 
cartilage depletion dunng arthritis were caused b\ de пою 
synthesized IL-1 (unpublished observations) 
Correspondence Dr Fons van de Loo Biologist Departmenl of 
Rheumatology Universit> Hospital Si Radboud Geerl Grooleplein 
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IL-1 is not only responsible for most of the pathology of 
connective tissues in the synovial joint but could also modulate 
the inflammatory process ofarthnlis Several reports demon­
strated that IL-1 also had an immunoregulalory role in several 
animal models of arthritis In collagen-induced arthritis in DBA 
mice and in the spontaneous arthritis in MRL mice IL-1 
trealment increased incidence and enhanced onset of arthritis 
[13 15] In rats pre- and post-treatment with IL-1 localis 
reduced joint swelling and histopathology of antigen-induced 
arthritis [16] In peptidoglycan-polysacchande-induced arthritis 
in rat ankles IL 1 induced exacerbations of arthritis but clear-
cut clinical and histological differences were only found after 
repeated IL-1 injections into those previouslvinjuredjoinls[l7] 
Overall exogenous IL-1 had intricate effects on pathogenesis of 
experimental arthritis and this may depend on route site (pre­
disposed) and time of administration 
The antigenic reacti\ation of the subsided antigen induced 
arthritis (AIA) in rabbits and mice closeh resembles the relapse 
in RA acute onset of the flare-up reaction marked joint 
swelling and abundant neutrophil influx are evident [18 19] The 
flare-up of AIA is Τ cell dependent [20] and H seems obvious that 
II -I played an important role in the flare-up because of Us well 
known Τ cell activating properties [21] 
In this studv we compared the effect of IL-1 in various stages 
of both immune and non-immune arthritis IL-1 caused a 
relapse of the smouldering joint inflammation in the chronic 
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phase of arthritis Joint swelling and marked neutrophil influx 
were evident The kinetics, mechanism and prerequisites of the 
flare-up were studied in more detail It was demonstrated that 
previously injured joints bearing a macrophage-nch infiltrate 
displayed clear-cut IL-1 hypersensitivity 
MATERIALS AND METHODS 
Chemu als 
Murine recombinant IL-la [22], and IL-1/Í were expressed in 
Escheruhia coli and the purified mature IL-1 was biologically 
active Biological activity was verified in the LAF assay and IL-1 
was Tound to give 1 unit activity (proliferation I '2 maximal) 
consistently in (he 10 40 pg'ml range Screening for endotoxin 
activity (Limulus assay) was negative up to a concentration of 
100 Mg ml 
Nitrogen-mustard (Mustine-hydrochlondc) was obtained 
from The Boots Company (Nottingham, UK), methylated 
bovine scrum albumin (mBSA), concanavalin A (Con A), and 
zymosan A (Saciharomyces cerei isiae) were obtained from 
Sigma Chemical Co (St Louis, MI) 
Immunization and induction of arthritis 
Male C57BI 6 mice 6 8 weeks of age were immunised with 100 
fig mBSA in l-C A and Bordetella pertussis as an additional 
adjuvant as described before[19] Monoarthritis was induced 21 
days after the start of the immunization by injecting 60 /jg 
mBSA in 6 μ\ phosphate-buffered saline (PBS) in the left knee 
joint 
The non-immune arthritis was induced by intra-articular 
injection of 18 180 ug zymosan Zymosan (30 mg) was 
dissolved in I ml saline through heating up to 100 С twice and 
sonificated afterwards to obtain a homogeneous suspension 
Indui tton of flare-up 
The flare-up reaction was induced 7-35 days after onset of 
arthritis by local or systemic injection of IL-1, mBSA or both 
Treatment of experimental arthritis 
L\mphoc\te depletion Goat anti-mouse lymphocyte serum 
(ALS), titre I 6400, showed a 98° о lysis of murine splenic 
lymphocytes in a cytotoxicity test Mice were injected with 0 5 
ml ALS intraperitoneal^ 72, 48 and 24 h before flare-up 
induction The control group received the same amount of heal-
înactivatcd normal goal serum intraperitoneal^ As a control, 
delaycd-type hypersensitivity (DTH) reaction (24 h) against 
mBSA (5 //g) in the ear was completely prevented by ALS 
treatment 
Neutrophil depletion Nitrogen-mustard, 1 mg'kg, was ad-
ministered orally once a day for four consecutive days or 2 days 
intravenously 2 mg/kg before IL-1 administration After these 
regimens, the number of neutrophils in the blood was decreased 
by 90% The DTH-rcaction against mBSA (5 /jg) was approxi-
mately 50% diminished by these nitrogen mustard treatments, 
indicating that an inflammatory reaction was still possible in 
these mice 
KmTc uptake measurements 
Joint inflammation was determined by measurements of ""'Tc 
pertechnetate uptake in the knee joint [23,24] Briefly, approxi-
mately 10 uG T c in 0 2 ml saline were injected subcutaneously 
in the neck region of mice After 10 min, animals were sedated by 
intraperitoneal administration of 4 5% (w ») chloral hydrate, 
0 1 ml 10 mg of body weight, and the accumulation of the 
isotope in the knee due to increased blood flow and tissue 
swelling was determined by external gamma counting The 
seventy of inflammation was expressed as the ratio of the WmTc 
uptake in the affected (left) over the contralateral control (right) 
knee joint 
IL-l retention measurements 
IL-1 was radioiodinated using Bolton and Hunter reagent 
(Amcrsham, UK) according to the manufacturer's instructions 
[''TJlabelled IL-1 was injected into the right knee joint, whereas 
the left knee joint received saline At various hourly time points 
therealter, the [,2!I]radioacttvity of both knees was measured by 
external gamma counting Readings for the right knee were 
corrected by subtraction of background activity in the left knee 
Retention was expressed as a percentage of the initial count rate 
measured immediately after [l!,I]IL-l injection Subsequently 
quantitative measurements were made on dissected patellae 
Histologi of knee ¡oints 
For histological scoring of the inflamed knees, the left and right 
joints were dissected and processed for histology as previously 
described [19] Standard frontal sections (7 μπ\) were prepared 
and stained with haematoxyhn and eosin The arthritic score 
was determined by grading the infiltrate and the exudate, the 
extent was graded 0-3 where 0 = no change and 3 —large cell 
numbers 
RESULTS 
ÌL-1-indue ed /omt snelling in the chronic phase of antigen-induced 
arthritis 
Inlra-arlicular injection of mrIL-la into a previously inflamed 
joint (week 4) caused a dose-dependent joint swelling oedema 
and plasma leakage into the joint space (Fig la) The IL-1 
hypersensitivity existed for both types, II -1 χ and IL-/Ì (Fig 1 b) 
Hcat-inactivatcdIL-1 was without effect The arthritic joint also 
responded to circulating I I -1 , although high doses must be 
applied (Fig lb) A naive normal joint was less sensitive for IL-1 
and lacked a significant joint swelling response after injection 
The onset of IL-1 induced joint swelling in arthritic joints was 
rapid, a peak was found at 6 h, and a decline to baseline had 
already occurred at 24 h (Fig 2) 
The hypersensitivity of arthritic knees was not due to an 
altered clearance of IL-1 The retention ofiodinaled IL-1, still 
fully biologically active, was similar in a naive and an arthritic 
joint, Τι ; = 45 min (data not shown) 
Histology of IL-i-mducedflare-up 
Histological sections taken from arthritic joints after IL-1 
injection demonstrated that joint swelling coincided with a 
marked influx of polymorphonuclear (PMN) cells, predomin­
antly neutrophils, into the joint (Fig 2) By contrast, in week 2 
of AIA the background inflammation consisted of a synovial 
infiltrate of mononuclear cells Although less distinct, high 
doses of IL-1 also elicited a granulocyte influx into a naive joint, 
but without joint swelling 
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Hg. I. IL-1-induccd joint swelling (oedema) in 4-week old antigen-
induced smouldering joint inflammation (a) Dose response of ïnlra-
articularly injected IL-1 in arthritic compared to naive joints O, control 
joint D arthritic joint (b) Comparison of flare-up induced by intra 
articular injections of IL-la and IL-10, and systemic IL-10 О Statistical 
analysis of WmTc uptake as described in Table I 
Time after IL I injection ( h i 
Fig. 2. Kinetic of flare-up of arthritis IL-I (300 U) was injected into 2 
week-old zymosan- (A) or mBSA- (•) induced arthritis At different 
time points after IL-1 injection the w , nTc uptake was measured in 
separate groups of mice As a control, saline was injected into antigen 
induced arthritic joints (•) Histology of AIA showed both synovial 
infiltration (D) and exudation into the joint space (•) of neutrophils 
Table 1. IL-1-induced flare-up of experimental arthntis is independent 
of neutrophil accumulation and de novo prostaglandin synthesis 
Oedema ( " T c ratio)* Exudate 
Pre-treatmenl Salme IL-1 
Nitrogen mustard 
Indomethacin 
1 14±008 1 36±0 lOt 0 2 1 0 3 2 1 ±0 5 
1 15 ±0 04 1 32±0 03{ 0 2±0 3 0 4±0 4 
1 03+003 I 62±02l§ 0 4 ± 0 4 2 9 ± 0 2 
ND 134 + 0 27 ND 2 I ±0 5 
Nitrogen mustard (2 mg/kg) was injected intravenously (into orbital 
plexus) at day — 3, and —1, before induction оГ IL-1 flare, and caused 
>90% depletion of circulating neutrophils Indomethacin (2 mg kg) 
(solubilized in methyl cellulose) was given orally for three successive 
days ( 3, minus ( χ 3) -2, and —1), before the IL-1 injection 
•Oedema (joint swelling) was expressed as ratio of " T c uptake by 
inflamed joint over the contralateral (non-inflamed)joint A value near 
1 0 is typical for non-inflamed joints Statistical analysis of W mTc ratios 
of IL-1-injected joint compared with sahnc-injccled joints was done by 
the two tailed Wilcoxon matched pairs signed rank test тЯ<005, 
%P<0 001, ί}/*< 0 001 Representee experiment earned out in week two 
of AIA, and identical results were obtained in zymosan-mduced 
arthntis ND Not done 
Characteristics of the IL-1 flare-up 
PM N cell influx and joint swelling are independent phenomena, 
as demonstrated by the IL-1-induced joint swelling in neutro­
penic arthritic mtce (Table 1) This indicates that oedema 
formation is not dependent on the IL-1-induced PMN cell 
extravasation 
In general, joint swelling can be effectively suppressed by 
preventing prostaglandin synthesis [25] Mice were treated with 
indomethacin (2 mg'kg per day, orally) for 3 successive days 
before injection of IL-1 into the smouldering arthritis Appar­
ently, the IL-1-induced joint swelling was only partly mediated, 
and the extravascular neutrophil accumulation not mediated, 
by prostaglandin (Table 1) 
Reactivation of various types of joint inflammation mth IL-1 
Antigen-induced exacerbation of the smouldering arthritis 
(AIA) is known to be Τ cell mediated We now investigated 
whether the IL-1 flare-up was also Τ cell dependent Animals 
were pre-treated for 3 successive days with ALS This did not 
affect the subsequent joint swelling after IL-1 injection, and had 
only a minor effect on the neutrophil influx (Table 2) Τ cell 
independence of the IL-1 hypersensitivity was further empha­
sized by the reactivation of the non-immunologically mediated 
zymosan-induced arthritis (ZIA) by IL-1 (Fig 2) 
ZIA and AIA differ in their chronicity ZIA remits within 
2-3 weeks whereas in AIA the smouldering inflammation is 
maintained for 4-5 weeks The subacute phases of ZIA and AIA 
were equally sensitive to IL-1, bul IL-1 hypersensitivity lasted 
longer in AIA than in ZIA Overall, the hypersensitivity for IL-1 
followed the arthritic course (Fig 3a) 
The above data indicate that IL-1-induced flare-up reflects a 
general hypersensitivity in previously injured joints In addition, 
we injected IL-1 into a joint previously injured with IL-1 
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Table 2 II 1 induced exacerbation is nol Τ cell media led bul depends 
on resident inflammatory cells 
Pre treatment 
Saline 
Nitrogen mustard* 
Saline 
Nitrogen mustard 
Goat serum 
ALS+ 
Goat serum 
ALS 
Challenge 
Substance 
Saline 
Saline 
IL 1 
IL 1 
IL I 
IL I 
m BSA 
mBSA 
Route 
IA 
IA 
IA 
IA 
IA 
IA 
IV 
IV 
Oedema 
" " T c ratio 
I 18 + 0 12 
I 0 1 + 0 10 
1 5 1 + 0 10 
0 98 + 0 28Í 
1 56 + 0 II 
1 48 + 0 14 
1 18 + 0 17 
1 I7±008§ 
Histology 
exudate 
0 9 + 0 5 
0 1 + 0 2 
2 2 + 1 2 
0 I ± 0 2 
2 1 + 0 6 
1 2 + 1 0 
1 81-I 1 
01 ± 0 3 4 
* Nitrogen mustard ( l mg kg) was given daily for 4 successive davs 
and 2 days later flare up was induced tArlhriliL miLe were pre treated 
with 0 5 ml anti lymphocyte serum (ALS) intraperitoneal^ at days — 1 
— 2 and —3 before antigen (mBSA) or IL 1 challenge This completely 
abrogated the antigen induced delayed type hypersensitivity (DTH) 
reaction in the ear mBSA (300 /ig) was injected intravenously and the 
exacerbation was measured 24 h later IL I (300 U) was intra articularly 
injected and the exacerbation was measured 6 h later % Statistical 
analysis of WmTc ranos of treated (nitrogen mustard or ALS) mice 
compared with the control (saline or normal goat serum) treated mice 
with the same (saline IL I or mBSA) challenge Method and statistics as 
described in legend of Table 1 
Significant joint swelling (M™Tc ratio 1 27 + 0 10 іегш! 
I 02 + 0 02 background value) was found 6 h after the third of a 
series of IL 1 injections given on alternate days Rechallenge 
with IL I 1 week later did not induce oedema ( " T c ratio 
I 0 2 + 0 08) indicating that this state of hypersensitivity was 
short lived 
Prerequisites for IL I hypersenstliiily 
IL I hypersensitivity depended on seventy of primary arthritis 
Various doses of zymosan were injected into the knee joints and 
IL 1 induced flare ups were determined 2 weeks later Zymosan 
induced a dose-dependent joint inflammation in the range of 6 
180 /jg as measured with T c uptake at day 3 (Fig 3b) There 
was almost complete remission of the inflammation 2 weeks 
later at which time marked flare ups produced by IL 1 were 
only seen in the joints previously injured with the highest 
zymosan doses 
Total depletion of the cellular infiltrate by prolonged 
nitrogen mustard treatment resulted in the complete abrogation 
of the IL 1 induced flare up (Table 2) This indicates that the 
infiltrate is involved in the IL I induced flare up and probably 
not a mere change in the endothelium 
To investigate this further Con A was injected into naive 
knees to induce a mononuclear cellular (MNC) infiltrate [26] 
with little joint swelling After only 2 days the joint swelling had 
vanished but a clear MNC infiltrate remained This kind of 
infiltrate renders the knee joint susceptible to IL-1 induced 
oedema and suggest that macrophages mediate the IL 1 flare 
up (Table 3) 
Additive effect of IL J on antigen induced flare up of AIA 
Chronic AIA could be reactivated by liny amounts of antigen 
dependent on the state of Τ cell mediated local hypersensitivity 
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Fig Э Exacerbation of arthritis depended on course of the joint 
inflammation (a) and extent of pnmar> joint inflammation (b) (a) 
InduLlion of flare up at different lime points after onset of 7ymosan 
induced arthritis (ZIA) (180 μ% zymosan) (A) or antigen induced 
arthritis (AIA) (60 μ% mBSA) (•) with intra articularly injected II I 
(300 U) Oedema formation was measured 6 h later and background 
inflammation was subtracted from the IL I induced flare up (b) 
Various concentrations of the arthntogen zymosan were injected into 
the knee joints After 3 days the primary joint inflammation was 
measured with W mTc uptake (A) Twoweekslaler IL 1 was injected into 
the subsided arthritis ( · ) and joint swelling was measured after 6 h asa 
control salme was injected into the arthritic joints (O) 
One hundred nanograms are always sufficient but 10 ng gives 
variable exacerbations We investigated whether IL 1 could 
synergize with the antigen induced flare up Figure 4 shows that 
mBSA caused a small but insignificant joint swelling The 
combination of mBSA and IL I resulted in a profound flare up 
which was higher than that found with antigen or IL 1 alone 
Moreover the flare up was more protracted (big 4) The same 
additive effect ofIL-1 was also found in the antigenic reactiva 
tion of the Streptococcal cell wall induced arthritis in mice (data 
not shown) In contrast, seventy of primary inflammation was 
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Table 3. IL-l-induced exacerbation of Con Α-affected knee joints 
Histology 
Time Injection Oedema, Dominant 
(h) at 42 h T c ratio Exudate Infiltrate cell type 
6 — 1-22 ±0-11 0-7±0-3 1-2+0-6 PMN 
24 — 116+017 ND ND ND 
48 - 0-98+006 0-5±0-6 0·9±0·2 M N O P M N 
48 Saline Ι·09±0·06 0-5 + 0-0 0-8 + 0-3 M N O P M N 
48 IL-1 1-45 + 0-11* 2-5 + 0-5 2-0 + 0-6 PMNi>MNC 
Knee joints were injected with 5 /xg Con A, a second injection of 
saline or IL-1 was given 42 h thereafter. PMN, Polymorphonuclear cell; 
MNC, mononuclear cell; ND. not done. Statistical analysis as described 
in Table I. 
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Fig. 4. Additive effect of 1L-Í on antigen-induced exacerbation of the 
smouldering inflammation. Mice were intra-articularly injected with IL-
1 (300 U), mBSA (10 ng) or a combination of both at week 2 of arthritis. 
Joint swelling was measured at 6 h and 24 h after induction of the flare-
up. *, § Statistical analysis of "mTc uptake as described in Table 1. Ш, 
After 6 h; D, after 24 h. 
not enhanced when antigen with IL-I was used to elicit arthritis 
in a naive joint (data not shown). 
D I S C U S S I O N 
The arthritic knee joint represents a hypersensitive area for 
systemic or local IL-1 of both types, IL-la and IL-10. IL-1 
provoked an acute but transient relapse of the smouldering joint 
inflammation; severe joint swelling and marked neutrophil 
accumulation were evident. From our study, evidence emerged 
that a previously injured joint bearing a macrophage-rich 
synovial infiltrate displayed IL-i hypersensitivity. 
Unlike many other predisposed tissues, e.g. lung, vitreous 
tissue and rat ankles [17,27,28], the naive murine knee joint 
lacked oedema formation in response to IL-1. In general, full 
blown oedema is often found in the presence of a capillary 
permeability enhancer and a vasodilator, e.g. prostaglandin E2 
(PGE2). In some tissues, addition of extra PGE 2 is necessary, 
while in other tissues sufficient PGE 2 is present anyway. 
Intradermal plasma leakage by IL-t was only evident with 
added PGE 2 [29,30] and a similar situation probably exists for 
the murine knee joint. In contrast to a naive joint, an arthritic 
knee joint did display oedema formation upon IL-1 challenge. 
Surprisingly, even this oedema was not fully dependent on 
PGE 2, since indomethacin treatment only partly suppressed the 
oedema (Table 1). It is noteworthy that IL-1 is incapable of 
inducing PGE2 synthesis in a naive joint [9,31], and it remains to 
be investigated whether this is different in an arthritic joint. 
We and others have found that IL-1 induced neutrophil 
influx in a naive joint, although the mechanism is largely 
unknown. IL-1 itself is not chemotactic for polymorphonuclear 
cells (PMNs) in vitro [32,33], PMN influx is not dependent on 
prostaglandins [25], and leukotrien-B4 (LTB4), a potent chemo-
attractant in vitro, is a poor chemoattractant in mice in vivo [34]. 
Neutrophil accumulation by IL-1 is more pronounced in an 
arthritic joint. One mechanism could be the enhanced ex­
pression of adhesion molecules (ICAM, ELAM-I) on vascular 
endothelium [35,36], or even vascular damage facilitating non­
specific cell entrance. Although IL-1 sensitivity depends on the 
severity of the preceding inflammation (Fig. 3b), it is highly 
unlikely that the IL-1-induced flare-up is a result of the initial 
damage to the vessels by the primary inflammation, e.g. IL-1· 
induced flare-up exceeded the initial inflammation induced by 
Con A (Table 3). In addition, products of neutrophils, activated 
during the flare-up, might have accounted for the vascular 
damage causing indirect plasma leakage [37,38]. However, the 
IL-1-induced flare-up of arthritis in neutropenic animals 
denotes that neutrophil influx and oedema occurred indepen­
dently of each other. 
It seems likely that neutrophil influx is mediated by macro­
phage products, which are released upon IL-1 challenge. A 
recent report provided evidence that the IL-1-induced neutro­
phil accumulation in the peritoneal cavity in the rat is mediated 
by the resident macrophages [39]. 
Three novel macrophage-derived mediators are described 
with in vivo inflammatory properties, IL-8 (NAP-1) and the 
macrophage inflammatory proteins MIP 1 and MIP 2 [40-42]. 
IL-8 has recently been detected in synovial fluid and could be 
produced by the inflammatory exudate cells and synovium of 
arthritic patients [43,44]. IL-1-induced accumulation of neutro­
phils exceeded the monocyte accumulation [30,45] and this is in 
concordance with IL-8-induced Chemotaxis (40]. Besides an 
acute neutrophil accumulation after injection, IL-8 also caused 
oedema formation, but the plasma leakage is prostaglandin— 
and neutrophil dependent [28,46]. IL-8 may therefore mediate 
the PMN influx into the arthritic joint after IL-1 injection, but is 
probably not solely responsible for the observed oedema 
formation. 
The macrophage products, MIP I and MIP 2 injected into 
the footpads of mice resulted in a PMN-rich infiltrate [47,48]. It 
is not clear yet if MIP synthesis by the macrophages could be 
induced by IL-1 or that MIP could give rise to oedema 
formation. 
Suggestive evidence is presented that IL-1 hyperreactivity in 
an arthritic joint is mediated by the macrophages in the synovial 
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infiltrate. IL-I hypersensitivity occurred after 1 week, at the 
m o m e n t that m a c r o p h a g e s b e c o m e the p r e d o m i n a n t cells. 
M o r e o v e r , IL-1 hypersensitivity was d e m o n s t r a t e d in the j o i n t 
after C o n A injection, which elicited mainly a m o n o n u c l e a r 
infiltrate. Depict ion exper iments e l iminated b o t h granulocytes 
(n i t rogen-mustard t r e a t m e n t ) a n d Τ cells ( A L S t r e a t m e n t ) a s 
relevant cells in the IL-1 hypersensitivity. Finally, m a c r o p h a g e s 
m a y generate IL-8 u p o n IL-1 chal lenge, which may mimic a 
n u m b e r of t h e features of the IL-1 flare-up. 
Exacerbat ions of a c h r o n i c Τ cell-medialed arthr i t i s m a y 
occur in two ways: u p o n react ivat ion with Lhe specific ant igen 
a n d via IL-1. T h e first kind of flare-up d e p e n d s on the specificity 
of the Τ cell infiltrate [20] and the ba lance between help a n d 
suppress ion. T h e IL-1 flare-ups a r c non-specific a n d may in fact 
occur at any m o m e n t that there is systemic generat ion of IL-1 by 
whatever process. It is t e m p t i n g t o speculate that al least part of 
the flare-ups in h u m a n RA are caused by this latter m e c h a n i s m . 
T h e r a p y should then be a imed at e l iminat ion o r b l o c k a d e of 
systemic IL-1 . T h e recent c loning of t h e IL-1 receptor a n t a g o ­
nist [49.50] m a y provide a useful tool for further research a long 
lhis line. A n o t h e r interesting IL-1 m o d u l a t o r for further s tudy is 
TGK-/Ï . which is known to downregu la t e or counterac t m a n y 
IL-1-driven processes, e.g. the lL-1- induced neut rophi l ad-
hesion to the endothel ium [51]. 
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Role of interleukin-1 (IL-1) in antigen-induced 
exacerbations of murine arthritis. 
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Abstract 
The mechanism underlying the chronic and intermittent course of 
rheumatoid arthritis is not elucidated. In the present study, the role of 
interleukin-1 (IL-1) was investigated in exacerbations of antigen-induced 
arthritis (AIA) in mice. A flare-up of the smouldering inflammation 
(week 3-4 of AIA) was inducible by injection of a small amount of 
methylated bovine serum albumin (mBSA), into the hypersensitive knee 
joint. Immunohistochemistry showed IL-1 expression in the synovial 
lining layer and in focal areas of the inflamed synovium during the flare-
up. IL-1 was also measured in 1 hour culture supernatant of synovial 
tissue taken during the flare-up using a bioassay. The expression of both 
immunoreactive - and bioactive IL-1 in the hypersensitive joint, peaked 
around 6 hours after antigen (2 μ% mBSA) injection and declined 
thereafter. Antigen rechallenge of the arthritic joint induced an acute 
joint swelling but not in the naive joint of the sensitized mouse although 
synovia of both joints produced IL-1 in response. Remarkably, a single 
intravenous injection of rabbit anti-IL-1 (α+β) antibodies 1 hour before 
antigen rechallenge neutralized IL-1 in the joint. Anti-IL-1 treatment 
significantly reduced the antigen-induced joint swelling (30-40%) but did 
not affect the profound influx of polymorphonuclear (PMN) cells in the 
onset of the exacerbation. A profound relief of the inflammation 
(synovitis) was obtained by blocking IL-1 at day 4 of the exacerbation. 
Chondrocyte proteoglycan (PG) synthesis was markedly suppressed in 
the antigen challenged naive knee joints suggesting that this was a direct 
IL-1 effect as the inflammation was insignificant. Anti-IL-1 treatment 
maintained the PG synthesis in the antigen rechallenged joint which was 
highly suppressed in the control group. Furthermore, the enhanced PG 
breakdown in the antigen rechallenged joints was significantly decreased 
by anti-IL-1. We concluded that IL-1 is an important mediator produced 
during the onset of the exacerbations of arthritis causing cartilage 
destruction. 
Introduction 
There is increasing evidence to suggest that the pluripotent cytokine IL-1 
plays an important role in the pathogenesis of inflammatory joint diseases, 
including rheumatoid arthritis (RA)· IL-1 has been identified in the synovial 
membrane and cartilage-pannus junction of arthritic joints from RA 
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patients.1,2 Moreover, numerous studies reported a striking corrrelation 
between the IL-1 levels in rheumatoid synovial fluid or plasma and the 
disease activity in these patients.3"5 The two important features of arthritis 
namely inflammation and cartilage destruction, can be attributed to local IL-
1 activity. In several mammalian species it was demonstrated that IL-1 
injected into the synovial joints causes and arthritic insult.*" In vitro studies 
showed that the chondrocyte PG synthesis was more susceptible for IL-1 
than the chondrocyte mediated PG degradation.^" 
To prove the importance of IL-1 recent studies have adressed the 
effect of blocking IL-1 in experimental arthritis either by neutralizing IL-1 
using antibodies or soluble IL-1 receptors, or by antagonizing the IL-1 
binding to its receptor with IL-lra and related proteins (M20). These 
different therapeutic approaches were able to diminish joint inflammation and 
also to reduced cartilage destruction in collagen-induced arthritis (CIA), 
immune complex arthritis (ICA), adjuvant arthritis (AA) and in the 
autoimmune prone MRL/lpr mice.12"17 In murine AIA, anti-IL-1 treatment 
did not affect the acute joint inflammation (edema, influx of PMNs) nor the 
accelerated PG breakdown, yet the marked chondrocyte PG synthesis 
inhibition was completely prevented.1*"20 We were the first to demonstrate 
impressive reduction both in inflammation as well as in cartilage destruction 
in established CIA using rabbit anti-IL-1 polyclonal antibody treatment.13 
These studies at least suggest that IL-1 blockade is worth pursuing as a 
therapeutic strategy for human arthritis. 
In 70% of the RA-patients the disease is characterized by an 
intermittent course of the inflammation.21 In humans, a rise in plasma IL-1/? 
levels followed the secondary flare-ups in RA and isolated peripheral 
monocytes spontaneously produced IL-1 during the flare-up.3,22 In the 
present study, experiments were carried out to examine the role of IL-1 in 
the flare-up using an animal model. A flare-up of the smouldering 
inflammation in the chronic phase of AIA was inducible in a predictable and 
synchronized manner by injection of a small amount of mBSA into the 
hypersensitive knee joint. 
Recently, Schwab et al.23 demonstrated that IL-1 played a key role in 
the peptidoglycan-polysaccharide (PG-APS) polymer reactivation of 
Streptoccal cell wall (SCW)-induced arthritis. It cannot be excluded that at 
least part of the flare-reaction in this model was non-immunologically 
mediated.24 Apart from PG-APS, flares can also be induced with cell wall 
derived lipopolysaccharide (LPS) and these fragments can directly activate 
macrophages. In AIA, T-lymphocytes as part of the residual inflammation in 
the arthritic joints, mediated the antigen-induced flare-up.25,26 Antigen-
stimulated T-cells could either produce IL-1 themselves or stimulate IL-1 
production in other cells. In RA, it is still a matter of debate whether the 
arthritic process was driven by T-cells, immune complexes (1С), both, or by 
non-immunological pathways. Our study clearly demonstrate that IL-1 plays 
a key role in the antigen-induced exacerbation of murine arthritis. 
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Materials and methods 
ANIMALS 
Female New Zealand White rabbits, male Wistar rats, and male C57B1/6 
mice (Jackson Lab., USA) were fed a standard diet and tapwater freely. 
CYTOKINES 
Murine recombinant IL-la and IL-Iß was a generous gift from I.G. 
Otterness (Pfizer Central Research, Groton CT, USA). 
GENERATION OF RABBIT ANTI-MOUSE IL-1 ANTISERUM 
Rabbits were immunization with murine recombinant IL-la or IL-l/S, 
according to the method as described by Hogquist et al.27, with some 
modifications. In short, 250 μg IL-1 in 2.25 ml PBS was emulsified with 
500 μΐ IMJECT™ ALUM (aluminium hydroxide, Pierce, Rockford, Illinois, 
USA). Each rabbit received 4 subcutaneous injections each 500 μΐ of the IL-
1/ALUM suspension at the back of the animal and adjacent to each of these 
sites 4 500 μΐ CF A/PBS subcutaneously. Each rabbit recieved three booster 
injection of 50 μg IL-1/ALUM, adjacent injections with incomplete freunds 
adjuvant emulsified in PBS, and additionally 5 μg IL-1 intravenously, every 
4-6 weeks. Ten days after every booster, 50 ml blood was aspirated, 
coagulated, decomplemented at 56°C, and stored at -70°C. The neutralizing 
capacity was 300 μg IL-1 per ml of the pooled antiserum. 
PURIFICATION AND CHARACTERIZATION OF RABBIT ANTI-IL-1 
ANTIBODIES 
Immunoglobulins were purified by affinity chromatographic separation on a 
Protein G sepharose 4B (albumin binding region genetically deleted, Sigma, 
St Louis, Missouri, USA) column. Immunoglobulins were eluted with 0.1 M 
Glycine-HCl pH 3.0 and immediately neutralized with 50 mM Tris-HCl pH 
8.0. Fractions were pooled, concentrated and dialysed against PBS at room 
temperature (RT). The anti-IL-1 antibodies showed no neutralizing reactivity 
against the other IL-1 subtype, IL-2, IL-4, IL-6, and TNF. 
GENERATION OF RAT ANTI-MOUSE IL-1 ANTISERUM 
Wistar rats were injected subcutaneously with 50 μg of murine recombinant 
IL-10 emusified in 0.5 ml CFA. After 2 weeks a booster injection was given 
of 25 μg IL-1 in 0.5 ml CFA. Rats were bled by orbital punction at a 
regular basis two weeks after the booster injection. 
FLARE-UP OF ARTHRITIS 
Mice of 8 to 12 weeks of age received 100 μg mBSA (Sigma Chemical 
Company, St. Louis, Missouri, U.S.A.) emulsified in 100 μΐ complete 
freunds adjuvant (CFA) subcutaneously per animal, injections were divided 
over both flanks and footpads of the forelegs. Heat-killed (2x10s) Bordetella 
pertussis organisms (National Institute of Public Health, Bilthoven, The 
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Netherlands) was administered intraperitoneally as an additional adjuvant. 
Mice received two booster injections of 50 μg mBSA/CFA in the neck 
region on day 7. Three weeks later, arthritis was induced by injection 6 μΐ 
of 60 μg mBSA in saline into the right knee joint cavity. At week 3 or 4 of 
arthritis, 0.2-2 μg mBSA was injected intra-articularly into the arthritic joints 
to induce a flare-up of the smouldering inflammation. 
JOINT SWELLING 
Mice were sedated by intraperitoneal injection of 4,5% chloral hydrate, 0.1 
ml/10mg of body weight. Approximately 10 /tCi "Technetium pertechnetate 
( T c ) in 0.2 ml saline was injected subcutaneously in the neck region. 
After 15 minutes the accumulation of the isotope in the knee was determined 
by external gamma counting and expressed as the ratio of the ""Tc uptake in 
inflamed over contralateral knee joint. A ratio higher than 1.1 indicates joint 
swelling. 
IL-1 PRODUCTION BY SYNOVIAL TISSUE 
Patellae were dissected with surrounding soft-tissue consisting out of the 
tendon, and synovium in a standardized manner. Each patella was incubated 
in 200 μΐ serum free RPMI 1640 (Dutch modification) medium with 
Glutamax-1 (Gibco BRL, Life Technologies, Schotland, UK) for 1 hour at 
room temperature. Dilutions of these wash-outs were tested for IL-1 and IL-
2 bioactivity. 
BIOASSAY FOR IL-1 
IL-1 activity was measured in the one-stage bioassay for IL-1 as described 
by Gearing et al.28: The murine thymoma cell line EL-4 NOB-1 (ECACC, 
Porton Down, Salisbury, Wilts, UK) was used as an IL-1 specific cell 
producing IL-2 in response, in combination with the IL-2 sensitive CTLL2-
cells (ECACC). The cells were plated out in concentrations of lxlOVwell 
NOBl-cells and 4xl03/well CTLL-cells in RPMI supplemented with 5% fetal 
calf serum (FCS), after 18-20 hour 0.5 jtCi of 3H-Thymidine (specific 
activity 20 Ci/mmol, Dupont, NENproducts, Boston, MA, USA) was added 
per well. Three hours later, cells were harvested and thymidine 
incorporation (NOB1 cell are thymidine kinase deficient) was determined. 
Detection limit of the assay was 0.1 pg/ml murine recombinant IL-1.18 
ASSESSMENT OF PROTEOGLYCAN SYNTHESIS 
Patellae (n=6), in a minimal amount of adjoining soft tissue (parts of 
synovium, tendon and muscle), were placed in 2 ml RPMI-1640 medium 
with gentamycin (50 Mg/ml), and 40 μΟ ^S-sulfate. At the end of the 3 h 
incubation period, patellae were fixed in 10% formalin and subsequently 
decalcified in formic acid (4%), dissected and dissolved in 0.5 ml 
Lumasolve (Hicol, Oud-Beijerland, The Netherlands). The 3îS-content of 
each patella was measured by liquid scintillation counting and expressed as 
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counts per minute (CPM) or as a percentage of normal cartilage. 
HISTOLOGY 
Standard frontal sections (7 μτα) of the whole knee joint, including both 
menici, crucial ligaments, and the patella, were prepared and mounted on 
gelatin (2%)-coated slides as previously described. Slides were stained with 
safranin-0 and counterstained with fast green. Cartilage depletion 
(diminished red staining) and inflammation was scored by a blinded 
observer. 
AUTORADIOGRAPHY 
33S-sulfate (100 μΟ) (specific activity 1200-1400 Ci/mmol, NENproducts) 
was injected intraperitoneally 6 hours before dissection of the knee joints. 
After histological processing, 7 μπι sections mounted on 0.5% gelatin coated 
slides were dipped in K5 emulsion (Ilford, Basildon, Essex, UK). The slides 
were developed and stained with hematoxylin and eosin after an exposure 
period of weeks. PG-synthesis was scored on the blackening of the 
chondrocytes by a blinded observer. 
IL-1 IMMUNOSTAINING 
Paraffin embedded sections were mounted on 2% gelatin coated slides, 
deparaffinized in xylene 2x5 minutes, rehydrated to deionized water. 
Endogenous peroxidase activity was blocked with 1 % H202 in phosphate 
buffered saline (PBS) for 20 minutes at RT. Rinse in water. Slides were 
overnight incubation with the primary antibody, rat anti-IL-1/3 antiserum or 
irrelevant rat antibody, 1/150 diluted in PBS plus 5% non fat dry milk at 
4°C in a humidified box. Wash in excess of PBS plus 0.1% tween-20, 3 χ 
10 minutes. Incubate slides with biotinylated secondary antibody, rabbit anti 
rat 1/200 diluted in PBS plus 5% non fat dry milk and 2% normal mouse 
serum for 1 hour at RT. Wash again in PBS/Tween, 3x10 minutes. Prepare 
avidin biotin/ peroxidase conjugated complex according to Vectastain's 
directions for preparation (Vectastain ABC kit, Vector Lab Ine, USA) and 
incubate slides with the ABC reagent diluted in PBS plus 5% non fat dry 
milk for 30 minutes at RT. Wash again in PBS/Tween. Develop slides with 
0.5 mg/ml diaminibenzidine (DAB) in Tris-HCl pH 7.6 and 0.02% H202 for 
10 minutes. Counterstain with haema-toxyline for 15 seconds. Anti-IL-1 
antiserum preincubated on IL-l/S coated plates, 8 χ 20 minutes at RT, or 
normal rat serum was used as a negative control. For control of IL-Iß 
specificity, antiserum was preincubated on IL-la or BSA coated plates. 
TREATMENT OF MICE WITH ANTI-IL-1 ANTIBODIES 
Mice received 200 μΐ of standard dose of 1 mg purified rabbit anti-IL-la 
antibody and 1 mg of anti-IL-lß antibody intra-venously into the orbita 
plexus, 1 hour before induction of the flare-up. These antibodies had an 
excellent half-life of more than 3 days. Total neutralizing capacity of the 
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received dose was about 32 ng of both subtypes of IL-1 as was tested in the 
IL-1 bioassay (NOB-1), and blocked the effect of 1 ng of IL-la or ß on 
proteoglycan synthesis completely and that of 10 ng IL-1 partially in vivo 
(not shown). Normal rabbit IgG's or polyclonal anti-ovalbumin antibodies, 
served as controls for non-specific effects of the treatment. 
Results 
IL-1 expression in antigen-rechallenged knee joints of chronic arthritis. 
At the time of antigen-rechallenge, week 3 of AIA, avidin-biotin immuno-
histochemistry using rat antiserum to IL-Iß failed to demonstrate IL-1 on 
whole knee joint sections (not shown). A single intra-articular injection of a 
small amount of antigen (2 μg mBSA) caused a transient expression of cell 
associated IL-lß. The number of IL-lß positive cells was small in the joint 
sections taken at 1 hour, high at 3 hour, low but still evident at 6 and 12 
hours, and absent at 24 hour after the antigen-rechallenge (not shown). The 
IL-lß signal was predominantly localized in the synovial lining layer and 
frequently in focal areas in the inflamed synovium (Figure 1). No immuno-
staining was evident using normal rat serum, nor using anti-IL-lß antiserum 
preincubated on microtiter plates coated with murine recombinant IL-lß 
(Figure 1). In some sections, chondocytes and the exudate 
polymorphonuclear cells were non-specifically stained. 
A single intra-articular injection of mBSA into hypersensitive joints 
(week 3 AIA) caused a dose-related joint swelling at 6 hour (Figure 2). 
Synovial tissue culture supernatants demonstrated increased levels of IL-1 
bioactivity 6 hours after antigen rechallenge in the tested dose range of 0.06 
to 2 jig mBSA (Figure 2). Time course experiments demonstrated a rapid 
onset of joint swelling increasing at least upto 24 hours after antigen (2 μg 
mBSA) rechallenge of AIA (Figure 3). The level of bioactive IL-1 in 
synovial tissue culture supernatants of arthritic joints was high at 3 and 6 
hour after antigen rechallenge (Figure 3). The expression of IL-1 was more 
transient compared to the joint swelling. At 24 hour after antigen injection, 
IL-1 released by the synovial tissue was low yet joints were profoundly 
swollen. Joint swelling was not inducible with 2 μg mBSA injected into 
naive joints of sensitized animals (Figure 3). Interestingly, the antigen 
challenged naive joints released IL-1 in levels and time course comparable to 
the rechallenged arthritic joints (Figure 3). 
Role of IL-1 in the antigen-induced exacerbation of the chronic joint 
inflammation. 
At the time of antigen rechallenge, week 3 of AIA, swelling of the arthritic 
joints subsided, the inflammatory exudate cells disappeared but joints had a 
mild ongoing synovitis (Table 1). Intra-articular injection of 2 μg mBSA into 
the arthritic joints caused an acute transient joint swelling. At day 2 of the 
flare-up a Tc-ratio of 1.22 + 0.14 was measured. 
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Figure 1: Immunoperoxidase localization of whole knee joint sections showing cells stained for 
IL-lß (magnification χ 250) in focal areas of the inflamed synovium (a) and in the synovial 
lining layer (b). Antigen (2 μ# mBSA) was injected intraarticularly at week 3 of AIA and joints 
were dissected 3 hours thereafter. Serial sections stained with normal rat serum (c) or with anti-
IL-lß antiserum preincubated on IL-lß coated microtiter plates (d) served as negative controls. 
Abbreviations: C, cartilage; E, exudate; JS, joint space; L, lining layer; S, synovium. 
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Figure 2: Dose related joint swelling and IL-1 production in antigen rechallenged hypersensitive 
knee joints. Antigen (0.06-2 ßg mBSA) was injected intra-articularly into arthritic joints at week 
3 of AIA. Joint swelling was measured 6 hour after the antigen rechallenge by external gamma 
counting of ""Technetium pertechnetate uptake. Values represent the mean ratio of arthritic (R) 
over the naive contralateral joint (L) (± S.D.) of 7 animals. A 1/80 fold dilution of culture 
supematants of synovial tissue taken 6 hours after antigen rechallenge was tested for IL-1 using 
a cell proliferation assay. Values represent the mean stimulation index (± S.D.) of 6 individual 
synovia. Highest signal (SI) is comparable with the response to 4 pg/ml of IL-1 in the assay 
(10.000 CPM). Statistical significance was tested by using the Wilcoxon's rank sum tests. 
Ρ<0.05 (*) was considered significant. 
The same antigen dose injected into the naive contralateral joints of these 
arthritic animals did not cause joint swelling (Table 1). 
To investigate the role of de novo synthesized IL-1, neutralizing 
polyclonal anti-IL-1 (α+β) antibodies were injected intravenously one hour 
before antigen rechallenge. Blocking IL-1 decreased joint swelling at 6 hour 
(-29%) and significantly reduced joint swelling at 24 hour (-41%) after 
antigen rechallenge as compared to the untreated mice (Table 1). This was a 
consistent finding in all experiments, mean joint swelling of 1.60 ± 0.21 in 
the untreated mice (n=47), 1.52 ± 0.24 in the normal rabbit IgG treated 
mice (n=68), and 1.37 + 0.29 in the anti-IL-1 treated mice (n=75) at day 1 
after antigen rechallenge. Antigen injection also caused a marked influx of 
polymorphonuclear neutrophils (PMN) into the cavity, and exacerbated the 
ongoing synovitis in the hypersensitive joint (Table 1). A moderate 
inflammation was inducible in the naive contralateral joints of these 
sensitized animals with the same antigen dose (2 μg mBSA) used (Table 1). 
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Figure 3: те related changes in joint swelling and IL-1 production in antigen rechallenged 
hypersensitive knee joints (A) and in naive joints of sensitized mice (B). Antigen (2 μg mBSA) 
was injected intra-artiadarly and both joint swelling and EL-1 production by the synovial tissues 
was measured (as described in figure 2) at several timepoints thereafter in б animals each. 
Statistical significance was tested by using the Wilcoxon's rank sum tests, *=P<0.05. 
Table 1: Role of IL-1 in the antigen-induced exacerbation of the smouldering joint inflammation. 
Anti 
gen1 
_ 
+ 
+ 
+ 
+' 
Pre-
treat 
None 
None 
NRS 
AIL1 
None 
Joint swelling 
Tc-ratio 
6h 
(n=8)* 
1.07 (.07) 
1.49 (.26) 
1.46 (.15) 
1.35 (.23) 
ND 
(R/Lr 
24 h 
(n=12) 
1.05 (.08) 
1.70 (.10) 
1.66 (.20) 
1.41 (.17)* 
1.06 (.08) 
Histology 
Exudate* 
6 h 24 h 
(
П
=7) (n=8) 
0.0(0.0) 0.0(0.0) 
1.4(0.5) 1.7(0.9) 
1.8(0.9) 1.8(0.8) 
1.6(1.0) 1.8(0.8) 
0.3 (0.3) 0.6 (0.4) 
Histology 
Infiltrate h 
6 h 24 h 
(n=7) (n=7) 
0.8 (0.6) 0.4 (0.4) 
1.7(0.8) 1.6(0.8) 
2.1(1.1) 1.9(0.6) 
2.1(1.2) 1.6(0.8) 
0.2(0.3) 0.4(0.1) 
96h 
(n=8) 
0.4 (0.2) 
1.4(0.9) 
1.4 (0.9) 
0.5 (0.1)* 
ND 
Arthritic knee joints rechallenged with 2 μg mBSA at week 3 of AIA (+). 
Antigen injected into the naive contralateral knee joints. 
Number of mice per group are indicated between brackets. 
Mice pretreated with normal rabbit antibodies (NRS) or anti-IL-l(a+j3) antibodies (AIL1). 
Joint swelling was measured at six and 24 hours after the antigen injection by 
"Technetium (Tc) uptake (S.D.). 
Histological analysis of cell exudate (PMNs) in the joint cavity at 6 and 24 hour after 
antigen injection. Arbitrary scoring from 0 (no cells) to 3 (large number of inflammatory 
cells) by a blinded observer. 
Histological analysis of cell infiltrate (at 6 and 24 hour) and synovial thickness (at 96 
hour) after antigen injection. Statistical significance was tested by using the Wilcoxon's 
rank sum tests. Ρ <0.05 (*) was considered significant. 
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Anti-IL-1 (a+/S) antibody pretreatment had no effect on the number of 
inflammatory cells (PMN) in the 6 and 24 hour exudate and on the extent of 
the synovitis at these time points (Table 1). A marked amelioration of the 
synovitis was observed at day 4 after antigen-rechallenge in the anti-IL-1 
treated group (Table 1, Figure 5). This was a consistent finding in 3 out of a 
total of 4 experiments. Synovitis (1.55 ± 0.69) in the normal rabbit IgG 
treated mice (n=21) was significantly higher than in the anti-IL-1 treated 
mice (0.63 ± 0.23, a reduction of 59%). 
Role of IL-1 in the flare-up related cartilage pathology. 
Chondrocyte PG synthesis, markedly suppressed the first weeks of AIA, 
returned to a normal rate at week 3 of AIA. A marked suppression of the 
PG synthesis was evident at day 1 (-28%) and day 2 (-23%) after antigen 
rechallenge in patellar cartilage as was measured by 35S-sulfate incorporation 
ex vivo (Table 2). Pretreatment of mice with anti-IL-1 antibodies completely 
prevented the proteoglycan synthesis suppression to occur (Table 2). 
Autoradiography of whole knee joint sections also demonstrated reduced 35S-
sulfate incorporation by the chondrocytes in cartilage of the arthritic joints 
from day 1 upto day 4 after antigen rechallenge (Table 3, Figure 4). 
Blocking the IL-1 activity with antibodies significantly enhanced the PG 
synthesis in the antigen rechallenged mice (Table 3, Figure 4). 
Table 2: Effect of anti-IL-1 treatment on PG synthesis suppression and PG degradation in 
antigen challenged joints. 
Anti 
gen1 
_ 
+ 
+ 
+ 
-
+ 
Treat 
meno 
None 
None 
NRS 
AIL-1 
None' 
None' 
Proteoglycan metabolism (CPM ± SD) 
Synthesis'* 
Day 1 
1118 ± 104 
739 ± 54 (-28%) 
732 ± 103 (-35%) 
1068 ± 143" (4%) 
1153 ±258 
860 ± 170*(-25%) 
Synthesis'* 
Day 2 
(n = 7) 
1238 ± 289 
958 ±251 (-23%) 
913 ± 343 (-26%) 
1519 ± 778 (+23%) 
ND 
ND 
Degradation* 
Day 1 
(n=6) 
360 ± 99 
ND 
148 ± 39 (-59%) 
226 ± 40"(-37%) 
ND 
ND 
f Arthritic knee joints rechallenged with 2 μ% mBSA at week 3 of AIA ( + ) . 
l· Antigen injected into the naive contralateral knee joints. Number of mice per group are indicated between brackets. -j| Normal rabbit antibodies (NRS) or anti-IL-1 (ot+fi) antibodies (AIL-1) injected 1 hour 
before antigen rechallenge. 
=j 35S-sulfate incorporation into patellar cartilage ex vivo. Values between brackets indicate 
the inhibition of PG synthesis as a percentage of the unchallenged joint. Representative of 
two experiments. 
=j| 35S-sulfate content in patellar cartilage. MS-sulfate was injected subcutaneously 24 hour 
before antigen injection. 
Statistical significance was tested by using the student's t test, * = P < 0 . 0 5 . 
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Table 3: Histological analysis of the anti-IL-1 treatment effect on PG synthesis and cartilage PG 
depletion in antigen challenged joints. 
Anti Treat Proteoglycan synthesis'* Depletion 
gen1 menfi 
Day 1 Day 2 Day 4 Day 4 
(n=7)v (n=S) (n=6) (n=8) 
None 2.0 ± 0.9 2.2 ± 0.3 2.1 ± 0.9 0.4 ± 0.8 
+ None 0.5 ± 0.3 (-77%) ND ND 2.1 ± 0.6 
+ NRS 0.7 ± 0.4 (-70%) 0.9 ± 0.6 (-60%) 0.9 ± 0.7 (- 60%) 1.9 ± 0.9 
+ AIL-1 1.4 ±0.7"(-30%) 1.9 ± О.Г(-14%) 2.5 ± 0.5'(+17%) 0.3 ± 0.5" 
None' 1.3 ± 0.6 ND ND 0.0 ± 0.0 
+ None' 0.5 ± 0.3'(-63%) ND ND 0.4 ± 0.2 
f Arthritic knee joints rechallenged with 2 μg mBSA at week 4 of AIA (+). 
J Antigen injected into the naive contralateral knee joints. 
||- Number of mice per group are indicated between brackets. 
-|| Normal rabbit antibodies (NRS) or anti-IL-1 (a+/J) antibodies (AIL-1) injected 1 hour 
before antigen rechallenge. 
=| Autoradiography of whole knee joint sections. "S-sulfate incorporation into patellar 
cartilage in vivo as scored arbitrary from 0 (no black spots) to 3 (strong blackening as seen 
in the growth plates). Values between brackets indicate PG synthesis inhibition. 
|= Histological analysis of patellar cartilage PG depletion as scored arbitrary from 0 (strong 
safranin-O staining = no depletion) to 3 (unstained cartilage = strong depletion) by a 
blinded observer. 
Statistical significance was tested by using the Wilcoxon's rank sum tests, *=P<0.05. 
Interestingly, injection of 2 μ% mBSA into the naive contralateral joints of 
these mice also resulted in a significant suppression of the PG synthesis at 
day 1 (Table 2 and 3). 
Enhanced proteoglycan degradation (-59%) was found in the 
hypersensitive joints 1 day after antigen rechallenge as was measured on 35S-
sulfate prelabeled patellar cartilage in vivo (Table 2). The accelerated 
degradation could be significantly reduced by anti-IL-1 treatment but was 
still remarkable (-37%) (Table 2). 
Histology taken at week 4, but not at week 3, of AIA showed full 
recovery of the cartilage matrices (Figure 5). Antigen (2 μg mBSA) 
rechallenge caused severe PG depletion of the cartilage matrices as was 
shown on safranin-O stained whole knee joint sections (Table 3, Figure 5). 
Pretreatment with anti-IL-1 antibodies, but not with control IgG, 
significantly ameliorated the cartilage pathology at day 4 of the antigen-
induced exacerbation (Table 3, Figure 5). Anti-IL-1 (α+β) pretreatment 
completely prevented the antigen-induced cartilage depletion in the 
hypersensitive joints in 4 out of 5 experiments. Antigen injection into the 
naive contralateral joints of the arthritic mice caused only minor cartilage 
depletion (Table 3). 
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Figure 4: Autoradiographic analysis of 
the chondrocyte proteoglycan synthesis. 
Mice received 75/xCi î 5S-sulfate 
spontaneously and 4 hours later them knee 
knee joints were dissected and processed 
for histology. A) Arthritic joint at week 3 
of ΑΙΑ. В) Arthritic joint of normal 
rabbit IgG treated mouse one day after 
antigen rechallenge (2 μg mBSA) C) 
anttigen rechallenged arthritic joint in an 
anti-IL-1 antibody treated mouse. 3 5 S 0 4 
incorporation indicated by the black spots 
in cartilage and growth-plates. Original 
magnification xlOO; P, patella; F, femur; 
JS, joint space; S, synovium; C, 
cartilage; GP.growth plate. 
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Figure 5: Histology of whole knee joint 
sections stained with safranin-O. 
A) Arthritic knee joint at week 4 of AIA, 
B) Arthritic joint in a normal rabbit IgG 
treated mouse 4 days after antigen 
rechallenge (2 μg mBSA), note the 
thickening of the synovium (thin arrow) 
and PG loss in the cartilage matrix 
(compact arrow), C) antigen rechallenged 
joint in an anti-IL-1 antibody treated 
mouse. Original magnification xlOO; 
P, patella; F, femur; JS, joint space; 
S, synovium; C, cartilage. 
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Discussion 
This study clearly demonstrates that IL-1 is an important determinator in 
antigen-induced exacerbations of murine arthritis. In the conducted 
experiments, pretreatment of mice with rabbit polyclonal antibodies directed 
against murine recombinant IL-la and IL-1)3 markedly alleviated joint 
swelling and ameliorated cartilage pathology of the antigen rechallenged 
joints. 
Using avidin biotin immunohistochemistry we showed IL-l/S 
expression in the synovium of antigen rechallenged joints, predominantly 
located in the lining layer, in distinct cell clusters, and positive cells were 
more sparsely distributed in the deeper area. An identical localization was 
found in synovial membranes of rheumatoid arthritis for IL-la and IL-1/3.1,2 
The expression of IL-Ira was identical to IL-1 in the rheumatoid synovium 
although the number of positive cells was considerably smaller.1 We found 
an identical kinetic for both the expression of bioactive and immunoreactive 
IL-1 in hypersensitive joints after antigen rechallenge. This indicates that IL-
1 inhibitors (e.g. IL-lra), although they may be produced, were not 
responsible for the transient IL-1 expression in the flare-up. 
IL-1 was inducible in both virgin and hypersensitive joints of 
sensitized mice but not in joints of normal mice.18 This shows that the 
stimulation of IL-1 was not a property of the antigen but that either 
lymphocytes or immune-complexes were involved. IL-1 production in 
rheumatoid synovial membranes was considerably higher in membranes 
possessing lymphocyte aggregates compared to membranes with a disperse 
infiltrate.29 These focal areas consisted out of В cells, plasma cells and CD4+ 
Τ cells in the center and macrophages at the periphery. Τ helper type 2 cells 
but also В cells as almost all accessory cells (e.g. macrophages) can produce 
IL-1. We did not quantitatively compare the IL-1 production in antigen 
challenged naive and hypersensitive joints, but only in the later we found 
distinct staining of cell clusters. 
The antigen dose used to elicited a flare-up of AIA was not 
arthritogenic in normal knee joints of sensitized mice. This suggest that the 
anigen-induced IL-1 production was too low to induce joint inflammation. 
We previously demonstrated that a single injection of 10 ng IL-1 could not 
induce joint swelling and cell exudate in naive joints but induced a short 
lasting flare-up of the inflammation in hypersensitive joints of AIA as was 
displayed by increased joint swelling and a marked cell exudate.8·30 A highly 
likely explanation for the hypersensitive state could be the increased 
expression of adhesion molecules (VCAm-1, ICAMs) in the inflamed 
synovium.31 In the present study, we found using anti-IL-l(o!+/3) antibodies 
that the cell exudate and the joint swelling for the greater part (60-70%), 
were not IL-1 mediated in the antigen-induced exacerbation of AIA, and this 
suggest that other mediators are involved in this process. 
Indisputable evidence was presented that CD4 positive T-cells are 
mediating the antigen-induced exacerbation of murine arthritis.32 It was 
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concluded from the full blockade of the flare-up by anti-la 
(histocompatibility type II antigens) antibodies that antigen presentation was 
of importance.26 Although IL-1 is capable of activating lymphocytes, we 
found that the IL-1 induced exacerbation of AIA was not lymphocyte 
mediated.30 Evidence is emerging that IL-1 does not play a prominent role in 
the antigen induced T-cell activation.33,34 For instance, Schwab et al.M 
demonstrated that reactivation of SCW arthritis by the T-cell superantigen, 
toxin shock syndrome toxin-1, was neither IL-1 nor TNFa dependent and 
this contrasted with the peptidoglycan polysaccharide reactivation suggesting 
that the latter was not solely T-cell mediated. 
We selectively blocked the TH1 derived IL-2 and the TH2 derived IL-
4 with antibodies and this markedly reduced joint swelling, cell exudate and 
infiltrate during the antigen-induced flare-up.32 Co-injection of large amounts 
of IL-2 or IL-4 with the antigen significantly enhanced cell exudate and it 
was concluded both cytokines acted proinflammatory in the hypersensitive 
joint. 
A more pivotal role of IL-1 was found in immune-complex (1С) 
mediated inflammations.36·37 Recently we developed an immune-complex 
mediated arthritis model (ICA) by passive immunization in mouse.14 In this 
model, IL-1 and complement activation acted synergistically in the onset of 
the inflammation. Striking anti-inflammatory effects using anti-IL-1 
antibodies or IL-1 receptor antagonist protein (IL-Ira) were also found in 
CIA, even when treatment was started in already established disease.13 In 
contrast, anti-IL-1 treatment had no effect on the onset of AIA.18"20 CIA is 
probably more 1С- than T-cell mediated.38,39 For instance, although CIA 
could be transferred by T-cells and 1С, a combination resulted in a more 
pronounced inflammation.40 However, AIA and the subsequent 
hypersensitive state of the joints could be transferred with antigen (mBSA)-
specific T-cells to naive recipients.41 Up till now, we were unable to transfer 
the disease (AIA) by B-cells or immunoglobulins (unpublished data). The 
importance of IL-1 could be related to the type of inflammation or the site of 
the inflammation.16,42 
Antigen rechallenge of the hypersensitive joints induced a marked 
inhibition of the chondrocyte proteoglycan synthesis for at least 4 days. This 
was not a property of the antigen as PG synthesis suppression was not 
inducible in joints of non-immune mice.18 The flare-up of the inflammation 
was not responsible for the suppression of the chondrocyte synthetic function 
for two reasons. First, antigen injection into naive joints of sensitized mice 
induced both IL-1 production and inhibition of the PG synthesis without a 
significant joint inflammation. Second, blocking IL-1 with neutralizing anti-
IL-1 (οί+β) antibodies protected the chondrocyte synthetic function without 
affecting the onset of the flare-up. We previously demonstrated a key role of 
IL-1 in the inhibition of proteoglycan synthesis in several murine arthritis 
models i.e. CIA, AIA, and ICA.13,18,1'43 
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The enhanced cartilage degradation in the antigen-challenged arthritic 
joints was for about 50% IL-1 mediated. In ICA and CIA, the anti-IL-1 also 
significantly reduced proteoglycan degradation but this was probably related 
to the alleviation of the joint inflammation.13,44 A more likely explanation for 
the protective effect of anti-IL-1 treatment on the flare-up is a higher 
vulnerability for IL-1 induced degradation of cartilage in the recovery phase 
of arthritis (Manuscript in preparation). Pelletier et al.45 presented evidence 
for an enhanced number of IL-1 receptors on chondrocytes in human OA 
cartilage and showed that the IL-1 required for half-maximal 
metalloproteinase stimulation was 3-4 times lower compared to normal 
cartilage. 
Protection of the chondrocyte synthetic function and reduction of the 
enhanced PG degradation probably resulted in the observed amelioration of 
the cartilage pathology at day 4 after antigen rechallenge. Mini-osmotic 
pumps releasing 30 μg IL-Ira per hour (Synergen) into the peritoneal cavity 
from day 2 before antigen rechallenge upto 7 days thereafter, verified the 
anti-IL-1 antibody effects (not shown). 
Another impressive effect of the anti-IL-1 treatment was the reduction 
in the synovial thickness (hyperplasia) at day 4 of the exacerbation. IL-1 is a 
potent growth factor for synovial fibroblasts and this can explain this anti-IL-
1 effect.46 Synoviocytes can actively participate in the local hypersensitivity 
for a number of reasons. First, synovial fibroblasts (synoviocytes) are 
accessory eels by their capacity of antigen presentation and IL-1 
expression.47,48 Second, adhesion molecules can be induced by cytokines on 
type В synoviocytes and this may facilitate leukocyte recruitment.49,50 
Moreover, unrestricted synoviocyte proliferation caused arthritis in animals 
and synovial tissue implants caused cartilage destruction.51·52 For this, the 
reduction of the synovial hyperplasia in the antigen rechallenged joints could 
be responsible for the amelioration of arthritis. Interestingly, IL-4 is an 
major regulatory molecule in the inflamed tissue by inducing IL-Ira and 
MCP-1 and reducing PGF^ release and synoviocyte proliferation.53,54 
This study indicate that IL-1 is involved as key mediator in the 
pathological changes of cartilage not only in IC-mediated inflammation but 
also in T-cell mediated inflammations. Our study strengthen the need for 
further research of the role of IL-1 even in the case IL-1 is not involved in 
the onset of the inflammation. 
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10.1 Outline of the general discussion. 
Rheumatoid arthritis is a systemic illness with polyarticular 
manifestations of chronic inflammation. The levels of IL-1 in the 
circulation correlates with the index of disease activity (chapter 
1.3). In animal models of arthritis, IL-1 expression is associated 
with onset and course of the joint inflammation (chapter 1.4). IL-1 
production can take place in the arthritic joint and at the systemic 
level, for example, the IL-1 production by peritoneal macrophages 
and bone marrow cells in rat adjuvant arthritis and the bone 
marrow cells in collagen-induced arthritis (CIA). The spontaneous 
IL-1 production by human peripheral blood monocytes coincided 
with exacerbations of the inflammation in RA patients [1]. It 
remains to be seen whether the IL-1 production at the local or at 
the systemic level modulates the course of the joint inflammation. 
For this, the effect of intra-articular or systemic administration of 
IL-1 on the inflammation was studied in experimental arthritis 
(chapter 10.2). 
The role of endogenous IL-1 in the arthritic process will be 
evaluated in chapters 10-3 and 10-4. It is known that IL-1 takes 
part in both immuno-regulatory and inflammatory processes, 
however, the involvement of both processes and their interplay 
may differ between the arthritis models. Furthermore, anti-IL-1 
was either given in a prophylactic regimen, before or during the 
immunization, or in a therapeutic regimen, started after full blown 
immunity, in the different studies. This makes it difficult to define 
at which level (process) of the disease anti-IL-1 interferes with. 
In RA, the spontaneous IL-1 production by isolated 
synoviocytes was maintained by de novo TNF production and for 
this anti-TNF treatment was expected to mimic anti-IL-1 
treatment. The role of TNF in the arthritic process in the animal 
models is reviewed (chapter 10.5) and the future perspective of 
anti-IL-1 treatment of RA is evaluated and compared with recent 
clinical findings of the anti-TNFa treatment (chapter 10.6). 
10.2 Effect of exogenous IL-1 on experimental arthritis. 
ACCELERATION OF (COLLAGEN-INDUCED) ARTHRITIS 
Daily subcutaneous injections of human recombinant IL-Iß during 
the immunization against heterologous type II collagen, accelerated 
onset, increased incidence, and enhanced the progression of CIA in 
mice and rats [2-6]. The circulating antibody levels against type II 
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collagen (chicken or bovine) are comparable between sensitized 
non-arthritic mice and age-matched, IL-1 injected arthritic animals. 
Furthermore, IL-1 was only able to promote arthritis in susceptible 
mouse strains and not in genetically resistent strains although the 
later had comparable antibody levels against type II collagen [6]. 
The circulating antibody levels against heterologous type II 
collagen did, however, not correlate with the number of affected 
joints or the histological grade [7]. CIA is more likely to be 
initiated by cross-reactive antibodies against autologous type II 
collagen [8]. For this, it is possible that IL-1 promotes CIA in 
prone animals by an enhanced anti-collagen antibody response 
against autologous collagen but this was not assessed in these 
studies. 
T-cells are also involved in CIA, since anti-IL-2 receptor 
antibody treatment effectively suppressed murine CIA [9]. 
Systemically administered IL-1 did not induce arthritis in 
'susceptible', L3T4+ Τ cells depleted mice [6], however, IL-1 
injections in adoptively (Τ -I- В cells) transferred mice increased 
the anti-type II collagen antibody levels and caused a transient 
arthritis [3,6]. A possible explanation for this is that IL-1 changes 
the humoral response through T-cell activation. Another 
explanation could be that IL-1 stimulates T-cells to cause arthritis. 
As circumstantial evidence, prolonged treatment with human 
TNFa started before the immunization increased the T-cell 
response (DTH-reaction) against type II collagen rather than the 
antibody response and simultaneously aggravated CIA in rats [10]. 
On the other hand, IL-1 or TNF may lower a threshold in animals 
with nascent illness. Exogenous IL-1 may bypass the IL-1 inhibitory 
effects of IL-4 and IL-10, both Th2 subset derived cytokines [11-
16], and by this initiates inflammation. 
Crucial in this model is the immune response against 
autologous type II collagen. In normal cartilage the collagen fibrils 
are surrounded by proteoglycan aggregates and this makes it 
unlikely that type II collagen epitopes are exposed to B- or T-cells. 
The epitopes becomes available during cartilage breakdown. A 
likely mechanism since in IL-1 challenged prone animals 
(established immunity (day 14)) arthritis developed within the first 
day after IL-1 injection [6]. Interestingly, IL-1 is more potent on 
cartilage of the ankle joint than the knee [17] and since the ankle 
joint is the prevalent site of CIA, this implies that IL-1 exerts its 
potentiating effect on CIA by direct action on cartilage rather than 
on the immunity. A likely explanation also for the IL-1 
acceleration of the spontaneous arthritis in autoimmune MRL/lpr 
mice [18]. 
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EXACERBATION OF THE JOINT INFLAMMATION 
In Streptococcal œil wall (SCW)-induced arthritis in rat, intra-
articular IL-1 injections into the arthritic ankle joint exacerbated 
the smouldering inflammation. Clear-cut aggravation of arthritis 
was found after repeated IL-1-induced flares [19]. We showed that 
local or systemic administration of IL-1 induced a flare-up of the 
smouldering inflammation in antigen-induced arthritis (AIA) in 
mice (AIA) (chapter 8). The IL-1 induced flare-up of AIA was 
more transient compared to the IL-1 induced flare-up of SCW-
arthritis but in both models marked cartilage degradation was 
shown (preliminary data) and this was not induced by IL-1 in naive 
knee joints (chapter 3). In humans, affected cartilage of 
osteoarthritic - and RA-patients is more vulnerable to IL-1 induced 
proteoglycan loss than normal cartilage [20]. 
The antigen-induced exacerbation of SCW-arthritis with 
peptidoglycan polysaccharide (PG-APS) and AIA with methylated 
bovine serum albumin (mBSA) are both T-cell dependent. In AIA, 
the antigen-induced flare-up could be blocked by pretreatment 
with either anti-lymphocyte sera and anti-la antibodies and this was 
recently confirmed with anti-CD4 treatment. Anti-lymphocyte 
pretreatment did not prevent the IL-1 induced flare-up of chronic 
AIA [21]. This and the IL-1 induced flare-up of zymosan-induced 
arthritis (ZIA) and concanavalin Α-induced inflammation in knee 
joints, implies that not T-cells but more likely the macrophage rich 
infiltrate is responsible for the observed IL-1 hypersensitivity 
(chapter 8). 
Studies in the rabbit failed to note joint swelling in spite of 
the heavy infiltration of leukocytes [22]. We found no swelling in 
the murine knee joint up to 10 ng IL-Ια/knee (measured as Tc) 
(chapter 3). Stimpson et al. [19], measured an ankle joint swelling 
to murine IL-la in the rat and found a measurable response at 
around 5 ng of IL-1. Chandrasekhar et al. [23] compared the ankle 
with the knee and found a good swelling response from 1-10 ng 
huIL-10 i.a. into the ankle whereas 5-10 μ% were required for a 
similar swelling response in the knee. This indicate that the ankle 
is more sensitive to IL-1 than the knee joint. IL-1 also induce a 
profound edema in highly vascularized tissues such as lung and 
vitreous tissue, suggesting that the IL-1 induced plasma leakage in 
previously inflamed joints is related to impaired endothelial vessel 
wall integrity or neovascularization. 
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10.3 Effect of anti-IL-1 treatment on joint inflammation in 
experimental arthritis. 
NON-T-CELL MEDIATED ARTHRITIS MODELS. 
Van Lent et al. [24] developed an immune complex arthritis model 
(ICA) induced in the mouse by passive immunization with rabbit 
anti-lysozyme antibodies followed by i.a. injection of low amounts 
of poly-LL-lysine coupled lysozyme (3 ¿ig). Pre-treatment with 
rabbit anti-IL-1 (a + β) polyclonal antibodies markedly suppressed 
joint swelling and influx of polymorphonuclear leucocytes (PMN) 
but did not prevent thickening of the synovial membrane [24]. 
Joint inflammation could not be induced with aBSA into passively 
immunized (rabbit anti-aBSA antibodies) mice. The difference is 
that poly-LL-lysine coupled lysozyme is a potent IL-1 inducer in 
the joint whereas aBSA is not. In ICA, both IL-1 and complement 
activation acted synergically in the induction phase of arthritis. 
Depleting macrophage-like synovial lining layer cells by 
dichloromethylene diphosphonate encapsulated liposomes reduced 
IL-1 production and subsequently prevented arthritis [25,26]. In 
RA, the numbers of synovial tissue macrophages significantly 
correlates with the degree of joint erosions [27]. 
Zymosan is also a potent trigger of IL-1 production in 
monocytes whereas the IL-1 receptor antaginist protein (IL-Ira) 
could not be induced by zymosan in the same cells [28-30]. Intra­
articular injected zymosan caused an acute joint inflammation and 
cartilage destruction. In zymosan-induced arthritis (ZIA), the anti-
IL-1 treatment significantly reduced joint swelling (maximal -24%) 
but the influx of PMN was not affected (chapter 7). A conflicting 
result with the potent anti-inflammatory effect of anti-IL-1 on 
zymosan-induced pleurisy and subcutaneous inflammation (tissue 
chamber) [30,31]. It is concluded that although zymosan 
(alternatively) activates complement factors and stimulates IL-1 
production, zymosan induced joint inflammation by an IL-1 
independent pathway. 
T-CELL INVOLVED ARTHRITIS MODELS 
In the above mentioned arthritis models (ICA,ZIA) no active 
immunization against the trigger is required and there is no 
evidence that T-cells are involved in the onset of the disease. 
Wooley et al. [32] treated CIA with human IL-Ira by daily 
intraperitoneal injections (3-300 /xg) started at day 14 of the 
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immunization, and this delayed onset and reduced the incidence of 
CIA in DBA/1 LacJ mice. The IL-Ira treatment significantly 
reduced the levels of circulating anti-collagen type II antibodies (-
30%) but this was unrelated to the anti-inflammatory effect of IL-
lra in CIA. Van den Berg et al. [33] showed that a single intra-
peritoneal injection of neutralizing rabbit anti-IL-1 (or + ß) 
polyclonal antibodies completely protected mice in developing 
arthritis and almost completely attenuated arthritis when injected 
in the progressive phase of the disease [33]. Anti-IL-1 decreased 
the number of affected joints, diminished synovitis, and markedly 
reduction cartilage pathology [33]. Intraperitoneal injections of 
monoclonal antibody against IL-Iß three times per week, started at 
day 3 of the immunization, prohibited mice to develop arthritis 
[34]. Treatment started at day 21 of the immunization significantly 
reduced the incidence of arthritis (80% --> 30% at day 60) and 
joint destruction (X-ray assessment). Van den Berg et al. [33] 
showed that a full recovery of established arthritis is only possible 
after blocking both IL-1 subtypes. 
Again the humoral and cellular responses to homologous 
type II collagen were not assessed in these studies. The immunity 
against homologous collagen does not have to develop synchronic 
with the immune response against heterologous type II collagen. 
The same IL-lra treatment regimen as used in CIA, either 
started during or after the immunization, did not modulate AIA 
nor the humoral and cellular immune-responses against the antigen 
in rat [32]. Injections of huIL-lra, 4 mg/Kg subcutaneously every 
six hours, had no effect on the acute joint inflammation at day 3 of 
ovalbumin-induced arthritis (AIA) in the rabbit [35]. Faherty et al. 
[36] showed ongoing antigen specific immune responses in vivo 
after treatment with IL-lra or with the monoclonal anti-IL-1 RI 
antibodies (35F5). IL-lra and 35F5 antibodies are blocking the IL-
1 type 1 receptors on, for example, Th2-cells. Thl-cells pre-
dominantly expressed the type II IL-1 receptor which has a low 
affinity for IL-lra and this suggests that the Thl cells could supply 
sufficient help for the development of the humoral response 
[37,38]. The antigen specific T-cells in patients with reactive 
arthritis are predominantly of the Thl cell-type [39]. 
A single injection of anti-IL-1 (or -I- ß) polyclonal antibodies 
intravenously one day before arthritis induction completely 
neutralized de novo synthesized IL-1 during the acute phase of 
murine AIA, however, did not reduce the acute joint swelling (day 
1 and 2) nor the exudate of neutrophils (chapter 5,6). The acute 
inflammation remains IL-1 independent even when the antigen 
dose was lowered in AIA. A significant reduction of the joint 
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swelling and synovitis was evident at day 4 and 7 of AIA by the 
anti-IL-1 pre-treatment. Repeated IL-lra injections (10mg/kg every 
3-6 hours) or even continuous delivery of IL-lra (37.5 ^g/hour) by 
implantation mini-osmotic pumps intra-peritoneally did also not 
prevent the joint inflammation in murine AIA (chapter 7). 
The anti-inflammatory effect of IL-lra might depend on the 
localisation of arthritis, the ankle in CIA and the knee joint in 
AIA. IL-lra is more efficacious in prevention of IL-1 induced 
suppression of the proteoglycan synthesis in cartilage of the ankle 
joint than in cartilage of the knee joint [17].* The IL-1 receptor 
type I expression of chondrocytes is considerably lower in the ankle 
compared to the knee joint. Zymosan injected into naive knee 
joints induced an acute joint inflammation restricted to that joint in 
normal mice but induced joint inflammation in the ankle of the 
draining paw in type II collagen sensitized mice. Anti-IL-1 antibody 
treatment prevented the zymosan accelerated CIA [77]. IL-1 
derived from the zymosan-injected knee joint probably increased 
the type II collagen epitopes expression and this triggers the 
inflammatory reaction in the ankle. 
The anti-inflammatory effect of the anti-IL-1 in other arthritis 
models implies that IL-1 is involved in the immune development in 
these animals. The disorder in MRL/lpr autoimmune mice is 
characterized by excessive lymphocyte proliferation and 
development of autoantibodies most prevalently directed against 
dsDNA and collagen type II. Either treatment of nascent or 
established disease with a soluble IL-1 receptor type I (sIL-lRI), 
with equal affinities for IL-la and β, reduced autoantibodies 
production (-75%), alleviated inflammation, ameliorated cartilage 
destruction and arrested the development of polyarthritis [40]. 
Treatment with M20, an IL-lra related protein, inhibited the joint 
swelling, peri-articular erythema, limping of the rats, and reduced 
the mononuclear cell infiltrate in joints of adjuvant arthritis (AA) 
in the rat [41]. In a standardized A A model, treatment with sIL-
1RI prevented the disease symptoms, even when starting therapy in 
the established disease. sIL-lRI inhibited the disorder from 
spreading to the non-injected extremity, probably by its strong 
immunosuppressive effects on the production of autoreactive anti­
type II collagen antibodies (-43%). Furthermore, this treatment 
suppressed joint swelling in the secundary lesions [40]. 
1 Plenary lecture, KE. Kuettner, IAIS, Vienna, 1993. 
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T-CELL DEPENDENT ARTHRITIS MODELS. 
The arthritis models may differ in their relative contribution of 
both the humoral and T-cell immunity in the disease. 
In the chronic phase of SCW-arthritis in rats, an i.v. 
injection of the superantigen (TSST-1) resulted in an acute 
reactivation of the inflammation. IL-Ira treatment failed to reduce 
the acute joint swelling [42]. In the chronic phase of murine AIA, a 
T-cell dependent flare-up of the smouldering inflammation could 
be induced with low amounts of antigen (2 μ% mBSA), and anti-IL-
1 (α + β) antibody treatment significantly reduced joint swelling (-
30%) without affecting neutrophil infiltration. Blocking IL-1 
significantly reduced the flare-up related synovitis (chapter 8). 
In rabbbit AIA, IL-lra treatment started after arthritis induction 
moderately reduced the synovium collagen content (-22.4%) [43]. 
These studies suggest that T-cell mediated inflammation are for 
the major part, if not at all, IL-1 independently regulated. 
MISCELLANEOUS INFLAMMATION MODELS 
The inflammation in peptidoglycan polyssaccharide (PG-APS) 
reactivation of SCW-arthritis was less acute and lasted several days 
compared with the antigen-induced flare-up of murine AIA. 
Cyclosporin pretreatment of the animals prevented the TSST-1 
flare-up completely but the suppression was less complete in the 
first two weeks of the PG-APS induced flare-up, indicating that 
PG-APS induced flares are not strictly T-cell dependent [42]. In 
the PG-APS reactivation model, Schwab et al. [44] found an 
ambiguous role for endogenous IL-1 in the onset of the flare-up. 
Blocking IL-1 with IL-lra for the first 6 hours of the flare 
enhances joint swelling but blocking for 24 hours suppressed the 
joint swelling for 55% at the most. This indicates that IL-1 is pro­
inflammatory, but at the same time may initiate anti-inflammatory 
homeostatic responses. For example, an intravenous injection of 
IL-1 induced a flare-up and induced feedback mechanisms able to 
suppress a subsequent PG-APS reactivation [44]. 
Strain differences were also noted in the synthesis of IL-lra by the 
same stimuli. Macrophages of rats susceptible for PG-APS induced 
SCW-arthritis, produced equivalent amounts of II-1 but reduced 
amounts of IL-lra in comparison to resistant rat strains [45]. 
Collagen-induced arthritis is also strain specific and DBA/lac mice 
may also have an impaired (feedback) suppressor mechanism 
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probably at the levels of macrophage IL-1 /IL-Ira expression as 
exogenous IL-1 could initiate arthritis. T-cell derived lymphokines 
as IL-4 and IL-10 of subset TH2 are known to antagonize IL-1 at 
more than one level [11-16]. Moreover, evidence emerged that 1С 
stimulate monocyte to synthesize both IL-1 and IL-Ira 
[24,28,46,4η. 
10.4 IL-1 induced cartilage pathology and its role in arthritis. 
IL-1 INDUCED SUPPRESSION OF PROTEOGLYCAN (PG) 
SYNTHESIS 
We (chapter 2 and 3) showed that murine recombinant IL-1 
markedly suppressed PG synthesis in murine articular cartilage in 
vitro and in vivo. Chandrasekhar et al. [48] found similar results 
with huIL-lß in rat. Arner et al. [49] measured proteoglycan 
synthesis in the rabbit and found that 100 ng of huIL-lß/knee is 
required for significant suppression. The IL-1-induced proteoglycan 
synthesis suppression is probably mediated by nitric-oxide (NO) 
production in the chondrocytes.2 The IL-1 induced inflammation is 
too mild to be involved in the PG synthesis suppression (chapter 
3). 
Topographical variations in chondrocyte responses towards 
in vivo IL-1 challenge are described [50]. The inhibition of 
proteoglycan synthesis at the periphery of patellar cartilage was 
considerably smaller than that at the central part of the patella, 
femur and tibial plateau. After repeated IL-1 injections, prolonged 
suppression of chondrocyte proteoglycan synthesis in both the 
central part of the patella and the medial side of the femur was 
demonstrated by autoradiography [50]. It was hypothesized that 
environmental influences (e.g. distance to the synovium) and 
loading conditions predisposed certain areas in the joint. As 
circumstantial evidence, short-term immobilization of the knee 
joint in extension after IL-1 injection prevented II-1 induced 
proteoglycan synthesis inhibition [51]. Dingle et al. [52] showed 
that the femur was more easily depleted than the tibia. Page-
Thomas et al. [53] reported topographical differences in the 
proteoglycan synthetic recovery rate which is slower in patellae 
than in tibial cartilage of rabbits. 
2
 Hickery MS, Palmer RMJ, Charles IG, Moneada S, Bayliss MT: The role 
of nitric oxide in IL-1 and TNF-a-induced inhibition of proteoglycan synthesis in 
human articular cartilage. Trans Orthopeadic Res Soc 1994; 19: 77. 
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ROLE OF IL-1 IN THE SUPPRESSION OF PG SYNTHESIS IN 
EXPERIMENTAL ARTHRITIS 
We showed that blocking IL-1 activity with either rabbit polyclonal 
antibodies or with human IL-Ira prevented the suppression of 
chondrocyte PG synthesis in both murine AIA and ZIA (chapter 5-
7). This protective effect was not due to a relieve of the 
inflammation since anti-IL-1 had no anti-inflammatory effect in 
these models. Starting the anti-IL-1 treatment 6 hours after 
arthritis induction, so at the time of profound neutrophils influx, 
still completely prevented the PG synthesis suppression. 
Normalization of PG-synthesis was also shown in arthritis models 
in which anti-IL-1 treatment had a strong anti-inflammatory effect 
such as murine CIA and ICA. ICA induction in neutropenic mice 
inhibited the PG synthesis even in the absence of exudate and 
infiltrate. This parallels with expression of IL-1 bioactivity in joints 
during ICA elicited in neutropenic mice. 
IL-1 INDUCED CARTILAGE PROTEOGLYCAN 
DEGRADATION 
Intra-articular injections of IL-1 caused a short lasting but marked 
loss of articular cartilage proteoglycans in rabbits, rats, and mouse 
[48,48,52,54-58](chapter 3) and the insult was more profound after 
repeated injections (chapter 4). Human IL-lß injected into a 
normal, non-inflamed rabbit knee joints caused a short-lasting (48 
hours) leucocyte infiltrate into the synovium and exudate into the 
joint space and resulted in significant cartilage proteoglycan loss 
[59]. Henderson et al. [60] showed that intravenous injection of IL-
lra inhibited both proteoglycan loss and inflammation that follows 
after intraarticular huIL-lß injection in rabbits. The same extent of 
joint inflammation induced by zymosan or LPS as seen after IL-1 
did not induce proteoglycan loss (chapter 3)[59]. Furthermore, IL-1 
injected into neutropenic rabbits still caused cartilage proteoglycan 
depletion [62,62]. These observations suggest that IL-1 induced 
inflammation (neutrophil influx) and IL-1 induced cartilage loss 
are unrelated. Intra-articularly injected huIL-la or β caused 
infiltration of approximately equal numbers of PMNs and 
monocytes [63]. Human TNF preferentially stimulated the 
infiltration of monocytes [64,65] but this did not cause cartilage 
proteoglycan depletion. 
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ROLE OF IL-1 IN CARTILAGE PG DEGRADATION IN 
EXPERIMENTAL ARTHRITIS 
The relief of joint inflammation and amelioration of PG 
degradation after anti-IL-1 treatment coincided in murine CIA and 
ICA. For this reason, a direct link between IL-1 and the observed 
arthritic cartilage changes could not be proven in these models. 
IL-Ira treatment did not diminishe cartilage PG loss in 
rabbit AIA [43,66]. Anti-IL-1 antibodies also did not reverse the 
accelerated PG degradation in the first two days of murine AIA 
(chapter 7). The normalization of PG synthesis after anti-IL-1 
treatment probably accounts for the observed amelioration of the 
cartilage loss in murine AIA (chapter 5 and 7). We cannot exclude 
that the reduction of synovitis by anti-IL-1 in the acute phase of 
AIA and the antigen-induced exacerbation of AIA causes a 
reduction of the PG breakdown at later time points in the disease. 
In ICA, pretreatment with anti-IL-1 antibodies suppressed 
the accelerated PG degradation by 30-50%. ICA in neutropenic 
mice failed to show PG degradation, since IL-1 was still generated 
in the joint, it proves that the PG degradation was not a direct 
consequence of IL-1 in this model [67]. 
The role of the neutrophils is intriguing. The cartilage proteoglycan 
loss induced by the reversed passive arthus reaction in the rabbit 
joint did not occur in neutropenic animals [68]. In contrast, 
cartilage loss induced by AIA was unaffected in neutropenic 
rabbits and mice [62,69]. Although the PMNs are highly destructive 
for cartilage in vitro through the release of elastase, evidence for a 
role of elastase in vivo is lacking [70,71]. 
10.5 Role of TNF in arthritis models 
Recently, transgenic mouse lines have been generated which 
express the human TNF gene [72]. These transgenic mice show 
dysregulated patterns of TNF expression and develop a chronic 
polyarthyritis, which is demonstrated by a swelling of the ankles, 
impaired movement, hyperplasia of the synovial membrane, and 
PMN and lymphocyte inflammatory infiltrates by week 3 of age. In 
addition, pannus formation, articular cartilage destruction and 
massive production of fibrous tissue were observed in the advanced 
stages of the disease. 
A transgenic animal with over-expression of IL-1 has not 
yet been reported. Moreover, IL-1 involvement in the TNF 
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transgenic mouse is not evaluated although Brennan et al. [72] 
clearly demonstrated a direct link between IL-1 production and 
TNF activity in the rheumatoid synovium. 
The role of TNF in murine CIA has been extensively studied. 
Blocking TNF in situ has been attempted by pretreatment with a 
number of agents; anti-TNF (a + β) antibodies, soluble human 
p55 TNF receptor, and a recombinant human soluble TNF 
receptor FC fusion (rhuTNF:Fc) protein [72-77]. In general, 
blocking TNF in the imunization period resulted in a marked (50-
60%) reduction of paw swelling, significant reduction of the 
number of severely affected joints (erosions, synovitis), and 
reduced the incidence significantly from 86% to 28%. IL-Ira 
treatment also reduced incidence from 80% to 10% and 
ameliorated arthritis to the same extent (see previous chapters). 
Both anti-TNF and anti-IL-1 treatments are reported to delay 
onset of arthritis [76,77]. In contrast to the anti-IL-1 treatment, 
anti-TNF treatment only moderately (-15%) improved the clinical 
score (edema, erythema, joint rigidity). 
Van den Berg et al. compared both the anti-IL-1 and anti-
TNF treatments in collagen arthritis. Anti-TNF treatment resulted 
in an arrest of the disease whereas anti-IL-1 treatment resulted in 
complete recovery even in fully established arthritis [78]. These 
results with anti-TNF antibodies are identical to the results 
obtained by Wooley et al. using the rhuTNF:Fc fusion protein, 
reduced arthritic score by a combination of less severe disease and 
fewer involved joints [77]. Multiple anti-TNF antibody injections at 
the onset of arthritis (day 1) also arrested joint swelling, reduced 
the clinical score and the number of severely affected joints [74]. 
No therapeutic effect was found when anti-TNF treatment was 
started in more established arthritis (month 2 after immunization) 
although anti-IL-1 antibody treatment suppressed arthritis 
completely [33,34,75]. In CIA, blocking IL-1 seemed to be more 
effective than blocking TNF, and this could not be explained by 
reduced anti-type II collagen antibody levels as huTNF:Fc fusion 
protein was as effective as IL-lra in this respect [32,77]. 
TNF and IL-1 are locally proinflammatory and intra-articular 
injections caused a transient neutrophil influx which lasted several 
hours in the joint [79]. Cooper et al. [80] demonstrated that intra­
articular injections of human TNFa in either knee or ankle, 
accelerated onset of CIA, increased incidence and joint swelling in 
Wistar rats. In passively immunized rats with antibodies against 
type II collagen, i.a. injections of TNFa into the ankle resulted in 
an acute transient joint swelling [80]. Brahn et al. [10] 
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demonstrated that a human TNFa administered by osmotic pumps 
from the start of the immunization, aggravated both the clinical 
and radiographic parameters of CIA in rats. In mice, prolonged 
treatment with murine TNFa by daily i.p. injections from the day 
of immunization, resulted in an increased incidence and severity of 
CIA in mice [76]. 
Lewthwaite et al.3 treated ovalbumin-sensitized rabbits with rat 
anti-rabbit TNFa monoclonal antibodies during the onset of AIA 
and joint swelling (-39%) and leucocyte infiltration (-42%) were 
reduced but the histopathology of the synovial lining was not 
affected. Moreover, anti-TNF treatment did not diminish articular 
cartilage depletion although the inflammation was reduced by anti-
TNF treatment. We treated murine AIA with anti-TNF antibodies 
and we found no effect on the joint swelling or exudate (chapter 
7). Moreover, anti-TNF treatment did not protect the proteoglycan 
synthesis in AIA (chapter 7) and CIA [81]. In the chronic phase of 
murine AIA, i.a. injections of muTNFa caused a short-lasting flare 
of the smouldering inflammation and cartilage destruction (not 
shown). 
In SCW-arthritis, TNF seemed to play a more prominent 
role, Schwab et al. [42,44] demonstrated that the the flare-up 
induced with PG-APS but not with the superantigen TSST-1 could 
be suppressed by either IL-Ira or anti-TNF antibody treatment. 
Joint inflammation was IL-1 and to a lesser extent TNF dependent 
in CIA and the PG-APS flare of SCW-induced arthritis. In more T-
cell mediated arthritis (AIA, TSST-1 flare of SCW) both IL-1 and 
TNF seemed to play a minor role. A clear discrepancy was found 
in murine ICA: IL-1 played a major role in inflammation and 
pathology whereas anti-TNF antibody treatment had no effect on 
these parameters of arthritis (unpublished data). A possible 
explanation for this could be the IL-1 inducing property of the 
cationic antigen used in this model. 
Lewthwaite JC, Blake SM, Vetterlein О, Foulkes R, Bodmer M, 
Hardingham TE, Henderson В: The effect of anti-TNFa monoclonal antibodies 
on the induction of antigen-induced arthritis in the rabbit. ORS abstract, Feb 21-
24, 1994. 
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10.6 Perspective of anti-IL-1 treatment of rheumatoid arthritis. 
The applicability of inhibition of arthritis by anti-IL-1 and anti-
TNF reagents to human arthritis is currently an important area of 
research. 
Recently in the first clinical trial, the chimeric monoclonal 
anti-TNF antibody (cA2) was highly effective in the treatment of 
RA. A cumulative dose of 20 mg/Kg of cA2 had no adverse effect 
and resulted in a clearcut improvement of clinical and laboratory 
parameters in 19/19 patients [82,83]. Although the anti-TNF 
treatment of RA showed good efficacy in this open trial, the 
proper controls were lacking. For instance, control chimeric 
antibodies or proteins were not included in the trial. Furthermore, 
no prove was presented that the treatments reduced cytokine 
bioactivity, to show that the cytokines were indeed blocked. A nice 
example was found in RA-patients treated with IL-6 neutralizing 
monoclonal antibodies. Marked clinical improvements were 
obtained but unexpectedly these antibodies neutralized IL-6 in vitro 
but in vivo functioned as a carrier and elevated IL-6 levels were 
found in these patients [84]. 
The rational of targetting TNF in rheumatoid arthritis is presented 
in the previous chapter: TNF overexpression in mice causes 
arthritis [72]. TNF plays a role in the onset of inflammation in 
CIA. IL-1 production by rheumatoid synoviocytes could be blocked 
by anti-TNF-antibodies [73]. However, false conclusions may be 
drawn using bioassays to measure IL-1 synthesis. For instance, no 
bioactive IL-1 was present in the exudate of the Bordetella pertussis 
vaccine induced inflammation in sensitized mouse. However, the 
IL-1 activity seemed to be antagonized in the bioassay as 
measurements of the immunoreactive IL-1 showed increased 
synthesis during the inflammation [29]. Brennan et al. [73] did not 
measure immunoreactive IL-1 and the effect of anti-TNF 
antibodies on the spontaneous IL-1 production by synoviocytes 
could be due to increased synthesis of e.g. IL-lra by aspecific 
stimulation of the cells [47]. An important point to adress is that in 
the experimental arthritis models clear evidence for an 
incontestable TNF — > IL-1 cascade is lacking. 
Nevertheless, the results obtained in the first clinical trial with the 
chimeric monoclonal anti-TNF antibodies are impressive. Clearly 
the experimental arthritis models showed that blocking IL-1 is as 
effective as blocking TNF and in many models even better. 
Thompson, R.C. presented preliminary results of phase I trials with 
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IL-1га in RA-patients.4 IL-Ira treatment in 15 RA-patients 
reduced the number of tender joints. No adverse effects were 
noted, it did not affect the immune responses or evoked 
autoantibodies against IL-Ira in these patients [85,86]. The use of 
IL-Ira has major drawbacks because molecular excess of 1000 was 
needed to fully block IL-1. The novel technic of gene-transfer was 
employed and local expression of huIL-lra in the synovial joint was 
able to block the effects of i.a. IL-1 injections [87-89]. Gene-
transfer could be a suitable new strategy for RA, expression is 
restricted to the inflamed area and this will narrow down possible 
side effects. Using recombinant chimeric proteins of high avidity 
anti-IL-1 antibodies with human FC may increase the efficacy of 
the anti-IL-1 antibody treatment of RA. 
It is highly likely that RA forms a heterogenous group with 
complex profiles and interrelationships of cytokines. Mulligan and 
Ward [90] showed an organ specificity with respect to the 
requirement for TNF and IL-1 in IgG immune complex-induced 
injury. In the lung, both TNF and IL-1 are important, whereas in 
similar induced injury in the skin IL-1, but not TNF is required. A 
similar observation was made with zymosan-induced inflammation. 
In the joint, inflammation was IL-1 independent and this is in 
conflict with the more prominent of IL-1 in the zymosan-induced 
pleurisy and in the subcutaneous tissue chamber model [30,31]. 
The influx of neutrophils was almost completely attenuated. In 
previous chapters we mentioned frequently another feature that of 
the cytokine sensitivity between the different joints, the ankle joints 
more sensitive for IL-1 induced injury than the knee joints, but 
also gender differences in the IL-1 response of cartilage are 
reported. The femoral head cartilage of the female rat to be more 
sensitive to IL-1 induced proteoglycan synthesis suppression, but 
male cartilage more vulnerable to IL-1 induced degradation [91]. 
The net IL-1 effect on proteoglycan content was the same in both 
sexes. The inhibition of proteoglycan synthesis and acceleration of 
proteoglycan degradation by IL-1 are mediated by independent 
post receptor pathways [92,93]. 
Can the RA-patient group be divided into either TNF or IL-1 
producers. This was substantiated by the following findings: First, 
in rheumatoid arthritis, levels of IL-1 and TNF in synovial fluids 
do not correlate (chapter 1.3 of this thesis). Second, IL-1 and TNF 
Thrird international workshop on cytokines, Stresa, Italy, 1991 
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production of rheumatoid synovium do not correlate [73,94]. Third, 
IL-4 exposure of some rheumatoid synovia resulted in complete 
inhibition of the TNF production while IL-1 was only slightly 
suppressed [95]. Fourth, evidence is presented that both syntheses 
are independently regulated, e.g. the TNF but not the IL-1 
production was completely attenuated in LPS tolerized animals 
[96,9η. 
RA-patients could also be divided with regard to their anti­
inflammatory response on non-steroidal antiiflammatory drugs 
(NSAIDS). A link was suggested with the anti-inflammatory effects 
after NSAIDS or anti-IL-1/TNF treatment in certain experimental 
arthritis models (CIA and AA). Moderate or no anti-inflammatory 
effects were found with anti-IL-1/TNF treatments in arthritis 
models which are less responsive to NSAIDS, e.g. AIA in rabbit 
and mice. Suggesting that IL-1-induced prostaglandin (PG)E2 
production may be more important in the former models of 
arthritis and that anti-IL-1 blocked the synthesis of prostaglandin 
or the related eicosanoids. This is supported by the observation 
that NSAIDs inhibit the acceleration of CIA by exogenous IL-1 but 
that indomethacin did not suppress the IL-1 induced flare of AIA 
[4,21]. 
One should also consider the impact of NSAID-treatment 
on the cytokine profile in RA-patients. Prostaglandins are potent 
feed-back mediators of the IL-1 and TNF synthesis. For example, 
fysiological levels of prostaglandins decreased TNF synthesis for 
about 50% in rheumatoid synovium [98]. Indomethacin treatment 
of AIA resulted in marked suppression of joint swelling and 
synovial PGEj levels but increased the lymphocyte numbers 
infiltration and aggravated cartilage proteoglycan loss [99]. During 
the course of RA, patients may shift into higher IL-1 or TNF 
producers due to the effect of NSAIDS. 
In summary, the clinical trials with anti-TNF and anti-IL-1 lacked 
radiographic analysis of cartilage pathology. Targetting IL-1 in RA 
may have a larger impact as we clearly demonstrated that IL-1 was 
more potent in inducing cartilage pathology than TNF. 
Comparative studies in three different experimental arthritis 
models (AIA, CIA, ICA) were performed, all demonstrating a 
more important role for IL-1 than TNF. AU the evidence points to 
IL-1 as a pivotal mediator in the inhibition of chondrocyte 
proteoglycan synthesis during arthritis. A marked reduction of the 
accelerated proteoglycan degradation was shown in animal models 
with IL-1 playing a key role in the inflammation. 
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CHAPTER 11 
NEDERLANDSE SAMENVATTING 
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Rheumatoide arthritis (RA) wordt gekenmerkt door pijnlijke en 
ontstoken gewrichten. De behandeling van 'reuma' wordt 
bemoeilijkt door dat de oorzaak van de gewrichtsontsteking nog 
onbekend is. De onstekingsreactie kan gericht zijn tegen 
lichaamsvreemde stoffen (antigenen) afkomstig van virussen, 
bacteriën, of uit ons voedsel of door een dwaling van het 
afweersysteem (b.v. kruisreactie), tegen de bouwstenen van het 
kraakbeen; de proteoglycanen en collagenen. In RA en in sommige 
experimentele artritis modellen zijn aanwijzingen hiervoor 
gevonden echter blijft de vraag of zij de oorzaak dan wel het 
gevolg zijn van de ontsteking? Vooralsnog is de argumentatie niet 
sluitend welk proefdier nu model staat voor humane RA. Het zal 
duidelijk zijn dat een observatie in meerdere experimentele artritis 
modellen gezien, aan betekenis wint. 
Globaal zijn drie niveaus te onderscheiden in het 
ontstekingsproces. Ten eerste, de instroom van ontstekingcellen in 
het gewricht. Hierbij zijn adhesie molekulen en chemokines van 
belang. Ten tweede, de cytokinen voor de communicatie tussen 
alle betrokken cellen in het ontstoken gewricht en daar buiten. 
Ten derde, de enzymen welke verantwoordelijk zijn voor 
kraakbeenmatrix destructie. Het zal duidelijk zijn dat deze drie 
niveaus nauw verbonden zijn met elkaar. In de strijd tegen RA 
staan we voor de keuze om het ontstekingsproces bij te sturen dan 
wel te stoppen of de kraakbeendestructie te verminderen en 
herstel te bevorderen. 
In mijn studie staat het cytokine, interleukine-1, centraal. 
Interleukine-1 (IL-1) bestaant uit twee sterk homologe 17 KDa 
grote eiwitten die voor een zelfde membraan-receptor competeren. 
Gebaseerd op in vitro waren er al aanwijzingen dat IL-1 mogelijk 
een belangrijke rol speelt in de kraakbeenschade en het 
ontstekingsproces. 
In hoofdstuk 2 toonden wij aan dat incubatie van gewrichts-
kraakbeen van de muis met recombinant muize IL-la of IL-Iß leid 
tot proteoglycan verlies. Dit verlies was chondrocyt (kraakbeencel) 
gemedieerd en werd veroorzaakt door een verhoogde proteoglycan 
afbraak en een sterk verminderde proteoglycan synthese. Deze 
verschijnselen traden ook op na injectie van het interleukin-1 in 
het muize gewricht (hoofdstuk 3). Een eenmalige IL-1 injectie in 
de knieholte remt de proteoglycan synthese in het kraakbeen sterk 
gedurende 2 á 3 dagen. Tevens vind er een verhoogde afbraak 
plaats de eerste dag na de injectie. De milde ontsteking die volgde 
op IL-1 was onvoldoende ernstig om verantwoordelijk te zijn voor 
de schade. Herhaalde IL-1 injecties veroorzaakt een histologisch 
duidelijk waarneembare kraakbeenschade in het hele kniegewricht. 
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In hoofdstuk 4 toonden we aan dat de verhoogde proteoglycan 
afbraak samenging met een verhoogde expressie van 
gelatinolytische enzymen in het gewrichtskapsel en kraakbeen. Tot 
op heden is het verantwoordelijke enzym voor de kraakbeen 
destructie echter nog niet geïdentificeerd. De door IL-1 
geïnduceerde kraakbeenschade was reversibel en herstel werd 
gekenmerkt door een sterk verhoogde proteoglycan synthese en 
een verminderde afbraak van de nieuw geproduceerde 
proteoglycanen. 
Tijdens de eerste dag van de antigeen-geinduceerde artritis 
(AIA) in de muis vind er IL-1 productie plaats in het knie 
gewricht. Het behandelen van muizen met neutraliserende konijne 
antilichamen gericgt tegen muize IL-1 had geen effect op de 
initiële gewrichtszwelling en instroom van ontstekingscellen. De 
synthese van proteoglycanen werd echter volledig behouden door 
deze behandeling (hoofdstuk 5). Ook al ging de verhoogde 
kraakbeen afbraak onverminderd door de schade aan het 
kraakbeen was duidelijk verminderd door de behandeling. Het was 
van belang om op tijd te starten met de therapie. Werd de anti-IL-
1 behandeling uitgesteld tot 24 uur na aanvang van arthritis dan 
kon de proteoglycan synthese niet meer beschermd worden 
(hoofdstuk 6). 
Tumor necrosis factor (TNF) kan ook kraakbeenschade 
induceren alhoewel IL-1 veel potenter is in de muis. Interleukine-6 
(IL-6) speelt mogelijk een rol als essentiële cofactor in de IL-1 
geïnduceerde proteoglycan synthese remming maar induceert zelf 
geen kraakbeenschade in de muis. In hoofdstuk 7 laten we zien dat 
neutralisatie van TNF en IL-6 met antilichamen geen effect had op 
AIA en de niet-immunologisch gemedieerde zymosan-geinduceerde 
artritis (ZIA). Echter ook in ZIA was IL-1 verantwoordelijk voor 
de proteoglycan synthese remming. Het blokkeren van de IL-1 
activiteit met een humaan IL-1 receptor antagonist protein leverde 
een zelfde resultaat op. Deze gegevens zijn recentelijk bevestigd in 
andere muizen modellen op ons laboratorium: de collageen-
geinduceerde artritis (CIA) en de immuuncomplex-artritis (ICA). 
De ziekteactiviteit in RA fluctueert in de tijd en het 
ziekteverloop kan gepaard gaan met opvlammingen die ernstige 
gevolgen kunnen hebben voor het gewricht. 
Interleukin-1, lokaal of systemisch toegediend in de muis 
was in staat tot een vergelijkbare kortstondige opvlamming van 
AIA (hoofdstuk 8). IL-1 was ook in staat tot gewrichtszwelling en 
influx van ontstekingscellen in ZIA. Dit, en het feit dat IL-1 nog 
steeds opvlammingen induceerde van AIA na anti-lymfocyt 
behandeling maakte het aannemelijk dat de macrofagen de IL-1 
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geïnduceerde opvlammingen medieerden. Dit werd bevestigd door 
IL-1 geïnduceerde opvlammingen in gewrichten met een macrofaag 
rijk infiltraat (concanavalin-A behandeld). 
De rol van IL-1 in de antigeen-specifieke opvlammingen 
van AIA werd nader onderzocht met neutraliserende antilichamen. 
Het blokkeren van IL-1 activiteiten leidde tot een duidelijk 
vermindering van de gewrichtszwelling en de kraakbeen schade 
(hoofdstuk 9). 
Gebaseerd op deze bovenstaande bevindingen in de muis 
acht ik het niet onwaarschijnlijk dat het blokkeren van IL-1 in het 
ontstoken gewricht een zeer belangrijke bijdrage kan leveren in de 
behandeling van rheumatoide arthritis. Mogelijk is IL-1 de 
verantwoordelijke mediator (cytokine) voor de remming van de 
proteoglycan synthese in humaan RA kraakbeen. Een anti-IL-1 
behandeling kan mogelijk leiden tot een verminderde schade aan 
het gewrichtskraakbeen en IL-1 speelt potentieel een nog grotere 
rol in het ontstekingsproces en de gerelateerde kraakbeenschade 
tijdens de veel voorkomende opvlammingen van RA. 
166 
DANKWOORD 
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Toen ik tijdens de bereiding van een stoofpotje de keuken rond 
keek trof mij de gelijkenis met mijn werk. Ook wij staan als een 
kok in potjes en pannetjes te roeren en creëren uit de 
verschillende ingrediënten onze gerechten. Welbeschouwd is de 
wetenschap nauw verwant aan de kookkunst en vice versa. Als in 
elke kunstvorm probeert de wetenschapper door combinatie en 
variatie, grenzen te verleggen. Het is mij opgevallen dat in beide 
disciplines het verslag veel overeenkomsten vertoont. De 
ingrediënten en het instrumentarium worden zorgvuldig 
beschreven en samen met een gedetailleerde receptuur moeten 
zij borg staan voor de met veel verve gepresenteerde resultaten. 
Ook in de kookkunst is de publikatie druk sterk toegenomen. 
Eten en wetenschap gaan hand in hand en een 
(Indonesisch) diner is dan ook onontbeerlijk tijdens een congres. 
Hier geldt dat een heerlijk gerecht smaakt naar meer. 
Dit proefschrift was dan ook nooit tot stand gekomen als niet alle 
ingrediënten aanwezig waren op de afdeling Reumatologie. 
Daarom wil ik dan ook IEDEREEN bedanken die mij terzijde 
stonden om van dit stoofpotje een meergangen menu te maken 
en mij voorzagen van een A-klasse kwaliteit. 
Door zijn aanwijzingen (kneepjes van het vak) en de in mijn 
gestelde vertrouwen heeft Wim van den Berg als chef de cuisine 
mij met woord en daad bijgestaan. Met Leo van de Putte als 
keurmeester op de achtergrond waakte ik ervoor niet al te grote 
misbaksels en rookwolken te produceren. 
Als iedere kok had ik ook mijn maatje, Onno Arntz. Zonder zijn 
inzet, zelfwerkzaamheid en kritisch volgen waren de gerechten 
zeker niet gaar geworden, daarnaast voorkwam hij regelmatig dat 
menig potje zou aanbrandden. Algauw werd FONNO een 
vertrouwd huismerk. 
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Velen onder jullie hebben smaak toegevoegd aan mijn gerecht. 
Met name Peter van Lent had creatieve ideeën en strooide royaal 
met peper en zout. Peter van der Kraan en Leo Joosten keken 
regelmatig onder de deksel en kruidde de gerechten naar 
believen. Het toetje dat Andrew als leerling kok heeft gemaakt 
past prima bij het menu. 
Het gezegde 'verandering van spijs doet eten ' was ook in mijn 
onderzoek van toepassing. Ivan Otterness stelde mij in staat om 
in de Amerikaanse keuken van Pfizer te kijken hetgeen geen 
fastfood restaurant bleek te zijn. Hij stak veel tijd en energie in 
mijn kookkunsten, maakte mij deelgenoot van zijn creatieve 
potjes en stimuleerde mij voor in lengte van dagen. Marcia Bliven 
wil ik bedanken omdat wij altijd op haar konden rekenen. 
Alhoewel zij een kleine eter is was het altijd prettig om met haar 
uit te gaan. 
Ten slotte wil ik Helma bedanken omdat zij de ware kok is achter 
mijn gerechten. 
Tot besluit wil ik opmerken dat een maaltijd pas tot zijn recht 
komt in gezelschap van vrienden. Vandaar dat ik mijn 
(w)etenschappelijke proeve van bekwaamheid wil besluiten met 
EET SMAKELIJK! 
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HUN PASSIE WERD ONZE MISSIE 
De passie van bovenstaande 
legendarische wetenschappers 
om manieren of middelen te 
vinden, waarmee zieke mensen 
konden worden geholpen, is 
voor ons een missie geworden. 
Het doel van Pfizer is haar 
continuïteit als researchgerichte 
organisatie te waarborgen, door 
optimaal ondersteuning te bie-
den aan de medische professie 
om zieken te genezen, lijden te 
verzachten of anderszins de 
levensomstandigheden en het 
welzijn van patiënten te bevor-
deren. 
Dit streven verplicht ons tot 
het ontwikkelen van genees-
middelen en therapieën die 
kwaliteit, betrouwbaarheid en 
gemak in zich bergen. 
Pfizer gelooft onvoorwaar-
delijk in fundamenteel weten-
schappelijk onderzoek als basis 
voor de ontwikkeling van inno-
vatieve geneesmiddelen. 
Zo werd wereldwijd in 1993 
aan Research & Development 
ca. 2 miljard gulden besteed. 
Een bedrag, dat nog jaarlijks 
toeneemt. 
Met name op het gebied 
van hart- en vaatziekten, gew-
richtsaandoeningen en infectie-
ziekten hebben we reeds een 
reputatie opgebouwd. 
Ons onderzoek naar nieuwe en 
betere geneesmiddelen gaat 
door. 
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